

FORM PTO-1390 (REV. 12-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 16516.130
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) To be Assigned 10/030537
INTERNATIONAL APPLICATION NO. PCT/US00/18813	INTERNATIONAL FILING DATE 11 Jul 2000 (11.07.00)	PRIORITY DATE CLAIMED 12 Jul 1999 (12.07.99)	
TITLE OF INVENTION NUCLEIC ACID MOLECULES AND PROTEINS ASSOCIATED WITH STEROL SYNTHESIS AND METABOLISM			
APPLICANT(S) FOR DO/EO/US KARUNANANDAA, Balasulojini, YU, Jaehyuk, KISHORE, Ganesh, M.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Paper copy of the Sequence Listing; Statement Regarding Sequence Listing; Form PCT/IB/306; Copy of International Search Report</p>			

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) To Assumed 0537		INTERNATIONAL APPLICATION NO. PCT/US00/18813		ATTORNEY'S DOCKET NUMBER 16516.130	
--	--	--	--	--	--

21. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO. **\$1040.00**

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO **\$890.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$740.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$710.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =

	\$	890.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$	130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	46 - 20 =	26	x \$18.00	\$	468.00
Independent claims	22 - 3 =	19	x \$84.00	\$	1,596.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+	\$280.00
TOTAL OF ABOVE CALCULATIONS =				\$	3,084.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+	0.00
SUBTOTAL =				\$	3,084.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0.00
TOTAL NATIONAL FEE =				\$	3,084.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	40.00
TOTAL FEES ENCLOSED =				\$	3,124.00
				Amount to be refunded:	\$
				charged:	\$

a. ☒ A check in the amount of \$ 3,124.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 50-1824. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David R, Marsh
ARNOLD & PORTER
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
Tel: 202-942-5068
Fax: 202-942-5999



SIGNATURE

David R. Marsh/June E. Cohan

NAME

41,408/43,741

REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Balasulojini KARUNANANDAA *et al.*

Intl. Appln.

No.: PCT/US00/18813

Art Unit: Not Yet Assigned

Intl. Filing

Date: 11 July 2000

Examiner Not Yet Assigned

Title: **Nucleic Acid Molecules and
Proteins Associated With Sterol
Synthesis and Metabolism**

Atty. Docket: 16516.130

Statement Regarding Sequence Submission


Commissioner for Patents
Washington, DC 20231

ATTN: Box PATENT APPLICATION

Sir:

In accordance with 37 C.F.R. § 1.821(f) and § 1.821(g), the paper copy of the Sequence Listing and the computer readable form (CRF) of the Sequence Listing on diskette filed herewith are the same and contain no new matter.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)
June E. Cohan (Reg. No. 43,741)

Date: 11 January 2002

ARNOLD & PORTER
555 12th Street, N.W.
Washington, D.C. 20004
(202) 942-5000 telephone
(202) 942-5999 facsimile

2002-01-11 10:40:00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KARUNANANDAA, *et al.*

Appln. No.: Not yet assigned

Filed: Herewith

For: Nucleic Acid Molecules and Other
Molecules Associated with Sterol
Synthesis and Metabolism

Art Unit: Not yet assigned

Examiner: Not yet assigned

Atty. Docket: 16516.130

Preliminary Amendment

Commissioner for Patents
Washington, DC 20231

Sir:

Prior to examination on the merits, Applicants hereby request entry of the following amendments in the above-captioned application:

In the Specification:

Please add the following paragraphs on page one, after the title:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is the National Stage of International Application No. PCT/US00/18813, filed 11 July 2000. This application claims the benefit of U.S. Provisional Application No. 60/142,981, filed on 12 July 1999.

INCORPORATION OF SEQUENCE LISTING

A paper copy of the Sequence Listing and a computer readable form of the sequence listing on diskette, containing the file named SeqList.txt, which is 55,428 bytes in size (measured in MS-DOS), and which was created on January 10, 2002, are herein incorporated by reference.


Remarks

The Sequence Listing has been formatted to comply with current 37 C.F.R. § 1.821 et seq. No new matter enters by this amendment. The specification has been amended to update cross-reference to related application information, and to specify that the present application is a National Stage of International Application No. PCT/US00/18813, filed 11 July 2000. No new matter enters by this amendment.

The presently pending claims are believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue. The Examiner is respectfully requested to contact Applicant's undersigned representative at 202.942.5071 to address any unresolved issues remaining in this application.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1824 referencing charge number 16516.130.

Respectfully submitted,


David R. Marsh (Reg. No. 41,408)
June E. Cohan (Reg. No. 43,471)

Date: 11 January 2002

ARNOLD & PORTER
555 Twelfth Street, N.W.
Washington, D.C. 20004
202.942.5000 telephone
202.942.5999 facsimile

202.942.5000 telephone
202.942.5999 facsimile

NUCLEIC ACID MOLECULES AND OTHER MOLECULES
ASSOCIATED WITH STEROL SYNTHESIS AND METABOLISM

FIELD OF THE INVENTION

5 This invention relates to the field of biotechnology, particularly as it pertains to the production of sterols in a variety of host systems particularly plants. More specifically, the invention relates to nucleic acid molecules encoding proteins and fragments of proteins associated with sterol and phytosterol metabolism as well as the encoded proteins and fragments of proteins and antibodies capable of binding to them. The invention also relates to methods of using the nucleic acid molecules, fragments of the nucleic acid molecules, proteins, and
10 fragments of proteins. The invention also relates to cells, organisms, particularly plants, or seeds, or progeny of plants, that have been manipulated to contain increased levels or overexpress at least one sterol or phytosterol compound.

BACKGROUND OF THE INVENTION

15 Sterols are a class of essential, natural compounds required by all eukaryotes to complete their life cycle. The types of sterols produced and predominantly present within each of the phylogenetic kingdoms varies. Plants produce a class of sterols called phytosterols. A phytosterol called sitosterol predominates. In animals, cholesterol is typically the major sterol while in fungi it is ergosterol.

20 Phytosterols from plants possess a wide spectrum of biological activities in animals and humans. Phytosterols are considered efficacious cholesterol-lowering agents (Pelletier *et al.*, *Annals Nutrit. Metab.* 39:291-295 (1995), the entirety of which is herein incorporated by reference). Lower cholesterol levels are linked to a reduction in the risk to cardiovascular disease. Phytosterols can also block cholesterol absorption in the intestine, which would also lead to lower cholesterol levels. Thus, enhancing the levels of phytosterols in edible plants
25 and seeds, or products derived from these plants and seeds, may lead to food products with increased nutritive or therapeutic value.

In one aspect, this invention provides these desirable plants and seeds as well as methods to produce them. Since, as will be discussed below, the genetic manipulation made

possible by this invention involves families of related genes that cross phylogenetic boundaries, the effects are not limited to plants alone.

Biochemistry of Sterol Synthesis

A number of the important sterol biosynthetic enzymes, reactions, and intermediates have been described. Sterol synthesis uses acetyl CoA as the basic carbon building block. Multiple acetyl CoA molecules form the five-carbon isoprene units, hence the name isoprenoid pathway. Enzymatic combination of isoprene units leads to the thirty-carbon squalene molecule, which is the penultimate precursor to sterols.

Throughout plants, animals, and fungus, the reactions proceed as: acetyl CoA → HMGCoA, mevalonate, mevalonate 5 phosphate, mevalonate 5-pyrophosphate, isopentyl diphosphate, 5-pyrophosphatemevalonate, isopentyl pyrophosphate (PIP), dimethylallyl pyrophosphate (DMAPP), PIP + DMAPP, geranyl pyrophosphate + IPP, farnesyl pyrophosphate, 2 farnesyl pyrophosphate, squalene and squalene epoxide

From squalene epoxide, the sterol biosynthesis pathway of plants diverges from that of animals and fungi. In plants, cycloartenol is produced next by cyclization of squalene epoxide. The plant pathway eventually leads to the synthesis of the predominant phytosterol, sitosterol.

Animals go on to produce lanosterol from squalene epoxide, eventually leading to cholesterol, which is the precursor to steroid hormones and bile acids, among other compounds. In fungi, lanosterol leads to the production of the predominant sterol, ergosterol.

An important regulatory control step within the pathway consists of the HMGCoA → Mevalonate step, catalyzed by HMGCoA reductase, and the condensation of 2 farnesyl pyrophosphates → squalene, catalyzed by squalene synthase. An early, reported rate-limiting step, in the pathway is the HMGCoA reductase-catalyzed reaction.

A number of studies have focused on the regulation of HMGCoA reductase. HMGCoA reductase (EC 1.1.1.34) catalyzes the reductive conversion of HMGCoA to mevalonic acid (MVA). This reaction is the controlling step in isoprenoid biosynthesis. The enzyme is regulated by feedback mechanisms and by a system of activation kinases and phosphatases (Gray, *Adv. Bot. Res.*, 14: 25 (1987); Bach *et al.*, *Lipids*, 26: 637 (1991);

Stermer *et al.*, *J. Lipid Res.*, 35: 1133 (1994), all of which are herein incorporated by reference in their entirety).

Another important regulation occurs at the squalene synthase step. Squalene synthase (EC 2.5.1.21) reductively condenses two molecules of FPP in the presence of Mg^{2+} and NADPH to form squalene. The reaction involves a head-to-head condensation and forms a stable intermediate, presqualene diphosphate. The enzyme is subject to regulation similar to that of HMGCoA reductase and acts by balancing the incorporation of FPP into sterols and other compounds.

The sterol pathway of plants diverges from that in animals and fungi after squalene epoxide. In plants, the cyclization of squalene epoxide occurs next, under the regulated control of cycloartenol synthase (EC 5.4.99.8). The cyclization mechanism proceeds from the epoxy end into a chair-boat-chair-boat sequence that is mediated by a transient C-20 carbocationic intermediate. The reported rate-limiting step in plant sterol synthesis occurs in the next step, S-adenosyl-L-methionine:sterol C-24 methyl transferase (EC 2.1.1.41) (SMT_I) catalyzing the transfer of a methyl group from a cofactor, S-adenosyl-L-methionine, to the C-24 center of the sterol side chain. This is the first of two methyl transfer reactions. The second methyl transfer reaction occurs further down in the pathway and has been reported to be catalyzed by SMT_{II}. An isoform enzyme, SMT_{II}, catalyzes the conversion of 24-methylene lophenol to 24-ethylidene lophenol (Fonteneau *et al.*, *Plant Sci Lett* 10:147-155(1977), the entirety of which is herein incorporated by reference). The presence of two distinct SMTs in plants were further confirmed by cloning cDNAs code the enzymes from *Arabidopsis* (Husselstein *et al.*, *FEBS Lett* 381:87-92(1996), the entirety of which is herein incorporated by reference), soybean (Shi *et al.*, *J Biol Chem* 271: 9384-9389(1996), the entirety of which is herein incorporated by reference), maize (Grebenok *et al.*, *Plant Mol Biol* 34: 891-896(1997), the entirety of which is herein incorporated by reference) and tobacco (Bouvier-Nave *et al.*, *Eur J Biochem* 246: 518-529 (1997); Bouvier-Nave *et al.*, *Eur J Biochem* 256: 88-96(1998), both of which are herein incorporated by reference in their entirety).

Later in the pathway, a sterol C-14 demethylase catalyzes the demethylation at C-14, removing the methyl group and creating a double bond. Interestingly, this enzyme also occurs in plants and fungi, but at a different point in the pathway. Sterol C14-demethylation

is mediated by a cytochrome P-450 complex. A large family of enzymes utilize the cytochrome P-450 complex. There is, in addition, a family of cytochrome P450 complexes. Sterol C-22 desaturase (EC 2.7.3.9) catalyzes the formation of the double bond at C-22 on the side chain. The C-22 desaturase in yeast, which is the final step in the biosynthesis of ergosterol, contains a cytochrome P450 that is distinct from the cytochrome P450 participating in the demethylation reaction. Additional cytochrome P450 enzymes participate in brassinosteroid synthesis (Bishop, *Plant Cell* 8:959-969 (1996), the entirety of which is herein incorporated by reference). Brassinosteroids are steroidal compounds with plant growth regulatory properties, including modulation of cell expansion and photomorphogenesis (Arteca, *Plant Hormones, Physiology, Biochemistry and Molecular Biology* ed. Davies, Kluwer Academic Publishers, Dordrecht, 66 (1995), Yakota, *Trends in Plant Science* 2:137-143 (1997), both of which are herein incorporated by reference in their entirety).

One class of proteins, oxysterol-binding proteins, have been reported in humans and yeast (Jiang *et al.*, *Yeast* 10: 341-353 (1994), the entirety of which is herein incorporated by reference). These proteins have been reported to modulate ergosterol levels in yeast (Jiang *et al.*, *Yeast* 10: 341-353 (1994)). In particular, Jiang *et al.*, reported three genes KES1, HES1 and OSH1, which encode proteins containing an oxysterol-binding region.

The present invention provides a gene, *hes1*, involved in plant phytosterol production. Expression of HES1 (protein) in organisms, such as plants, can increase phytosterol biosynthesis. The present invention also provides transgenic organisms expressing a HES1 protein, which can enhance food and feed sources.

SUMMARY OF THE INVENTION

The present invention includes a substantially purified nucleic acid molecule that encodes a protein comprising the amino acid sequence of SEQ ID NO: 30.

The present invention includes a substantially purified nucleic acid molecule that specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 1 or its complement, wherein the nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 30.

The present invention includes a substantially purified nucleic acid molecule that encodes a protein comprising the amino acid sequence of SEQ ID NO: 31.

The present invention includes a substantially purified nucleic acid molecule that specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 2 or its complement, wherein the nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 31.

The present invention includes a substantially purified nucleic acid molecule that encodes a protein comprising the amino acid sequence of SEQ ID NO: 32.

The present invention includes a substantially purified nucleic acid molecule that specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 3 or its complement, wherein the nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 32.

The present invention includes a substantially purified nucleic acid molecule that encodes a protein comprising the amino acid sequence of SEQ ID NO: 33.

The present invention includes a substantially purified nucleic acid molecule that specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 4 or its complement, wherein the nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 33.

The present invention includes a substantially purified nucleic acid molecule comprising a nucleic acid sequence which encodes a plant HES1 protein.

The present invention includes an antibody capable of specifically binding a protein comprising the amino acid sequence of SEQ ID NO: 30.

The present invention includes an antibody capable of specifically binding a protein comprising the amino acid sequence of SEQ ID NO: 31.

The present invention includes an antibody capable of specifically binding a protein comprising the amino acid sequence of SEQ ID NO: 32.

The present invention includes an antibody capable of specifically binding a protein comprising the amino acid sequence of SEQ ID NO: 33.

The present invention includes a plant having a nucleic acid molecule which comprises: (A) a promoter region which functions in a plant cell to cause the production of a

mRNA molecule; (B) an exogenous structural nucleic acid molecule encoding a protein or fragment thereof comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 31, 32, 33 and 34, and (C) a 3' non-translated sequence that functions in the plant cell to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of the mRNA molecule.

The present invention includes a transformed plant having a nucleic acid molecule which comprises: (A) an exogenous promoter region which functions in a plant cell to cause the production of a mRNA molecule; which is linked to (B) a transcribed nucleic acid molecule with a transcribed strand and a non-transcribed strand, wherein the transcribed strand is complementary to a nucleic acid molecule encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 31, 32, 33, and 34, which is linked to (C) a 3' non-translated sequence that functions in plant cells to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of the mRNA molecule.

The present invention includes a plant having a nucleic acid molecule which comprises: (A) a promoter region which functions in a plant cell to cause the production of a mRNA molecule; (B) an exogenous structural nucleic acid molecule encoding a plant HES1 protein or fragment thereof, and (C) a 3' non-translated sequence that functions in the plant cell to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of the mRNA molecule.

The present invention includes a plant having a nucleic acid molecule which comprises: (A) a promoter region which functions in a plant cell to cause the production of a mRNA molecule; (B) an exogenous structural nucleic acid molecule encoding a HES1 protein or fragment thereof, and (C) a 3' non-translated sequence that functions in the plant cell to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of the mRNA molecule.

The present invention includes and provides a method of producing a plant containing an expressed HES1 protein or fragment thereof in a plant comprising: (A) transforming the plant with a functional nucleic acid molecule, wherein the functional nucleic acid molecule comprises a promoter region, wherein the promoter region is linked to a structural region,

wherein the structural region comprises a nucleic acid sequence that encodes a protein having an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 31, 32, 33 and 34, wherein the structural region is linked to a 3' non-translated sequence that functions in the plant to cause termination of transcription and addition of polyadenylated ribonucleo-
5 tides to a 3' end of a mRNA molecule; and wherein the functional nucleic acid molecule results in overexpression of the protein; and (B) growing the transformed plant.

The present invention includes and provides a method of producing a plant containing an expressed HES1 protein or fragment thereof in a plant comprising: (A) transforming the plant with a functional nucleic acid molecule, wherein the functional nucleic acid molecule
10 comprises a promoter region, wherein the promoter region is linked to a structural region, wherein the structural region comprises a nucleic acid sequence that encodes a plant HES1 protein, wherein the structural region is linked to a 3' non-translated sequence that functions in the plant to cause termination of transcription and addition of polyadenylated ribonucleo-
15 tides to a 3' end of a mRNA molecule; and wherein the functional nucleic acid molecule results in overexpression of the protein; and (B) growing the transformed plant.

The present invention includes and provides a method for reducing expression of a HES1 protein in a plant comprising: (A) transforming a plant with a nucleic acid molecule, the nucleic acid molecule having an exogenous promoter region which functions in plant cells to cause the production of a mRNA molecule, wherein the exogenous promoter region is
20 linked to a transcribed nucleic acid molecule having a transcribed strand and a non-transcribed strand, wherein the transcribed strand is complementary to a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, and 29 or frag-
25 ment thereof; and wherein the transcribed nucleic acid molecule is linked to a 3' non-translated sequence that functions in the plant cells to cause termination of transcription and addition of polyadenylated ribonucleotides to the 3' end of the mRNA sequence; and (B) growing the transformed plant.

The present invention includes and provides a method for screening for increased phytosterol levels in a plant comprising interrogating genomic DNA for the presence or
30 absence of a marker molecule that specifically hybridizes to a nucleic acid molecule having a

nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, and 29 or complements thereof; and detecting the presence or absence of the marker.

The present invention includes and provides a method for determining a genomic polymorphism in a plant that is predictive of increased phytosterol levels comprising the steps:

5 (A) incubating a marker nucleic acid molecule, under conditions permitting nucleic acid hybridization, and a complementary nucleic acid molecule obtained from the plant, wherein the marker nucleic acid molecule specifically hybridizes to a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID Nos: 1, 2, 3, 4, 6, 7, 8, 9,

10 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, and 29 or complements thereof; (B) permitting hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule obtained from the plant; and (C) detecting the presence of the polymorphism.

The present invention includes and provides a method for determining a level or pattern of HES1 expression in a plant comprising: (A) incubating under conditions permitting nucleic acid hybridization: a marker nucleic acid molecule, the marker nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID Nos: 1, 2, 3, 4,

15 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, and 29 or complements thereof, with a complementary nucleic acid molecule obtained from a plant cell or plant tissue, wherein nucleic acid hybridization between the marker nucleic acid molecule;

20 (B) permitting hybridization between the marker nucleic acid molecule and the complementary nucleic acid molecule obtained from the plant; and (C) detecting the level or pattern of the complementary nucleic acid, wherein the detection of the complementary nucleic acid is predictive of the level or pattern of the HES1 protein.

The present invention includes and provides a method for determining a level or pattern of a HES1 in a plant cell or plant tissue under evaluation which comprises assaying the concentration of a molecule, whose concentration is dependent upon the expression of a gene, said gene having a nucleic acid sequence which specifically hybridizes to a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID Nos:

25 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, and

30

29 or complements thereof, said molecule being present in the plant cell or plant tissue, in comparison to the concentration of that molecule present in a plant cell or plant tissue with a known level or pattern of said HES1 protein, wherein the assayed concentration of said molecule is compared to the assayed concentration of said molecule in the plant cell or plant tissue with a known level or pattern of said HES1 protein.

DESCRIPTION OF THE NUCLEIC AND AMINO ACID SEQUENCES

SEQ ID NO: 1 sets forth the nucleotide sequence of a soybean HES1 homolog.

SEQ ID NO: 2 sets forth the nucleotide sequence of a soybean HES1 homolog.

SEQ ID NO: 3 sets forth the nucleotide sequence of a soybean HES1 homolog.

SEQ ID NO: 4 sets forth the nucleotide sequence of a maize HES1 homolog.

SEQ ID NO: 5 sets forth the nucleotide sequence of a *Saccharomyces cerevisiae*

HES1 homolog;

SEQ ID NO: 6 sets forth the partial nucleotide sequence of a soybean HES1 homolog;

SEQ ID NO: 7 sets forth the partial nucleotide sequence of a soybean HES1 homolog;

SEQ ID NO: 8 sets forth the partial nucleotide sequence of a soybean HES1 homolog;

SEQ ID NO: 9 sets forth the partial nucleotide sequence of a soybean HES1 homolog;

SEQ ID NO: 10 sets forth the partial nucleotide sequence of a soybean HES1 homo-

log. SEQ ID NO: 11 sets forth the partial nucleotide sequence of a soybean HES1

homolog.

SEQ ID NO: 12 sets forth the partial nucleotide sequence of a soybean HES1 homo-

log;

SEQ ID NO: 13 sets forth the partial nucleotide sequence of a soybean HES1 homo-

log;

SEQ ID NO: 14 sets forth the partial nucleotide sequence of a soybean HES1 homo-

log;

SEQ ID NO: 15 sets forth the partial nucleotide sequence of a soybean HES1 homo-

log;

SEQ ID NO: 16 sets forth the partial nucleotide sequence of a soybean HES1 homo-

log. SEQ ID NO: 17 sets forth the partial nucleotide sequence of a soybean HES1

homolog.

SEQ ID NO: 18 sets forth the partial nucleotide sequence of a soybean HES1 homolog.

SEQ ID NO: 19 sets forth the partial nucleotide sequence of a soybean HES1 homolog.

5 SEQ ID NO: 20 sets forth the partial nucleotide sequence of a soybean HES1 homolog.

SEQ ID NO: 21 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog;

10 SEQ ID NO: 22 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog.

SEQ ID NO: 23 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog.

SEQ ID NO: 24 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog.

15 SEQ ID NO: 25 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog.

SEQ ID NO: 26 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog.

20 SEQ ID NO: 27 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog.

SEQ ID NO: 28 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog.

SEQ ID NO: 29 sets forth the partial nucleotide sequence of an *Arabidopsis thaliana* HES1 homolog.

SEQ ID NO: 30 sets forth the amino acid sequences derived from a soybean HES1 gene.

SEQ ID NO: 31 sets forth the amino acid sequences derived from a soybean HES1 gene.

SEQ ID NO: 32 sets forth the amino acid sequences derived from a soybean HES1 gene.

SEQ ID NO: 33 sets forth the amino acid sequences derived from a maize HES1 gene.

SEQ ID NO: 34 sets forth the amino acid sequences derived from a *Saccharomyces cerevisiae* HES1 gene.

DETAILED DESCRIPTION

Utilizing a methodology that allows for the identification of genes that can influence phytosterol levels, plant HES1 genes were identified and isolated. HES1 are oxysterol-binding proteins. Overexpression of HES1 proteins in organisms can result in increased sterol levels in a variety of organisms. Moreover, the present invention provides a number of agents, for example, nucleic acid molecules encoding a plant HES1, and provides uses of such agents.

Agents:

The agents of the invention will preferably be "biologically active" with respect to either a structural attribute, such as the capacity of a nucleic acid to hybridize to another nucleic acid molecule, or the ability of a protein to be bound by an antibody (or to compete with another molecule for such binding). Alternatively, such an attribute may be catalytic and thus involve the capacity of the agent to mediate a chemical reaction or response. The agents will preferably be "substantially purified." The term "substantially purified," as used herein, refers to a molecule separated from substantially all other molecules normally associated with it in its native state. More preferably a substantially purified molecule is the predominant species present in a preparation. A substantially purified molecule may be greater than 60% free, preferably 75% free, more preferably 90% free, and most preferably 95% free from the

other molecules (exclusive of solvent) present in the natural mixture. The term "substantially purified" is not intended to encompass molecules present in their native state.

The agents of the invention may also be recombinant. As used herein, the term recombinant means any agent (*e.g.*, DNA, peptide *etc.*), that is, or results, however indirect, from human manipulation of a nucleic acid molecule.

It is understood that the agents of the invention may be labeled with reagents that facilitate detection of the agent (*e.g.*, fluorescent labels, Prober *et al.*, *Science* 238:336-340 (1987); Albarella *et al.*, EP 144914; chemical labels, Sheldon *et al.*, U.S. Patent 4,582,789; Albarella *et al.*, U.S. Patent 4,563,417; modified bases, Miyoshi *et al.*, EP 119448).

(a) Nucleic Acid Molecules

Agents of the invention include nucleic acid molecules. In a preferred aspect of the present invention the nucleic acid molecule comprises a nucleic acid sequence which encodes a HES1 protein. In a preferred embodiment, the HES1 protein is derived from a plant. In another preferred embodiment, the HES1 protein is derived from a yeast. Examples of HES1 proteins are those encoded by a nucleic acid sequence having SEQ ID NO: 30, 31, 32, 33 or 34.

In another preferred embodiment, the nucleic molecule encodes a HES1 protein, preferably a yeast or plant HES1 protein comprising an oxysterol-binding protein consensus sequence -- E(K, Q) xSH (H, R) PPx (S, T, A, C, F)A

In another preferred aspect of the present invention the nucleic acid molecule comprises a nucleic acid sequence selected from SEQ ID NOs: 1-4, 6-29 or complements thereof or fragment of either. In another preferred aspect of the present invention the nucleic acid molecules of the present invention comprise nucleic acid sequences that encode a protein having an amino acid sequence of SEQ ID NO: 30, 31, 32, or 33 or fragment thereof.

It is understood that in a further aspect of the nucleic acid sequences of the present invention can encode a protein which differs from any of the proteins in that amino acid have been deleted, substituted or added without altering the function. For example, it is understood that codons capable of coding for such conservative amino acid substitutions are known in the art.

One subset of the nucleic acid molecules of the invention is fragment nucleic acid molecules. Fragment nucleic acid molecules may consist of significant portion(s) of, or indeed most of, the nucleic acid molecules of the invention, such as those specifically disclosed. Alternatively, the fragments may comprise smaller oligonucleotides (having from about 15 to about 400 nucleotide residues and more preferably, about 15 to about 30 nucleotide residues, or about 50 to about 100 nucleotide residues, or about 100 to about 200 nucleotide residues, or about 200 to about 400 nucleotide residues, or about 275 to about 350 nucleotide residues).

A fragment of one or more of the nucleic acid molecules of the invention may be a probe and specifically a PCR probe. A PCR probe is a nucleic acid molecule capable of initiating a polymerase activity while in a double-stranded structure with another nucleic acid. Various methods for determining the structure of PCR probes and PCR techniques exist in the art. Computer generated searches using programs such as Primer3 (www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi), STSPipeline (www.genome.wi.mit.edu/cgi-bin/www-STS_Pipeline), or GeneUp (Pesole *et al.*, *BioTechniques* 25:112-123 (1998)), for example, can be used to identify potential PCR primers.

Another subset of the nucleic acid molecules of the invention include nucleic acid molecules that encode a protein or fragment thereof.

Nucleic acid molecules or fragments thereof of the present invention are capable of specifically hybridizing to other nucleic acid molecules under certain circumstances. Nucleic acid molecules of the present invention include those that specifically hybridize to nucleic acid molecules having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-4, 6-29 or complements thereof.

As used herein, two nucleic acid molecules are said to be capable of specifically hybridizing to one another if the two molecules are capable of forming an anti-parallel, double-stranded nucleic acid structure.

A nucleic acid molecule is said to be the "complement" of another nucleic acid molecule if they exhibit complete complementarity. As used herein, molecules are said to exhibit "complete complementarity" when every nucleotide of one of the molecules is complemen-

tary to a nucleotide of the other. Two molecules are said to be "minimally complementary" if they can hybridize to one another with sufficient stability to permit them to remain annealed to one another under at least conventional "low-stringency" conditions. Similarly, the molecules are said to be "complementary" if they can hybridize to one another with sufficient stability to permit them to remain annealed to one another under conventional "high-stringency" conditions. Conventional stringency conditions are described by Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual, 2nd Ed.*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1989) and by Haymes *et al.*, *Nucleic Acid Hybridization, A Practical Approach*, IRL Press, Washington, DC (1985). Departures from complete complementarity are therefore permissible, as long as such departures do not completely preclude the capacity of the molecules to form a double-stranded structure. Thus, in order for a nucleic acid molecule to serve as a primer or probe it need only be sufficiently complementary in sequence to be able to form a stable double-stranded structure under the particular solvent and salt concentrations employed.

Appropriate stringency conditions which promote DNA hybridization are, for example, 6.0 X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 X SSC at 20-25°C, are known to those skilled in the art or can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 X SSC at 20-25°C to a high stringency of about 0.2 X SSC at 65°C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22°C, to high stringency conditions at about 65°C. Both temperature and salt may be varied, or either the temperature or the salt concentration may be held constant while the other variable is changed.

In a preferred embodiment, a nucleic acid of the present invention will specifically hybridize to one or more of the nucleic acid molecules set forth in SEQ ID Nos:1-4, 6-29 or complements thereof under moderately stringent conditions, for example at about 2.0 X SSC and about 65°C.

In a particularly preferred embodiment, a nucleic acid of the present invention will include those nucleic acid molecules that specifically hybridize to one or more of the nucleic

acid molecules set forth in SEQ ID NOs: 1-4, 6-29 or complements thereof under high stringency conditions such as 0.2 X SSC and about 65°C.

In a particular preferred embodiment, a nucleic acid molecule of the present invention specifically hybridizes to a nucleic acid molecule having a nucleic acid sequence selected from the group SEQ ID Nos; 1-4, 6-29 or complements thereof but does not hybridize to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 5 or complement thereof under the same conditions.

In one aspect of the present invention, the nucleic acid molecules of the present invention have one or more of the nucleic acid sequences set forth in SEQ ID NOs: 1-4, 6-29 or complements thereof.

In another aspect of the present invention, one or more of the nucleic acid molecules of the present invention share between 100% and 90% sequence identity with one or more of the nucleic acid sequences set forth in SEQ ID NOs: 1-4, 6-29 or complements thereof. In a further aspect of the present invention, one or more of the nucleic acid molecules of the present invention share between 100% and 95% sequence identity with one or more of the nucleic acid sequences set forth in SEQ ID NOs: 1-4, 6-29 or complements thereof. In a more preferred aspect of the present invention, one or more of the nucleic acid molecules of the present invention share between 100% and 98% sequence identity with one or more of the nucleic acid sequences set forth in SEQ ID NOs: 1-4, 6-29 or complements thereof. In an even more preferred aspect of the present invention, one or more of the nucleic acid molecules of the present invention share between 100% and 99% sequence identity with one or more of the sequences set forth in SEQ ID NOs: 1-4, 6-29 or complements thereof.

In a preferred embodiment the percent identity calculations are performed using the Megalign program of the LASERGENE bioinformatics computing suite (default parameters, DNASTAR Inc., Madison, Wisconsin).

A nucleic acid molecule of the invention can also encode a homolog protein. As used herein, a homolog protein molecule or fragment thereof is a counterpart protein molecule or fragment thereof in a second species (*e.g.*, maize HES1 is a homolog of *Arabidopsis* HES1). A homolog can also be generated by molecular evolution or DNA shuffling techniques, so that the molecule retains at least one functional or structure characteristic of the original

protein (*see*, for example, U.S. Patent 5,811,238). Particularly preferred homologs are selected from the group consisting of alfalfa, *Arabidopsis*, barley, *Brassica*, broccoli, cabbage, citrus, cotton, garlic, oat, oilseed rape, onion, canola, flax, an ornamental plant, peanut, pepper, potato, rice, rye, sorghum, strawberry, sugarcane, sugarbeet, tomato, wheat, poplar, pine, fir, eucalyptus, apple, lettuce, lentils, grape, banana, tea, turf grasses, sunflower, soybean, maize, and *Phaseolus*. More particularly, preferred homologs are selected from maize, canola, soybean, crambe, mustard, castor bean, peanut, sesame, cottonseed, linseed, safflower, oil palm, flax and sunflower.

In a preferred embodiment, nucleic acid molecules having SEQ ID Nos: 1-4, 6-29 or complements thereof and fragments of either can be utilized to obtain such homologs.

In another further aspect of the present invention, nucleic acid molecules of the present invention can comprise sequences, which differ from those encoding a protein or fragment thereof in SEQ ID NOs: 30, 31, 32, and 33 due to fact that the different nucleic acid sequence encodes a protein having one or more conservative amino acid changes. It is understood that codons capable of coding for such conservative amino acid substitutions are known in the art.

It is well known in the art that one or more amino acids in a native sequence can be substituted with other amino acid(s), the charge and polarity of which are similar to that of the native amino acid, *i.e.*, a conservative amino acid substitution, resulting in a silent change.

Conservative substitutes for an amino acid within the native polypeptide sequence can be selected from other members of the class to which the amino acid belongs. Amino acids can be divided into the following four groups: (1) acidic amino acids, (2) basic amino acids, (3) neutral polar amino acids, and (4) neutral, nonpolar amino acids. Representative amino acids within these various groups include, but are not limited to, (1) acidic (negatively charged) amino acids such as aspartic acid and glutamic acid; (2) basic (positively charged) amino acids such as arginine, histidine, and lysine; (3) neutral polar amino acids such as glycine, serine, threonine, cysteine, cystine, tyrosine, asparagine, and glutamine; and (4) neutral nonpolar (hydrophobic) amino acids such as alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.

Conservative amino acid substitution within the native polypeptide sequence can be made by replacing one amino acid from within one of these groups with another amino acid from within the same group. In a preferred aspect, biologically functional equivalents of the proteins or fragments thereof of the present invention can have ten or fewer conservative amino acid changes, more preferably seven or fewer conservative amino acid changes, and most preferably five or fewer conservative amino acid changes. The encoding nucleotide sequence will thus have corresponding base substitutions, permitting it to encode biologically functional equivalent forms of the proteins or fragments of the present invention.

It is understood that certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Because it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence and, of course, its underlying DNA coding sequence and, nevertheless, a protein with like properties can still be obtained. It is thus contemplated by the inventors that various changes may be made in the peptide sequences of the proteins or fragments of the present invention, or corresponding DNA sequences that encode said peptides, without appreciable loss of their biological utility or activity. It is understood that codons capable of coding for such amino acid changes are known in the art.

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, *J. Mol. Biol.* 157, 105-132 (1982), the entirety of which is herein incorporated by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics (Kyte and Doolittle, *J. Mol. Biol.* 157:105-132 (1982)); these are isoleucine (+4.5), valine (+4.2), leucine (+3.8), phenylalanine (+2.8), cysteine/cystine (+2.5), methionine (+1.9), alanine (+1.8), glycine (-0.4), threonine (-0.7),

serine (-0.8), tryptophan (-0.9), tyrosine (-1.3), proline (-1.6), histidine (-3.2), glutamate (-3.5), glutamine (-3.5), aspartate (-3.5), asparagine (-3.5), lysine (-3.9), and arginine (-4.5).

In making such changes, the substitution of amino acids whose hydrophobic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101 states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0), lysine (+3.0), aspartate (+3.0 \pm 1), glutamate (+3.0 \pm 1), serine (+0.3), asparagine (+0.2), glutamine (+0.2), glycine (0), threonine (-0.4), proline (-0.5 \pm 1), alanine (-0.5), histidine (-0.5), cysteine (-1.0), methionine (-1.3), valine (-1.5), leucine (-1.8), isoleucine (-1.8), tyrosine (-2.3), phenylalanine (-2.5), and tryptophan (-3.4).

In making such changes, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

In a further aspect of the present invention, one or more of the nucleic acid molecules of the present invention differ in nucleic acid sequence from those encoding a protein or fragment thereof due to the fact that one or more codons encoding an amino acid has been substituted for a codon that encodes a nonessential substitution of the amino acid originally encoded.

Agents of the invention include nucleic acid molecules that encode at least about a contiguous 10 amino acid region of a protein of the present invention, more preferably at least about a contiguous 25, 40, 50, 100, or 125 amino acid region of a protein of the present invention.

(b) Protein and Peptide Molecules

A class of agents includes one or more of the protein or fragments thereof or peptide molecules encoded by a nucleic acid molecule having a nucleic acid sequence selected from

the group consisting of SEQ ID NO: 30, 31, 32, and 33 or fragments thereof or one or more of the protein or fragment thereof and peptide molecules encoded by other nucleic acid agents of the invention.

A further particularly preferred class of protein is a plant HES1 protein. A further particularly preferred class of protein is a yeast HES1 protein.

As used herein, the term "protein" or "peptide molecule" includes any molecule that comprises five or more amino acids. It is well known in the art that proteins may undergo modification, including post-translational modifications, such as, but not limited to, disulfide bond formation, glycosylation, phosphorylation, or oligomerization. Thus, as used herein, the term "protein" or "peptide molecule" includes any protein that is modified by any biological or non-biological process. The terms "amino acid" and "amino acids" refer to all naturally occurring L-amino acids. This definition is meant to include norleucine, norvaline, ornithine, homocysteine, and homoserine.

One or more of the protein or fragments thereof or peptide molecules may be produced via chemical synthesis, or more preferably, by expression in a suitable bacterial or eukaryotic host. Suitable methods for expression are described by Sambrook *et al.*, In: *Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, New York (1989)*, the entirety of which is herein incorporated by reference, or similar texts.

A "protein fragment" is a peptide or polypeptide molecule whose amino acid sequence comprises a subset of the amino acid sequence of that protein. A protein or fragment thereof that comprises one or more additional peptide regions not derived from that protein is a "fusion" protein. Such molecules may be derivatized to contain carbohydrate or other moieties (such as keyhole limpet hemocyanin, *etc.*). Fusion protein or peptide molecules of the invention are preferably produced via recombinant means.

Another class of agents comprise protein or peptide molecules or fragments or fusions thereof comprising SEQ ID NO: 30, 31, 32, or 33 or fragment thereof or encoded by SEQ ID NO: 1, 2, 3, or 4 in which conservative, non-essential or non-relevant amino acid residues have been added, replaced or deleted. Another particular preferred class of proteins are those having an amino acid sequence where the nucleic acid sequence is selected from the group

consisting of SEQ ID NOs: 6-29 in which conservative, non-essential or non-relevant amino acid residues have been added, replaced or deleted. A further particularly preferred class of protein is a HES1 protein in which conservative, non-essential or non-relevant amino acid residues have been added, replaced or deleted. Computerized means for designing modifications in protein structure are known in the art (Dahiyat and Mayo, *Science* 278:82-87 (1997), the entirety of which is herein incorporated by reference).

A protein of the invention can also be a homolog protein. As used herein, a homolog protein or fragment thereof is a counterpart protein or fragment thereof in a second species. A homolog can also be generated by molecular evolution or DNA shuffling techniques, so that the molecule retains at least one functional or structure characteristic of the original (*see*, for example, U.S. Patent 5,811,238, the entirety of which is herein incorporated by reference).

Particularly preferred homologs are selected from the group consisting of alfalfa, *Arabidopsis*, barley, *Brassica*, broccoli, cabbage, citrus, cotton, garlic, oat, oilseed rape, onion, canola, flax, an ornamental plant, peanut, pepper, potato, rice, rye, sorghum, strawberry, sugarcane, sugarbeet, tomato, wheat, poplar, pine, fir, eucalyptus, apple, lettuce, lentils, grape, banana, tea, turf grasses, sunflower, and *Phaseolus*. Other particularly preferred homologs are selected from the group consisting of blue green algae and bacteria. In a more preferred embodiment, the homologs are selected from the group of maize and soybean.

In a preferred embodiment, the nucleic acid molecules of the present invention or complements and fragments of either can be utilized to obtain such homologs.

The degeneracy of the genetic code, which allows different nucleic acid sequences to code for the same protein or peptide, is known in the literature (U.S. Patent No. 4,757,006, the entirety of which is herein incorporated by reference).

Agents of the invention include proteins comprising at least about a contiguous 10 amino acid region preferably comprising at least about a contiguous 20 amino acid region, even more preferably comprising at least a contiguous 25, 35, 50, 75 or 100 amino acid region of a protein of the present invention. In another preferred embodiment, the proteins of the present invention include between about 10 and about 25 contiguous amino acid region,

more preferably between about 20 and about 50 contiguous amino acid region, and even more preferably between about 40 and about 80 contiguous amino acid region.

(c) Plant Constructs and Plant Transformants

One or more of the nucleic acid molecules of the invention may be used in plant trans-
 5 formation or transfection. Exogenous genetic material may be transferred into a plant cell and the plant cell regenerated into a whole, fertile or sterile plant. Exogenous genetic material is any genetic material, whether naturally occurring or otherwise, from any source that is capable of being inserted into any organism. In a preferred embodiment, the exogenous genetic material includes a nucleic acid molecule of the present invention, preferably a nucleic
 10 acid molecule having a sequence selected from the group consisting of SEQ ID NOs: 1-29 or complements thereof or fragments of either. Another preferred class of exogenous genetic material is nucleic acid molecules that encode a protein or fragment thereof having an amino acid selected from the group consisting of SEQ ID NOs: 30, 31, 32, 33, and 34 or fragments thereof.

15 In another preferred aspect of the present invention, exogenous genetic material is nucleic acid molecules that comprise a nucleic acid sequence which encodes a HES1 protein or fragment thereof, more preferably a yeast HES1 protein or fragment thereof, even more preferably a plant HES1 protein or fragment thereof.

Such genetic material may be transferred into either monocotyledons and dicotyle-
 20 dons including, but not limited to maize, soybean, *Arabidopsis*, phaseolus, peanut, alfalfa, wheat, rice, oat, sorghum, rye, tritordeum, millet, fescue, perennial ryegrass, sugarcane, cranberry, papaya, banana, banana, muskmelon, apple, cucumber, dendrobium, gladiolus, chrysanthemum, liliacea, cotton, eucalyptus, sunflower, canola, turfgrass, sugarbeet, coffee and dioscorea (Christou, In: *Particle Bombardment for Genetic Engineering of Plants*, Bio-
 25 technology Intelligence Unit. Academic Press, San Diego, California (1996), the entirety of which is herein incorporated by reference). Particularly preferred plants are selected from maize, canola, soybean, Crambe, mustard, castor bean, peanut, sesame, cottonseed, linseed, safflower, oil palm, flax and sunflower.

Transfer of a nucleic acid that encodes a protein can result in expression or overex-
 30 pression of that protein in a transformed cell or transgenic plant. One or more of the proteins

or fragments thereof encoded by nucleic acid molecules of the invention may be overexpressed in a transformed cell or transformed plant. Such expression or overexpression may be the result of transient or stable transfer of the exogenous genetic material.

In a preferred embodiment, expression or overexpression of a HES1 protein in a plant provides in that plant, relative to an untransformed plant with a similar genetic background, an increased level of phytosterols.

In a preferred embodiment, expression or overexpression of a HES1 protein in a plant provides in that plant, relative to an untransformed plant with a similar genetic background, an altered composition of phytosterols.

In another embodiment, overexpression of a HES1 protein in a plant provides in that plant, relative to an untransformed plant with a similar genetic background, an increased level of a HES1 protein in a plastid.

In another preferred embodiment, overexpression of the HES1 protein in a transformed plant will result in a plant which provides when eaten acts exhibits an increased ability to act as a cholesterol lowering agent relative to an untransformed plant with a similar genetic background.

Exogenous genetic material may be transferred into a host cell by the use of a DNA vector or construct designed for such a purpose. Design of such a vector is generally within the skill of the art (*See, Plant Molecular Biology: A Laboratory Manual*, Clark (ed.), Springer, New York (1997), the entirety of which is herein incorporated by reference).

A construct or vector may include a plant promoter to express the protein or protein fragment of choice. A number of promoters, which are active in plant cells, have been described in the literature. These include the nopaline synthase (NOS) promoter (Ebert *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 84:5745-5749 (1987), the entirety of which is herein incorporated by reference), the octopine synthase (OCS) promoter (which is carried on tumor-inducing plasmids of *Agrobacterium tumefaciens*), the caulimovirus promoters such as the cauliflower mosaic virus (CaMV) 19S promoter (Lawton *et al.*, *Plant Mol. Biol.* 9:315-324 (1987), the entirety of which is herein incorporated by reference) and the CaMV 35S promoter (Odell *et al.*, *Nature* 313:810-812 (1985), the entirety of which is herein incorporated by reference), the figwort mosaic virus 35S-promoter, the light-inducible promoter from the

small subunit of ribulose-1,5-bis-phosphate carboxylase (ssRUBISCO), the Adh promoter (Walker *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 84:6624-6628 (1987), the entirety of which is herein incorporated by reference), the sucrose synthase promoter (Yang *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 87:4144-4148 (1990), the entirety of which is herein incorporated by reference), the R gene complex promoter (Chandler *et al.*, *The Plant Cell* 1:1175-1183 (1989), the entirety of which is herein incorporated by reference) and the chlorophyll a/b binding protein gene promoter, *etc.* These promoters have been used to create DNA constructs that have been expressed in plants; *see, e.g.*, PCT publication WO 84/02913. The CaMV 35S promoters are preferred for use in plants. Promoters known or found to cause transcription of DNA in plant cells can be used in the invention.

For the purpose of expression in source tissues of the plant, such as the leaf, seed, root or stem, it is preferred that the promoters utilized have relatively high expression in these specific tissues. Tissue-specific expression of a protein of the present invention is a particularly preferred embodiment. For this purpose, one may choose from a number of promoters for genes with tissue- or cell-specific or -enhanced expression. Examples of such promoters reported in the literature include the chloroplast glutamine synthetase GS2 promoter from pea (Edwards *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 87:3459-3463 (1990), the entirety of which is herein incorporated by reference), the chloroplast fructose-1,6-biphosphatase (FBPase) promoter from wheat (Lloyd *et al.*, *Mol. Gen. Genet.* 225:209-216 (1991), the entirety of which is herein incorporated by reference), the nuclear photosynthetic ST-LS1 promoter from potato (Stockhaus *et al.*, *EMBO J.* 8:2445-2451 (1989), the entirety of which is herein incorporated by reference), the serine/threonine kinase (PAL) promoter and the glucoamylase (CHS) promoter from *Arabidopsis thaliana*. Also reported to be active in photosynthetically active tissues are the ribulose-1,5-bisphosphate carboxylase (RbcS) promoter from eastern larch (*Larix laricina*), the promoter for the *cab* gene, *cab6*, from pine (Yamamoto *et al.*, *Plant Cell Physiol.* 35:773-778 (1994), the entirety of which is herein incorporated by reference), the promoter for the *Cab-1* gene from wheat (Fejes *et al.*, *Plant Mol. Biol.* 15:921-932 (1990), the entirety of which is herein incorporated by reference), the promoter for the *CAB-1* gene from spinach (Lubberstedt *et al.*, *Plant Physiol.* 104:997-1006 (1994), the entirety of which is herein incorporated by reference), the promoter for the *cab1R* gene from rice (Luan *et al.*,

Plant Cell. 4:971-981 (1992), the entirety of which is herein incorporated by reference), the pyruvate, orthophosphate dikinase (PPDK) promoter from maize (Matsuoka *et al.*, *Proc.*

Natl. Acad. Sci. (U.S.A.) 90: 9586-9590 (1993), the entirety of which is herein incorporated

by reference), the promoter for the tobacco Lhcb1*2 gene (Cerdan *et al.*, *Plant Mol. Biol.*

5 33:245-255 (1997), the entirety of which is herein incorporated by reference), the *Arabidop-*

sis thaliana SUC2 sucrose-H⁺ symporter promoter (Truernit *et al.*, *Planta*. 196:564-570

(1995), the entirety of which is herein incorporated by reference) and the promoter for the

thylakoid membrane proteins from spinach (psaD, psaF, psaE, PC, FNR, atpC, atpD, cab, rbcS). Other promoters for the chlorophyll a/b-binding proteins may also be utilized in the

10 invention, such as the promoters for Lhcb gene and PsbP gene from white mustard (*Sinapis alba*; Kretsch *et al.*, *Plant Mol. Biol.* 28:219-229 (1995), the entirety of which is herein incorporated by reference).

For the purpose of expression in sink tissues of the plant, such as the tuber of the potato plant, the fruit of tomato, or the seed of maize, wheat, rice and barley, it is preferred

15 that the promoters utilized in the invention have relatively high expression in these specific tissues. A number of promoters for genes with tuber-specific or tuber-enhanced expression

are known, including the class I patatin promoter (Bevan *et al.*, *EMBO J.* 8:1899-1906

(1986); Jefferson *et al.*, *Plant Mol. Biol.* 14:995-1006 (1990)), the promoter for the potato

tuber ADPGPP genes, both the large and small subunits, the sucrose synthase promoter

20 (Salanoubat and Belliard, *Gene* 60:47-56 (1987), Salanoubat and Belliard, *Gene* 84:181-185

(1989), both of which are herein incorporated by reference in their entirety), the promoter for

the major tuber proteins including the 22 kd protein complexes and protease inhibitors

(Hannapel, *Plant Physiol.* 101:703-704 (1993), the entirety of which is herein incorporated

by reference), the promoter for the granule-bound starch synthase gene (GBSS) (Visser *et al.*,

25 *Plant Mol. Biol.* 17:691-699 (1991), the entirety of which is herein incorporated by reference)

and other class I and II patatins promoters (Koster-Topfer *et al.*, *Mol Gen Genet.* 219:390-

396 (1989); Mignery *et al.*, *Gene.* 62:27-44 (1988), both of which are herein incorporated by

reference in their entirety).

Other promoters can also be used to express a protein or fragment thereof in specific

30 tissues, such as seeds or fruits. The promoter for β -conglycinin (Chen *et al.*, *Dev. Genet.* 10:

112-122 (1989), the entirety of which is herein incorporated by reference) or other seed-specific promoters such as the napin and phaseolin promoters, can be used. The zeins are a group of storage proteins found in maize endosperm. Genomic clones for zein genes have been isolated (Pedersen *et al.*, *Cell* 29:1015-1026 (1982), the entirety of which is herein incorporated by reference) and the promoters from these clones, including the 15 kD, 16 kD, 19 kD, 22 kD, 27 kD and genes, could also be used. Other promoters known to function, for example, in maize include the promoters for the following genes: *waxy*, *Brittle*, *Shrunken 2*, Branching enzymes I and II, starch synthases, debranching enzymes, oleosins, glutelins and sucrose synthases. A particularly preferred promoter for maize endosperm expression is the promoter for the glutelin gene from rice, more particularly the Osgt-1 promoter (Zheng *et al.*, *Mol. Cell Biol.* 13:5829-5842 (1993), the entirety of which is herein incorporated by reference). Examples of promoters suitable for expression in wheat include those promoters for the ADPglucose pyrosynthase (ADPGPP) subunits, the granule bound and other starch synthase, the branching and debranching enzymes, the embryogenesis-abundant proteins, the gliadins and the glutenins. Examples of such promoters in rice include those promoters for the ADPGPP subunits, the granule bound and other starch synthase, the branching enzymes, the debranching enzymes, sucrose synthases and the glutelins. A particularly preferred promoter is the promoter for rice glutelin, Osgt-1. Examples of such promoters for barley include those for the ADPGPP subunits, the granule bound and other starch synthase, the branching enzymes, the debranching enzymes, sucrose synthases, the hordeins, the embryo globulins and the aleurone specific proteins.

Root specific promoters may also be used. An example of such a promoter is the promoter for the acid chitinase gene (Samac *et al.*, *Plant Mol. Biol.* 25:587-596 (1994), the entirety of which is herein incorporated by reference). Expression in root tissue could also be accomplished by utilizing the root specific subdomains of the CaMV35S promoter that have been identified (Lam *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 86:7890-7894 (1989), the entirety of which is herein incorporated by reference). Other root cell specific promoters include those reported by Conkling *et al.* (Conkling *et al.*, *Plant Physiol.* 93:1203-1211 (1990), the entirety of which is herein incorporated by reference).

Additional promoters that may be utilized are described, for example, in U.S. Patent Nos. 5,378,619; 5,391,725; 5,428,147; 5,447,858; 5,608,144; 5,608,144; 5,614,399; 5,633,441; 5,633,435; and 4,633,436, all of which are herein incorporated by reference in their entirety. In addition, a tissue specific enhancer may be used (Fromm *et al.*, *The Plant Cell* 1:977-984 (1989), the entirety of which is herein incorporated by reference).

Constructs or vectors may also include, with the coding region of interest, a nucleic acid sequence that acts, in whole or in part, to terminate transcription of that region. A number of such sequences have been isolated, including the Tr7 3' sequence and the NOS 3' sequence (Ingelbrecht *et al.*, *The Plant Cell* 1:671-680 (1989); Bevan *et al.*, *Nucleic Acids Res.* 11:369-385 (1983), both of which are herein incorporated by reference in their entirety).

A vector or construct may also include regulatory elements. Examples of such include the Adh intron 1 (Callis *et al.*, *Genes and Develop.* 1:1183-1200 (1987), the entirety of which is herein incorporated by reference), the sucrose synthase intron (Vasil *et al.*, *Plant Physiol.* 91:1575-1579 (1989), the entirety of which is herein incorporated by reference) and the TMV omega element (Gallie *et al.*, *The Plant Cell* 1:301-311 (1989), the entirety of which is herein incorporated by reference). These and other regulatory elements may be included when appropriate.

A vector or construct may also include a selectable marker. Selectable markers may also be used to select for plants or plant cells that contain the exogenous genetic material. Examples of such include, but are not limited to: a neo gene (Potrykus *et al.*, *Mol. Gen. Genet.* 199:183-188 (1985), the entirety of which is herein incorporated by reference), which codes for kanamycin resistance and can be selected for using kanamycin, G418, *etc.*; a bar gene which codes for bialaphos resistance; a mutant EPSP synthase gene (Hinchee *et al.*, *Bio/Technology* 6:915-922 (1988), the entirety of which is herein incorporated by reference) which encodes glyphosate resistance; a nitrilase gene which confers resistance to bromoxynil (Stalker *et al.*, *J. Biol. Chem.* 263:6310-6314 (1988), the entirety of which is herein incorporated by reference); a mutant acetolactate synthase gene (ALS) which confers imidazolinone or sulphonylurea resistance (European Patent Application 154,204 (Sept. 11, 1985), the entirety of which is herein incorporated by reference); and a methotrexate resistant DHFR gene

(Thillet *et al.*, *J. Biol. Chem.* 263:12500-12508 (1988), the entirety of which is herein incorporated by reference).

A vector or construct may also include a transit peptide. Incorporation of a suitable chloroplast transit peptide may also be employed (European Patent Application Publication Number 0218571, the entirety of which is herein incorporated by reference). Translational enhancers may also be incorporated as part of the vector DNA. DNA constructs could contain one or more 5' non-translated leader sequences which may serve to enhance expression of the gene products from the resulting mRNA transcripts. Such sequences may be derived from the promoter selected to express the gene or can be specifically modified to increase translation of the mRNA. Such regions may also be obtained from viral RNAs, from suitable eukaryotic genes, or from a synthetic gene sequence. For a review of optimizing expression of transgenes, see Koziel *et al.*, *Plant Mol. Biol.* 32:393-405 (1996), the entirety of which is herein incorporated by reference.

A vector or construct may also include a screenable marker. Screenable markers may be used to monitor expression. Exemplary screenable markers include: a β -glucuronidase or uidA gene (GUS) which encodes an enzyme for which various chromogenic substrates are known (Jefferson, *Plant Mol. Biol. Rep.* 5:387-405 (1987); Jefferson *et al.*, *EMBO J.* 6:3901-3907 (1987), both of which are herein incorporated by reference in their entirety); an R-locus gene, which encodes a product that regulates the production of anthocyanin pigments (red color) in plant tissues (Dellaporta *et al.*, *Stadler Symposium* 11:263-282 (1988), both of which are herein incorporated by reference in their entirety); a β -lactamase gene (Sutcliffe *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 75:3737-3741 (1978), the entirety of which is herein incorporated by reference), a gene which encodes an enzyme for which various chromogenic substrates are known (*e.g.*, PADAC, a chromogenic cephalosporin); a luciferase gene (Ow *et al.*, *Science* 234:856-859 (1986), the entirety of which is herein incorporated by reference); a xylE gene (Zukowsky *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 80:1101-1105 (1983), the entirety of which is herein incorporated by reference) which encodes a catechol dioxygenase that can convert chromogenic catechols; an α -amylase gene (Ikata *et al.*, *Bio/Technol.* 8:241-242 (1990), the entirety of which is herein incorporated by reference); a tyrosinase gene (Katz *et al.*, *J. Gen. Microbiol.* 129:2703-2714 (1983), the entirety of which is herein incorporated by

reference) which encodes an enzyme capable of oxidizing tyrosine to DOPA and dopaquinone which in turn condenses to melanin; an α -galactosidase, which will turn a chromogenic α -galactose substrate.

Included within the terms "selectable or screenable marker genes" are also genes which encode a secretable marker whose secretion can be detected as a means of identifying or selecting for transformed cells. Examples include markers which encode a secretable antigen that can be identified by antibody interaction, or even secretable enzymes which can be detected catalytically. Secretable proteins fall into a number of classes, including small, diffusible proteins which are detectable, (e.g., by ELISA), small active enzymes which are detectable in extracellular solution (e.g., α -amylase, β -lactamase, phosphinothricin transferase), or proteins which are inserted or trapped in the cell wall (such as proteins which include a leader sequence such as that found in the expression unit of extension or tobacco PR-S). Other possible selectable and/or screenable marker genes will be apparent to those of skill in the art.

There are many methods for introducing transforming nucleic acid molecules into plant cells. Suitable methods are believed to include virtually any method by which nucleic acid molecules may be introduced into a cell, such as by *Agrobacterium* infection or direct delivery of nucleic acid molecules such as, for example, by PEG-mediated transformation, by electroporation or by acceleration of DNA coated particles, etc (Potrykus, *Ann. Rev. Plant Physiol. Plant Mol. Biol.* 42:205-225 (1991); Vasil, *Plant Mol. Biol.* 25:925-937 (1994), both of which are herein incorporated by reference in their entirety). For example, electroporation has been used to transform maize protoplasts (Fromm *et al.*, *Nature* 312:791-793 (1986), the entirety of which is herein incorporated by reference).

Other vector systems suitable for introducing transforming DNA into a host plant cell include but are not limited to binary artificial chromosome (BIBAC) vectors (Hamilton *et al.*, *Gene* 200:107-116 (1997), the entirety of which is herein incorporated by reference); and transfection with RNA viral vectors (Della-Cioppa *et al.*, *Ann. N.Y. Acad. Sci.* (1996), 792 (Engineering Plants for Commercial Products and Applications), 57-61, the entirety of which is herein incorporated by reference). Additional vector systems also include plant selectable

YAC vectors such as those described in Mullen *et al.*, *Molecular Breeding* 4:449-457 (1988), the entirety of which is herein incorporated by reference.

Technology for introduction of DNA into cells is well known to those of skill in the art. Four general methods for delivering a gene into cells have been described: (1) chemical methods (Graham and van der Eb, *Virology* 54:536-539 (1973), the entirety of which is herein incorporated by reference); (2) physical methods such as microinjection (Capecchi, *Cell* 22:479-488 (1980), the entirety of which is herein incorporated by reference), electroporation (Wong and Neumann, *Biochem. Biophys. Res. Commun.* 107:584-587 (1982); Fromm *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 82:5824-5828 (1985); U.S. Patent No.

5,384,253, all of which are herein incorporated by reference in their entirety); the gene gun (Johnston and Tang, *Methods Cell Biol.* 43:353-365 (1994), the entirety of which is herein incorporated by reference); and vacuum infiltration (Bechtold *et al.*, *C.R. Acad. Sci. Paris, Life Sci.* 316:1194-1199. (1993), the entirety of which is herein incorporated by reference); (3) viral vectors (Clapp, *Clin. Perinatol.* 20:155-168 (1993); Lu *et al.*, *J. Exp. Med.* 178:2089-2096 (1993); Eglitis and Anderson, *Biotechniques* 6:608-614 (1988), all of which are herein incorporated by reference in their entirety); and (4) receptor-mediated mechanisms (Curiel *et al.*, *Hum. Gen. Ther.* 3:147-154 (1992), Wagner *et al.*, *Proc. Natl. Acad. Sci. (USA)* 89:6099-6103 (1992), both of which are herein incorporated by reference in their entirety).

Acceleration methods that may be used include, for example, microprojectile bombardment and the like. One example of a method for delivering transforming nucleic acid molecules into plant cells is microprojectile bombardment. This method has been reviewed by Yang and Christou (eds.), *Particle Bombardment Technology for Gene Transfer*, Oxford Press, Oxford, England (1994), the entirety of which is herein incorporated by reference. Non-biological particles (microprojectiles) that may be coated with nucleic acids and delivered into cells by a propelling force. Exemplary particles include those comprised of tungsten, gold, platinum and the like.

A particular advantage of microprojectile bombardment, in addition to it being an effective means of reproducibly transforming monocots, is that neither the isolation of protoplasts (Cristou *et al.*, *Plant Physiol.* 87:671-674 (1988), the entirety of which is herein incorporated by reference) nor the susceptibility to *Agrobacterium* infection is required. An

illustrative embodiment of a method for delivering DNA into maize cells by acceleration is a biolistics α -particle delivery system, which can be used to propel particles coated with DNA through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with corn cells cultured in suspension. Gordon-Kamm *et al.*, describes the basic procedure for coating tungsten particles with DNA (Gordon-Kamm *et al.*, *Plant Cell* 2:603-618 (1990), the entirety of which is herein incorporated by reference). The screen disperses the tungsten nucleic acid particles so that they are not delivered to the recipient cells in large aggregates. A particle delivery system suitable for use with the invention is the helium acceleration PDS-1000/He gun, which is available from Bio-Rad Laboratories (Bio-Rad, Hercules, California) (Sanford *et al.*, *Technique* 3:3-16 (1991), the entirety of which is herein incorporated by reference).

For the bombardment, cells in suspension may be concentrated on filters. Filters containing the cells to be bombarded are positioned at an appropriate distance below the microprojectile stopping plate. If desired, one or more screens are also positioned between the gun and the cells to be bombarded.

Alternatively, immature embryos or other target cells may be arranged on solid culture medium. The cells to be bombarded are positioned at an appropriate distance below the microprojectile stopping plate. If desired, one or more screens are also positioned between the acceleration device and the cells to be bombarded. Through the use of techniques set forth herein one may obtain 1000 or more loci of cells transiently expressing a marker gene. The number of cells in a focus which express the exogenous gene product 48 hours post-bombardment often ranges from one to ten, and average one to three.

In bombardment transformation, one may optimize the pre-bombardment culturing conditions and the bombardment parameters to yield the maximum numbers of stable transformants. Both the physical and biological parameters for bombardment are important in this technology. Physical factors are those that involve manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps involved in manipulation of cells before and immediately after bombardment, the osmotic adjustment of target cells to help alleviate the trauma associated with bombardment and also the nature of the transforming DNA, such as linearized

DNA or intact supercoiled plasmids. It is believed that pre-bombardment manipulations are especially important for successful transformation of immature embryos.

In another alternative embodiment, plastids can be stably transformed. Methods disclosed for plastid transformation in higher plants include the particle gun delivery of DNA containing a selectable marker and targeting of the DNA to the plastid genome through homologous recombination (Svab *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 87:8526-8530 (1990); Svab and Maliga, *Proc. Natl. Acad. Sci. (U.S.A.)* 90:913-917 (1993); Staub and Maliga, *EMBO J.* 12:601-606 (1993); U.S. Patents 5, 451,513 and 5,545,818, all of which are herein incorporated by reference in their entirety).

Accordingly, it is contemplated that one may wish to adjust various aspects of the bombardment parameters in small scale studies to fully optimize the conditions. One may particularly wish to adjust physical parameters such as gap distance, flight distance, tissue distance and helium pressure. One may also minimize the trauma reduction factors by modifying conditions that influence the physiological state of the recipient cells and which may therefore influence transformation and integration efficiencies. For example, the osmotic state, tissue hydration and the subculture stage or cell cycle of the recipient cells may be adjusted for optimum transformation. The execution of other routine adjustments will be known to those of skill in the art in light of the present disclosure.

Agrobacterium-mediated transfer is a widely applicable system for introducing genes into plant cells because the DNA can be introduced into whole plant tissues, thereby bypassing the need for regeneration of an intact plant from a protoplast. The use of *Agrobacterium*-mediated plant integrating vectors to introduce DNA into plant cells is well known in the art. See, for example the methods described by Fraley *et al.*, *Bio/Technology* 3:629-635 (1985) and Rogers *et al.*, *Methods Enzymol.* 153:253-277 (1987), both of which are herein incorporated by reference in their entirety. Further, the integration of the Ti-DNA is a relatively precise process resulting in few rearrangements. The region of DNA to be transferred is defined by the border sequences and intervening DNA is usually inserted into the plant genome as described (Spielmann *et al.*, *Mol. Gen. Genet.* 205:34 (1986), the entirety of which is herein incorporated by reference).

Modern *Agrobacterium* transformation vectors are capable of replication in *E. coli* as well as *Agrobacterium*, allowing for convenient manipulations as described (Klee *et al.*, In: *Plant DNA Infectious Agents*, Hohn and Schell (eds.), Springer-Verlag, New York, pp. 179-203 (1985), the entirety of which is herein incorporated by reference). Moreover, technological advances in vectors for *Agrobacterium*-mediated gene transfer have improved the arrangement of genes and restriction sites in the vectors to facilitate construction of vectors capable of expressing various polypeptide coding genes. The vectors described have convenient multi-linker regions flanked by a promoter and a polyadenylation site for direct expression of inserted polypeptide coding genes and are suitable for present purposes (Rogers *et al.*, *Methods Enzymol.* 153:253-277 (1987), the entirety of which is herein incorporated by reference). In addition, *Agrobacterium* containing both armed and disarmed Ti genes can be used for the transformations. In those plant strains where *Agrobacterium*-mediated transformation is efficient, it is the method of choice because of the facile and defined nature of the gene transfer.

A transgenic plant formed using *Agrobacterium* transformation methods typically contains a single gene on one chromosome. Such transgenic plants can be referred to as being heterozygous for the added gene. More preferred is a transgenic plant that is homozygous for the added structural gene; *i.e.*, a transgenic plant that contains two added genes, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating (selfing) an independent segregant, transgenic plant that contains a single added gene, germinating some of the seed produced and analyzing the resulting plants produced for the gene of interest.

It is also to be understood that two different transgenic plants can also be mated to produce offspring that contain two independently segregating, exogenous genes. Selfing of appropriate progeny can produce plants that are homozygous for both added, exogenous genes that encode a polypeptide of interest. Back-crossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated, as is vegetative propagation.

Transformation of plant protoplasts can be achieved using methods based on calcium phosphate precipitation, polyethylene glycol treatment, electroporation and combinations of these treatments (*See, for example*, Potrykus *et al.*, *Mol. Gen. Genet.* 205:193-200 (1986);

Lorz *et al.*, *Mol. Gen. Genet.* 199:178 (1985); Fromm *et al.*, *Nature* 319:791 (1986); Uchimiya *et al.*, *Mol. Gen. Genet.* 204:204 (1986); Marcotte *et al.*, *Nature* 335:454-457 (1988), all of which are herein incorporated by reference in their entirety).

Application of these systems to different plant strains depends upon the ability to regenerate that particular plant strain from protoplasts. Illustrative methods for the regeneration of cereals from protoplasts are described (Fujimura *et al.*, *Plant Tissue Culture Letters* 2:74 (1985); Toriyama *et al.*, *Theor Appl. Genet.* 205:34 (1986); Yamada *et al.*, *Plant Cell Rep.* 4:85 (1986); Abdullah *et al.*, *Biotechnology* 4:1087 (1986), all of which are herein incorporated by reference in their entirety).

To transform plant strains that cannot be successfully regenerated from protoplasts, other ways to introduce DNA into intact cells or tissues can be utilized. For example, regeneration of cereals from immature embryos or explants can be effected as described (Vasil, *Biotechnology* 6:397 (1988), the entirety of which is herein incorporated by reference). In addition, "particle gun" or high-velocity microprojectile technology can be utilized (Vasil *et al.*, *Bio/Technology* 10:667 (1992), the entirety of which is herein incorporated by reference).

Using the latter technology, DNA is carried through the cell wall and into the cytoplasm on the surface of small metal particles as described (Klein *et al.*, *Nature* 328:70 (1987); Klein *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 85:8502-8505 (1988); McCabe *et al.*, *Bio/Technology* 6:923 (1988), all of which are herein incorporated by reference in their entirety). The metal particles penetrate through several layers of cells and thus allow the transformation of cells within tissue explants.

Other methods of cell transformation can also be used and include but are not limited to introduction of DNA into plants by direct DNA transfer into pollen (Hess *et al.*, *Intern Rev. Cytol.* 107:367 (1987); Luo *et al.*, *Plant Mol Biol. Reporter* 6:165 (1988), both of which are herein incorporated by reference in their entirety), by direct injection of DNA into reproductive organs of a plant (Pena *et al.*, *Nature* 325:274 (1987), the entirety of which is herein incorporated by reference), or by direct injection of DNA into the cells of immature embryos followed by the rehydration of desiccated embryos (Neuhaus *et al.*, *Theor. Appl. Genet.* 75:30 (1987), the entirety of which is herein incorporated by reference).

The regeneration, development and cultivation of plants from single plant protoplast transformants or from various transformed explants is well known in the art (Weissbach and Weissbach, In: *Methods for Plant Molecular Biology*, Academic Press, San Diego, CA, (1988), the entirety of which is herein incorporated by reference). This regeneration and growth process typically includes the steps of selection of transformed cells, culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage. Transgenic embryos and seeds are similarly regenerated. The resulting transgenic rooted shoots are thereafter planted in an appropriate plant growth medium such as soil.

The development or regeneration of plants containing the foreign, exogenous gene that encodes a protein of interest is well known in the art. Preferably, the regenerated plants are self-pollinated to provide homozygous transgenic plants. Otherwise, pollen obtained from the regenerated plants is crossed to seed-grown plants of agronomically important lines. Conversely, pollen from plants of these important lines is used to pollinate regenerated plants. A transgenic plant of the invention containing a desired polypeptide is cultivated using methods well known to one skilled in the art.

There are a variety of methods for the regeneration of plants from plant tissue. The particular method of regeneration will depend on the starting plant tissue and the particular plant species to be regenerated.

Methods for transforming dicots, primarily by use of *Agrobacterium tumefaciens* and obtaining transgenic plants have been published for cotton (U.S. Patent No. 5,004,863; U.S. Patent No. 5,159,135; U.S. Patent No. 5,518,908, all of which are herein incorporated by reference in their entirety); soybean (U.S. Patent No. 5,569,834; U.S. Patent No. 5,416,011; McCabe *et al.*, *Biotechnology* 6:923 (1988); Christou *et al.*, *Plant Physiol.* 87:671-674 (1988), all of which are herein incorporated by reference in their entirety); *Brassica* (U.S. Patent No. 5,463,174, the entirety of which is herein incorporated by reference); peanut (Cheng *et al.*, *Plant Cell Rep.* 15:653-657 (1996), McKently *et al.*, *Plant Cell Rep.* 14:699-703 (1995), both of which are herein incorporated by reference in their entirety); papaya; pea (Grant *et al.*, *Plant Cell Rep.* 15:254-258 (1995), the entirety of which is herein incorporated by reference); and *Arabidopsis thaliana* (Bechtold *et al.*, *C.R. Acad. Sci. Paris, Life Sci.* 316:1194-1199. (1993), the entirety of which is herein incorporated by reference). The latter

method for transforming *Arabidopsis thaliana* is commonly called "dipping" or vacuum infiltration or germplasm transformation.

Transformation of monocotyledons using electroporation, particle bombardment and *Agrobacterium* have also been reported. Transformation and plant regeneration have been achieved in asparagus (Bytebier *et al.*, *Proc. Natl. Acad. Sci. (USA)* 84:5354 (1987), the entirety of which is herein incorporated by reference); barley (Wan and Lemaux, *Plant Physiol* 104:37 (1994), the entirety of which is herein incorporated by reference); maize (Rhodes *et al.*, *Science* 240:204 (1988); Gordon-Kamm *et al.*, *Plant Cell* 2:603-618 (1990); Fromm *et al.*, *Bio/Technology* 8:833 (1990); Koziel *et al.*, *Bio/Technology* 11:194 (1993); Armstrong *et al.*, *Crop Science* 35:550-557 (1995), all of which are herein incorporated by reference in their entirety); oat (Somers *et al.*, *Bio/Technology* 10:1589 (1992), the entirety of which is herein incorporated by reference); orchard grass (Horn *et al.*, *Plant Cell Rep.* 7:469 (1988), the entirety of which is herein incorporated by reference); rice (Toriyama *et al.*, *Theor Appl. Genet.* 205:34 (1986); Part *et al.*, *Plant Mol. Biol.* 32:1135-1148 (1996); Abedinia *et al.*, *Aust. J. Plant Physiol.* 24:133-141 (1997); Zhang and Wu, *Theor. Appl. Genet.* 76:835 (1988); Zhang *et al.*, *Plant Cell Rep.* 7:379 (1988); Battraw and Hall, *Plant Sci.* 86:191-202 (1992); Christou *et al.*, *Bio/Technology* 9:957 (1991), all of which are herein incorporated by reference in their entirety); rye (De la Pena *et al.*, *Nature* 325:274 (1987), the entirety of which is herein incorporated by reference); sugarcane (Bower and Birch, *Plant J.* 2:409 (1992), the entirety of which is herein incorporated by reference); tall fescue (Wang *et al.*, *Bio/Technology* 10:691 (1992), the entirety of which is herein incorporated by reference) and wheat (Vasil *et al.*, *Bio/Technology* 10:667 (1992); U.S. Patent No. 5,631,152, both of which are herein incorporated by reference in their entirety).

Assays for gene expression based on the transient expression of cloned nucleic acid constructs have been developed by introducing the nucleic acid molecules into plant cells by polyethylene glycol treatment, electroporation, or particle bombardment (Marcotte *et al.*, *Nature* 335:454-457 (1988); Marcotte *et al.*, *Plant Cell* 1:523-532 (1989); McCarty *et al.*, *Cell* 66:895-905 (1991); Hattori *et al.*, *Genes Dev.* 6:609-618 (1992); Goff *et al.*, *EMBO J.* 9:2517-2522 (1990), all of which are herein incorporated by reference in their entirety).

Transient expression systems may be used to functionally dissect gene constructs (*see*

generally, Mailga *et al.*, *Methods in Plant Molecular Biology*, Cold Spring Harbor Press (1995), the entirety of which is herein incorporated by reference).

Any of the nucleic acid molecules of the invention may be introduced into a plant cell in a permanent or transient manner in combination with other genetic elements such as vectors, promoters, enhancers, *etc.* Further, any of the nucleic acid molecules of the invention may be introduced into a plant cell in a manner that allows for expression or overexpression of the protein or fragment thereof encoded by the nucleic acid molecule.

Cosuppression is the reduction in expression levels, usually at the level of RNA, of a particular endogenous gene or gene family by the expression of a homologous sense construct that is capable of transcribing mRNA of the same strandedness as the transcript of the endogenous gene (Napoli *et al.*, *Plant Cell* 2:279-289 (1990); van der Krol *et al.*, *Plant Cell* 2:291-299 (1990), both of which are herein incorporated by reference in their entirety).

Cosuppression may result from stable transformation with a single copy nucleic acid molecule that is homologous to a nucleic acid sequence found with the cell (Prolls and Meyer, *Plant J.* 2:465-475 (1992), the entirety of which is herein incorporated by reference) or with multiple copies of a nucleic acid molecule that is homologous to a nucleic acid sequence found with the cell (Mittlesten *et al.*, *Mol. Gen. Genet.* 244:325-330 (1994)). Genes, even though different, linked to homologous promoters may result in the cosuppression of the linked genes (Vaucheret, *C.R. Acad. Sci. III* 316:1471-1483 (1993); Flavell, *Proc. Natl. Acad. Sci. (U.S.A.)* 91:3490-3496 (1994)); van Blokland *et al.*, *Plant J.* 6:861-877 (1994); Jorgensen, *Trends Biotechnol.* 8:340-344 (1990); Meins and Kunz, In: *Gene Inactivation and Homologous Recombination in Plants*, Paszkowski (ed.), pp. 335-348, Kluwer Academic, Netherlands (1994), all of which are herein incorporated by reference in their entirety).

It is understood that one or more of the nucleic acids of the invention may be introduced into a plant cell and transcribed using an appropriate promoter with such transcription resulting in the cosuppression of an endogenous protein.

Antisense approaches are a way of preventing or reducing gene function by targeting the genetic material (Mol *et al.*, *FEBS Lett.* 268:427-430 (1990), the entirety of which is herein incorporated by reference). The objective of the antisense approach is to use a sequence complementary to the target gene to block its expression and create a mutant cell line

or organism in which the level of a single chosen protein is selectively reduced or abolished. Antisense techniques have several advantages over other 'reverse genetic' approaches. The site of inactivation and its developmental effect can be manipulated by the choice of promoter for antisense genes or by the timing of external application or microinjection. Antisense can
5 manipulate its specificity by selecting either unique regions of the target gene or regions where it shares homology to other related genes (Hiatt *et al.*, In: *Genetic Engineering*, Setlow (ed.), Vol. 11, New York: Plenum 49-63 (1989), the entirety of which is herein incorporated by reference).

The principle of regulation by antisense RNA is that RNA that is complementary to
10 the target mRNA is introduced into cells, resulting in specific RNA:RNA duplexes being formed by base pairing between the antisense substrate and the target mRNA (Green *et al.*, *Annu. Rev. Biochem.* 55:569-597 (1986), the entirety of which is herein incorporated by reference). Under one embodiment, the process involves the introduction and expression of an antisense gene sequence. Such a sequence is one in which part or all of the normal gene se-
15 quences are placed under a promoter in inverted orientation so that the 'wrong' or complementary strand is transcribed into a noncoding antisense RNA that hybridizes with the target mRNA and interferes with its expression (Takayama and Inouye, *Crit. Rev. Biochem. Mol. Biol.* 25:155-184 (1990), the entirety of which is herein incorporated by reference). An antisense vector is constructed by standard procedures and introduced into cells by transfor-
20 mation, transfection, electroporation, microinjection, infection, *etc.* The type of transformation and choice of vector will determine whether expression is transient or stable. The promoter used for the antisense gene may influence the level, timing, tissue, specificity, or inducibility of the antisense inhibition.

It is understood that the activity of a protein in a plant cell may be reduced or
25 depressed by growing a transformed plant cell containing a nucleic acid molecule of the present invention whose non-transcribed strand encodes a protein or fragment thereof.

Posttranscriptional gene silencing (PTGS) can result in virus immunity or gene silencing in plants. PTGS is induced by dsRNA and is mediated by an RNA-dependent RNA polymerase, present in the cytoplasm, that requires a dsRNA template. The dsRNA is formed by
30 hybridization of complementary transgene mRNAs or complementary regions of the same

transcript. Duplex formation can be accomplished by using transcripts from one sense gene and one antisense gene colocated in the plant genome, a single transcript that has self-complementarity, or sense and antisense transcripts from genes brought together by crossing. The dsRNA-dependent RNA polymerase makes a complementary strand from the transgene mRNA and RNase molecules attach to this complementary strand (cRNA). These cRNA-RNase molecules hybridize to the endogene mRNA and cleave the single-stranded RNA adjacent to the hybrid. The cleaved single-stranded RNAs are further degraded by other host RNases because one will lack a capped 5' end and the other will lack a poly(A) tail (Waterhouse *et al.*, *PNAS* 95: 13959-13964 (1998)).

It is understood that one or more of the nucleic acids of the invention may be introduced into a plant cell and transcribed using an appropriate promoter with such transcription resulting in the postranscriptional gene silencing of an endogenous transcript.

Antibodies have been expressed in plants (Hiatt *et al.*, *Nature* 342:76-78 (1989); Conrad and Fielder, *Plant Mol. Biol.* 26:1023-1030 (1994), both of which are herein incorporated by reference in their entirety). Cytoplasmic expression of a scFv (single-chain Fv antibody) has been reported to delay infection by artichoke mottled crinkle virus. Transgenic plants that express antibodies directed against endogenous proteins may exhibit a physiological effect (Philips *et al.*, *EMBO J.* 16:4489-4496 (1997); Marion-Poll, *Trends in Plant Science* 2:447-448 (1997), both of which are herein incorporated by reference in their entirety). For example, expressed anti-abscisic antibodies have been reported to result in a general perturbation of seed development (Philips *et al.*, *EMBO J.* 16: 4489-4496 (1997), the entirety of which is herein incorporated by reference).

Antibodies that are catalytic may also be expressed in plants (abzymes). The principle behind abzymes is that since antibodies may be raised against many molecules, this recognition ability can be directed toward generating antibodies that bind transition states to force a chemical reaction forward (Persidas, *Nature Biotechnology* 15:1313-1315 (1997); Baca *et al.*, *Ann. Rev. Biophys. Biomol. Struct.* 26:461-493 (1997), both of which are herein incorporated by reference in their entirety). The catalytic abilities of abzymes may be enhanced by site directed mutagenesis. Examples of abzymes are, for example, set forth in U.S. Patent No. 5,658,753; U.S. Patent No. 5,632,990; U.S. Patent No. 5,631,137; U.S. Patent

5,602,015; U.S. Patent No. 5,559,538; U.S. Patent No. 5,576,174; U.S. Patent No. 5,500,358; U.S. Patent 5,318,897; U.S. Patent No. 5,298,409; U.S. Patent No. 5,258,289 and U.S. Patent No. 5,194,585, all of which are herein incorporated by reference in their entirety.

It is understood that any of the antibodies of the invention may be expressed in plants and that such expression can result in a physiological effect. It is also understood that any of the expressed antibodies may be catalytic.

The present invention also provides for parts of the plants, particularly reproductive or storage parts, of the present invention. Plant parts, without limitation, include seed, endosperm, ovule and pollen. In a particularly preferred embodiment of the present invention, the plant part is a seed. In one embodiment the seed is a constituent of animal feed. In another embodiment, the plant part is constituent of human diet.

The present invention also provides a container of over 10,000, more preferably 20,000, and even more preferably 40,000 seeds where over 10%, more preferably 25%, more preferably 50% and even more preferably 75% or 90% of the seeds are seeds derived from a plant of the present invention.

The present invention also provides a container of over 10 kg, more preferably 25 kg, and even more preferably 50 kg seeds where over 10%, more preferably 25%, more preferably 50% and even more preferably 75% or 90% of the seeds are seeds derived from a plant of the present invention.

The present invention provides for oil produced from plants of the present invention or generated by a method of the present invention. Such oil may be a minor or major component of any resultant product. Moreover, such oil may be blended with other oils. In a preferred embodiment, the oil produced from plants of the present invention or generated by a method of the present invention constitutes greater than 0.5%, 1%, 5%, 10%, 25%, 50%, 75% or 90% by volume or weight of the oil component of any product. Oil produced from a plant of the present invention can be admixed with one or more organic solvents or petroleum distillates.

Plants of the present invention can be part of or generated from a breeding program. The choice of breeding method depends on the mode of plant reproduction, the heritability of the trait(s) being improved, and the type of cultivar used commercially (e.g., F₁ hybrid

cultivar, pureline cultivar, etc). Selected, non-limiting approaches, for breeding the plants of the present invention are set forth below. A breeding program can be enhanced using marker assisted selection of the progeny of any cross. It is further understood that any commercial and non-commercial cultivars can be utilized in a breeding program. Factors such as, for
5 example, emergence vigor, vegetative vigor, stress tolerance, disease resistance, branching, flowering, seed set, seed size, seed density, standability, and threshability etc. will generally dictate the choice.

For highly heritable traits, a choice of superior individual plants evaluated at a single location will be effective, whereas for traits with low heritability, selection should be based
10 on mean values obtained from replicated evaluations of families of related plants. Popular selection methods commonly include pedigree selection, modified pedigree selection, mass selection, and recurrent selection. In a preferred embodiment a backcross or recurrent breeding program is undertaken.

The complexity of inheritance influences choice of the breeding method. Backcross
15 breeding can be used to transfer one or a few favorable genes for a highly heritable trait into a desirable cultivar. This approach has been used extensively for breeding disease-resistant cultivars. Various recurrent selection techniques are used to improve quantitatively inherited traits controlled by numerous genes. The use of recurrent selection in self-pollinating crops depends on the ease of pollination, the frequency of successful hybrids from each pollination,
20 and the number of hybrid offspring from each successful cross.

Breeding lines can be tested and compared to appropriate standards in environments representative of the commercial target area(s) for two or more generations. The best lines are candidates for new commercial cultivars; those still deficient in traits may be used as parents to produce new populations for further selection.

25 One method of identifying a superior plant is to observe its performance relative to other experimental plants and to a widely grown standard cultivar. If a single observation is inconclusive, replicated observations can provide a better estimate of its genetic worth. A breeder can select and cross two or more parental lines, followed by repeated selfing and selection, producing many new genetic combinations.

The development of new cultivars requires the development and selection of varieties, the crossing of these varieties and the selection of superior hybrid crosses. The hybrid seed can be produced by manual crosses between selected male-fertile parents or by using male sterility systems. Hybrids are selected for certain single gene traits such as pod color, flower color, seed yield, pubescence color, or herbicide resistance, which indicate that the seed is truly a hybrid. Additional data on parental lines, as well as the phenotype of the hybrid, influence the breeder's decision whether to continue with the specific hybrid cross.

Pedigree breeding and recurrent selection breeding methods can be used to develop cultivars from breeding populations. Breeding programs combine desirable traits from two or more cultivars or various broad-based sources into breeding pools from which cultivars are developed by selfing and selection of desired phenotypes. New cultivars can be evaluated to determine which have commercial potential.

Pedigree breeding is used commonly for the improvement of self-pollinating crops. Two parents who possess favorable, complementary traits are crossed to produce an F_1 . An F_2 population is produced by selfing one or several F_1 's. Selection of the best individuals from the best families is carried out. Replicated testing of families can begin in the F_4 generation to improve the effectiveness of selection for traits with low heritability. At an advanced stage of inbreeding (*i.e.*, F_6 and F_7), the best lines or mixtures of phenotypically similar lines are tested for potential release as new cultivars.

Backcross breeding has been used to transfer genes for a simply inherited, highly heritable trait into a desirable homozygous cultivar or inbred line, which is the recurrent parent. The source of the trait to be transferred is called the donor parent. The resulting plant is expected to have the attributes of the recurrent parent (*e.g.*, cultivar) and the desirable trait transferred from the donor parent. After the initial cross, individuals possessing the phenotype of the donor parent are selected and repeatedly crossed (backcrossed) to the recurrent parent. The resulting parent is expected to have the attributes of the recurrent parent (*e.g.*, cultivar) and the desirable trait transferred from the donor parent.

The single-seed descent procedure in the strict sense refers to planting a segregating population, harvesting a sample of one seed per plant, and using the one-seed sample to plant the next generation. When the population has been advanced from the F_2 to the desired level

of inbreeding, the plants from which lines are derived will each trace to different F₂ individuals. The number of plants in a population declines each generation due to failure of some seeds to germinate or some plants to produce at least one seed. As a result, not all of the F₂ plants originally sampled in the population will be represented by a progeny when generation advance is completed.

In a multiple-seed procedure, breeders commonly harvest one or more pods from each plant in a population and thresh them together to form a bulk. Part of the bulk is used to plant the next generation and part is put in reserve. The procedure has been referred to as modified single-seed descent or the pod-bulk technique.

The multiple-seed procedure has been used to save labor at harvest. It is considerably faster to thresh pods with a machine than to remove one seed from each by hand for the single-seed procedure. The multiple-seed procedure also makes it possible to plant the same number of seed of a population each generation of inbreeding.

Descriptions of other breeding methods that are commonly used for different traits and crops can be found in one of several reference books (*e.g.* Fehr, *Principles of Cultivar Development* Vol. 1, pp. 2-3 (1987)), the entirety of which is herein incorporated by reference).

The transgenic plants of the present invention may also be reproduced using apomixis. Apomixis is a genetically controlled method of reproduction in plants where the embryo is formed without union of an egg and a sperm. There are three basic types of apomictic reproduction: 1) apospory where the embryo develops from a chromosomally unreduced egg in an embryo sac derived from the nucellus, 2) diplospory where the embryo develops from an unreduced egg in an embryo sac derived from the megaspore mother cell, and 3) adventitious embryony where the embryo develops directly from a somatic cell. In most forms of apomixis, psuedogamy or fertilization of the polar nuclei to produce endosperm is necessary for seed viability. In apospory, a nurse cultivar can be used as a pollen source for endosperm formation in seeds. The nurse cultivar does not affect the genetics of the aposporous apomictic cultivar since the unreduced egg of the cultivar develops parthenogenetically, but makes possible endosperm production. Apomixis is economically important, especially in transgenic plants, because it causes any genotype, no matter how heterozygous,

to breed true. Thus, with apomictic reproduction, heterozygous transgenic plants can maintain their genetic fidelity throughout repeated life cycles. Methods for the production of apomictic plants are known in the art. See, U.S. Patent No. 5,811,636, which is herein incorporated by reference in its entirety.

(d) Other Organisms

A nucleic acid of the present invention may be introduced into any cell or organism such as a mammalian cell, mammal, fish cell, fish, bird cell, bird, algae cell, algae, fungal cell, fungi, or bacterial cell. A protein of the present invention may be produced in an appropriate cell or organism. Preferred hosts and transformants include: fungal cells such as *Aspergillus*, yeasts, mammals, particularly bovine and porcine, insects, bacteria and algae. Methods to transform such cells or organisms are known in the art (EP 0 238 023; Yelton *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)*, 81:1470-1474 (1984); Malardier *et al.*, *Gene*, 78:147-156 (1989); Becker and Guarente, In: Abelson and Simon (eds.), *Guide to Yeast Genetics and Molecular Biology, Methods Enzymol.*, Vol. 194, pp. 182-187, Academic Press, Inc., New York; Ito *et al.*, *J. Bacteriology*, 153:163 (1983); Hinnen *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)*, 75:1920 (1978); Bennett and LaSure (eds.), *More Gene Manipulations in Fungi*, Academic Press, CA (1991), all of which are herein incorporated by reference in their entirety). Methods to produce proteins of the present invention are also known (Kudla *et al.*, *EMBO*, 9:1355-1364 (1990); Jarai and Buxton, *Current Genetics*, 26:2238-2244 (1994); Verdier, *Yeast*, 6:271-297 (1990); MacKenzie *et al.*, *Journal of Gen. Microbiol.*, 139:2295-2307 (1993); Hartl *et al.*, *TIBS*, 19:20-25 (1994); Bergeron *et al.*, *TIBS*, 19:124-128 (1994); Demolder *et al.*, *J. Biotechnology*, 32:179-189 (1994); Craig, *Science*, 260:1902-1903 (1993); Gething and Sambrook, *Nature*, 355:33-45 (1992); Puig and Gilbert, *J. Biol. Chem.*, 269:7764-7771 (1994); Wang and Tsou, *FASEB Journal*, 7:1515-1517 (1993); Robinson *et al.*, *Bio/Technology*, 1:381-384 (1994); Enderlin and Ogrydziak, *Yeast*, 10:67-79 (1994); Fuller *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)*, 86:1434-1438 (1989); Julius *et al.*, *Cell*, 37:1075-1089 (1984); Julius *et al.*, *Cell*, 32:839-852 (1983), all of which are herein incorporated by reference in their entirety).

(e) **Antibodies**

One aspect of the invention concerns antibodies, single-chain antigen binding molecules, or other proteins that specifically bind to one or more of the protein or peptide molecules of the invention and their homologs, fusions or fragments. In a particularly preferred embodiment, the antibody specifically binds to a protein having the amino acid sequence set forth in SEQ ID Nos: 30, 31, 32, or 33. Such antibodies may be used to quantitatively or qualitatively detect the protein or peptide molecules of the invention. As used herein, an antibody or peptide is said to "specifically bind" to a protein or peptide molecule of the invention if such binding is not competitively inhibited by the presence of non-related molecules.

Nucleic acid molecules that encode all or part of the protein of the invention can be expressed, via recombinant means, to yield protein or peptides that can in turn be used to elicit antibodies that are capable of binding the expressed protein or peptide. Such antibodies may be used in immunoassays for that protein. Such protein-encoding molecules, or their fragments may be a "fusion" molecule (*i.e.*, a part of a larger nucleic acid molecule) such that, upon expression, a fusion protein is produced. It is understood that any of the nucleic acid molecules of the invention may be expressed, via recombinant means, to yield proteins or peptides encoded by these nucleic acid molecules.

The antibodies that specifically bind proteins and protein fragments of the invention may be polyclonal or monoclonal and may comprise intact immunoglobulins, or antigen binding portions of immunoglobulins fragments (such as (F(ab'), F(ab')₂), or single-chain immunoglobulins producible, for example, via recombinant means. It is understood that practitioners are familiar with the standard resource materials which describe specific conditions and procedures for the construction, manipulation and isolation of antibodies (*see*, for example, Harlow and Lane, In: *Antibodies: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1988), the entirety of which is herein incorporated by reference).

As discussed below, such antibody molecules or their fragments may be used for diagnostic purposes. Where the antibodies are intended for diagnostic purposes, it may be desirable to derivatize them, for example with a ligand group (such as biotin) or a detectable marker group (such as a fluorescent group, a radioisotope or an enzyme).

The ability to produce antibodies that bind the protein or peptide molecules of the invention permits the identification of mimetic compounds derived from those molecules. These mimetic compounds may contain a fragment of the protein or peptide or merely a structurally similar region and nonetheless exhibits an ability to specifically bind to anti-

5 bodies directed against that compound.

Exemplary Uses

Nucleic acid molecules and fragments thereof of the invention may be employed to obtain other nucleic acid molecules from the same species (nucleic acid molecules from maize may be utilized to obtain other nucleic acid molecules from maize). Such nucleic acid

10 molecules include the nucleic acid molecules that encode the complete coding sequence of a protein and promoters and flanking sequences of such molecules. In addition, such nucleic acid molecules include nucleic acid molecules that encode for other isozymes or gene family members. Such molecules can be readily obtained by using the above-described nucleic acid molecules or fragments thereof to screen cDNA or genomic libraries. Methods for forming

15 such libraries are well known in the art.

Nucleic acid molecules and fragments thereof of the invention may also be employed to obtain nucleic acid homologs. Such homologs include the nucleic acid molecule of other plants or other organisms (*e.g.*, alfalfa, *Arabidopsis*, barley, *Brassica*, broccoli, cabbage, citrus, cotton, garlic, oat, oilseed rape, onion, canola, flax, an ornamental plant, pea, peanut,

20 pepper, potato, rice, rye, sorghum, strawberry, sugarcane, sugarbeet, tomato, wheat, poplar, pine, fir, eucalyptus, apple, lettuce, lentils, grape, banana, tea, turf grasses, sunflower, oil palm, *Phaseolus*, etc.) including the nucleic acid molecules that encode, in whole or in part, protein homologs of other plant species or other organisms, sequences of genetic elements, such as promoters and transcriptional regulatory elements. Particularly preferred plants are

25 selected from the group consisting of maize, canola, soybean, crambe, mustard, castor bean, peanut, sesame, cottonseed, linseed, safflower, oil palm, flax and sunflower.

Such molecules can be readily obtained by using the above-described nucleic acid molecules or fragments thereof to screen cDNA or genomic libraries obtained from such plant species. Methods for forming such libraries are well known in the art. Such homolog

30 molecules may differ in their nucleotide sequences from those found in one or more of SEQ

ID NOs: 1-4, 6-29 or complements thereof because complete complementarity is not needed for stable hybridization. The nucleic acid molecules of the invention therefore also include molecules that, although capable of specifically hybridizing with the nucleic acid molecules may lack "complete complementarity."

5 Any of a variety of methods may be used to obtain one or more of the above-described nucleic acid molecules (Zamechik *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 83:4143-4146 (1986); Goodchild *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 85:5507-5511 (1988); Wickstrom *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 85:1028-1032 (1988); Holt *et al.*, *Molec. Cell Biol.* 8:963-973 (1988); Gerwitz *et al.*, *Science* 242:1303-1306 (1988); Anfossi *et al.*, *Proc.*
10 *Natl. Acad. Sci. (U.S.A.)* 86:3379-3383 (1989); Becker *et al.*, *EMBO J.* 8:3685-3691 (1989)). Automated nucleic acid synthesizers may be employed for this purpose. In lieu of such synthesis, the disclosed nucleic acid molecules may be used to define a pair of primers that can be used with the polymerase chain reaction (Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 51:263-273 (1986); Erlich *et al.*, European Patent 50,424; European Patent 84,796;
15 European Patent 258,017; European Patent 237,362; Mullis, European Patent 201,184; Mullis *et al.*, U.S. Patent 4,683,202; Erlich, U.S. Patent 4,582,788; and Saiki *et al.*, U.S. Patent 4,683,194) to amplify and obtain any desired nucleic acid molecule or fragment.

Promoter sequences and other genetic elements, including but not limited to transcriptional regulatory flanking sequences, associated with one or more of the disclosed nucleic
20 acid sequences can also be obtained using the disclosed nucleic acid sequence provided herein. In one embodiment, such sequences are obtained by incubating nucleic acid molecules of the present invention with members of genomic libraries and recovering clones that hybridize to such nucleic acid molecules thereof. In a second embodiment, methods of
"chromosome walking," or inverse PCR may be used to obtain such sequences (Frohman *et*
25 *al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 85:8998-9002 (1988); Ohara *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 86:5673-5677 (1989); Pang *et al.*, *Biotechniques* 22:1046-1048 (1977); Huang *et al.*, *Methods Mol. Biol.* 69:89-96 (1997); Huang *et al.*, *Method Mol. Biol.* 67:287-294 (1997); Benkel *et al.*, *Genet. Anal.* 13:123-127 (1996); Hartl *et al.*, *Methods Mol. Biol.* 58:293-301 (1996)). The term "chromosome walking" means a process of extending a genetic map by
30 successive hybridization steps.

The nucleic acid molecules of the invention may be used to isolate promoters of cell enhanced, cell specific, tissue enhanced, tissue specific, developmentally or environmentally regulated expression profiles. Isolation and functional analysis of the 5' flanking promoter sequences of these genes from genomic libraries, for example, using genomic screening methods and PCR techniques would result in the isolation of useful promoters and transcriptional regulatory elements. These methods are known to those of skill in the art and have been described (See, for example, Birren *et al.*, *Genome Analysis: Analyzing DNA*, 1, (1997), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Promoters obtained utilizing the nucleic acid molecules of the invention could also be modified to affect their control characteristics. Examples of such modifications would include but are not limited to enhancer sequences. Such genetic elements could be used to enhance gene expression of new and existing traits for crop improvement.

Another subset of the nucleic acid molecules of the invention includes nucleic acid molecules that are markers. The markers can be used in a number of conventional ways in the field of molecular genetics. Such markers include nucleic acid molecules SEQ ID NOs: 1-4, 6-29 or complements thereof or fragments of either that can act as markers and other nucleic acid molecules of the present invention that can act as markers.

Genetic markers of the invention include "dominant" or "codominant" markers. "Codominant markers" reveal the presence of two or more alleles (two per diploid individual) at a locus. "Dominant markers" reveal the presence of only a single allele per locus. The presence of the dominant marker phenotype (e.g., a band of DNA) is an indication that one allele is in either the homozygous or heterozygous condition. The absence of the dominant marker phenotype (e.g., absence of a DNA band) is merely evidence that "some other" undefined allele is present. In the case of populations where individuals are predominantly homozygous and loci are predominately dimorphic, dominant and codominant markers can be equally valuable. As populations become more heterozygous and multi-allelic, codominant markers often become more informative of the genotype than dominant markers. Marker molecules can be, for example, capable of detecting polymorphisms such as single nucleotide polymorphisms (SNPs).

The genomes of animals and plants naturally undergo spontaneous mutation in the course of their continuing evolution (Gusella, *Ann. Rev. Biochem.* 55:831-854 (1986)). A "polymorphism" is a variation or difference in the sequence of the gene or its flanking regions that arises in some of the members of a species. The variant sequence and the "original" sequence co-exist in the species' population. In some instances, such co-existence is in stable or quasi-stable equilibrium.

A polymorphism is thus said to be "allelic," in that, due to the existence of the polymorphism, some members of a species may have the original sequence (i.e., the original "allele") whereas other members may have the variant sequence (i.e., the variant "allele"). In the simplest case, only one variant sequence may exist and the polymorphism is thus said to be di-allelic. In other cases, the species' population may contain multiple alleles and the polymorphism is termed tri-allelic, etc. A single gene may have multiple different unrelated polymorphisms. For example, it may have a di-allelic polymorphism at one site and a multi-allelic polymorphism at another site.

The variation that defines the polymorphism may range from a single nucleotide variation to the insertion or deletion of extended regions within a gene. In some cases, the DNA sequence variations are in regions of the genome that are characterized by short tandem repeats (STRs) that include tandem di- or tri-nucleotide repeated motifs of nucleotides. Polymorphisms characterized by such tandem repeats are referred to as "variable number tandem repeat" ("VNTR") polymorphisms. VNTRs have been used in identity analysis (Weber, U.S. Patent 5,075,217; Armour *et al.*, *FEBS Lett.* 307:113-115 (1992); Jones *et al.*, *Eur. J. Haematol.* 39:144-147 (1987); Horn *et al.*, PCT Patent Application WO91/14003; Jeffreys, European Patent Application 370,719; Jeffreys, U.S. Patent 5,175,082; Jeffreys *et al.*, *Amer. J. Hum. Genet.* 39:11-24 (1986); Jeffreys *et al.*, *Nature* 316:76-79 (1985); Gray *et al.*, *Proc. R. Acad. Soc. Lond.* 243:241-253 (1991); Moore *et al.*, *Genomics* 10:654-660 (1991); Jeffreys *et al.*, *Anim. Genet.* 18:1-15 (1987); Hillel *et al.*, *Anim. Genet.* 20:145-155 (1989); Hillel *et al.*, *Genet.* 124:783-789 (1990)).

The detection of polymorphic sites in a sample of DNA may be facilitated through the use of nucleic acid amplification methods. Such methods specifically increase the concentration of polynucleotides that span the polymorphic site, or include that site and sequences

located either distal or proximal to it. Such amplified molecules can be readily detected by gel electrophoresis or other means.

In an alternative embodiment, such polymorphisms can be detected through the use of a marker nucleic acid molecule that is physically linked to such polymorphism(s). For this purpose, marker nucleic acid molecules comprising a nucleotide sequence of a polynucleotide located within 1 mb of the polymorphism(s) and more preferably within 100kb of the polymorphism(s) and most preferably within 10kb of the polymorphism(s) can be employed.

The identification of a polymorphism can be determined in a variety of ways. By correlating the presence or absence of it in a plant with the presence or absence of a phenotype, it is possible to predict the phenotype of that plant. If a polymorphism creates or destroys a restriction endonuclease cleavage site, or if it results in the loss or insertion of DNA (e.g., a VNTR polymorphism), it will alter the size or profile of the DNA fragments that are generated by digestion with that restriction endonuclease. As such, organisms that possess a variant sequence can be distinguished from those having the original sequence by restriction fragment analysis. Polymorphisms that can be identified in this manner are termed "restriction fragment length polymorphisms" ("RFLPs") (Glassberg, UK Patent Application 2135774; Skolnick *et al.*, *Cytogen. Cell Genet.* 32:58-67 (1982); Botstein *et al.*, *Ann. J. Hum. Genet.* 32:314-331 (1980); Fischer *et al.*, (PCT Application WO90/13668; Uhlen, PCT Application WO90/11369).

Polymorphisms can also be identified by Single Strand Conformation Polymorphism (SSCP) analysis (Elles, *Methods in Molecular Medicine: Molecular Diagnosis of Genetic Diseases*, Humana Press (1996)); Orita *et al.*, *Genomics* 5:874-879 (1989)). A number of protocols have been described for SSCP including, but not limited to, Lee *et al.*, *Anal. Biochem.* 205:289-293 (1992); Suzuki *et al.*, *Anal. Biochem.* 192:82-84 (1991); Lo *et al.*, *Nucleic Acids Research* 20:1005-1009 (1992); Sarkar *et al.*, *Genomics* 13:441-443 (1992). It is understood that one or more of the nucleic acids of the invention, may be utilized as markers or probes to detect polymorphisms by SSCP analysis.

Polymorphisms may also be found using a DNA fingerprinting technique called amplified fragment length polymorphism (AFLP), which is based on the selective PCR amplification of restriction fragments from a total digest of genomic DNA to profile that DNA (Vos

et al., *Nucleic Acids Res.* 23:4407-4414 (1995)). This method allows for the specific co-amplification of high numbers of restriction fragments, which can be visualized by PCR without knowledge of the nucleic acid sequence. It is understood that one or more of the nucleic acids of the invention may be utilized as markers or probes to detect polymorphisms by AFLP analysis or for fingerprinting RNA.

Polymorphisms may also be found using random amplified polymorphic DNA (RAPD) (Williams *et al.*, *Nucl. Acids Res.* 18:6531-6535 (1990)) and cleaveable amplified polymorphic sequences (CAPS) (Lyamichev *et al.*, *Science* 260:778-783 (1993)). It is understood that one or more of the nucleic acid molecules of the invention, may be utilized as markers or probes to detect polymorphisms by RAPD or CAPS analysis.

Single Nucleotide Polymorphisms (SNPs) generally occur at greater frequency than other polymorphic markers and are spaced with a greater uniformity throughout a genome than other reported forms of polymorphism. The greater frequency and uniformity of SNPs means that there is greater probability that such a polymorphism will be found near or in a genetic locus of interest than would be the case for other polymorphisms. SNPs are located in protein-coding regions and noncoding regions of a genome. Some of these SNPs may result in defective or variant protein expression (*e.g.*, as a result of mutations or defective splicing). Analysis (genotyping) of characterized SNPs can require only a plus/minus assay rather than a lengthy measurement, permitting easier automation.

SNPs can be characterized using any of a variety of methods. Such methods include the direct or indirect sequencing of the site, the use of restriction enzymes (Botstein *et al.*, *Am. J. Hum. Genet.* 32:314-331 (1980), the entirety of which is herein incorporated reference; Konieczny and Ausubel, *Plant J.* 4:403-410 (1993), the entirety of which is herein incorporated by reference), enzymatic and chemical mismatch assays (Myers *et al.*, *Nature* 313:495-498 (1985), the entirety of which is herein incorporated by reference), allele-specific PCR (Newton *et al.*, *Nucl. Acids Res.* 17:2503-2516 (1989), the entirety of which is herein incorporated by reference; Wu *et al.*, *Proc. Natl. Acad. Sci. USA* 86:2757-2760 (1989), the entirety of which is herein incorporated by reference), ligase chain reaction (Barany, *Proc. Natl. Acad. Sci. USA* 88:189-193 (1991), the entirety of which is herein incorporated by reference), single-strand conformation polymorphism analysis (Labrune *et al.*, *Am. J. Hum.*

Genet. 48: 1115-1120 (1991), the entirety of which is herein incorporated by reference),
 single base primer extension (Kuppuswamy *et al.*, *Proc. Natl. Acad. Sci. USA* 88:1143-1147
 (1991), Goelet US 6,004,744; Goelet 5,888,819; all of which are herein incorporated by
 reference in their entirety), solid-phase ELISA-based oligonucleotide ligation assays (Niki-
 5 forov *et al.*, *Nucl. Acids Res.* 22:4167-4175 (1994), dideoxy fingerprinting (Sarkar *et al.*,
Genomics 13:441-443 (1992), the entirety of which is herein incorporated by reference),
 oligonucleotide fluorescence-quenching assays (Livak *et al.*, *PCR Methods Appl.* 4:357-362
 (1995a), the entirety of which is herein incorporated by reference), 5'-nuclease allele-specific
 hybridization TaqMan™ assay (Livak *et al.*, *Nature Genet.* 9:341-342 (1995), the entirety of
 10 which is herein incorporated by reference), template-directed dye-terminator incorporation
 (TDI) assay (Chen and Kwok, *Nucl. Acids Res.* 25:347-353 (1997), the entirety of which is
 herein incorporated by reference), allele-specific molecular beacon assay (Tyagi *et al.*,
Nature Biotech. 16: 49-53 (1998), the entirety of which is herein incorporated by reference),
 PinPoint assay (Haff and Smirnov, *Genome Res.* 7: 378-388 (1997), the entirety of which is
 15 herein incorporated by reference), dCAPS analysis (Neff *et al.*, *Plant J.* 14:387-392 (1998),
 the entirety of which is herein incorporated by reference), pyrosequencing (Ronaghi *et al.*,
Analytical Biochemistry 267:65-71 (1999); Ronaghi *et al* PCT application WO 98/13523;
 Nyren *et al* PCT application WO 98/28440, all of which are herein incorporated by reference
 in their entirety; <http://www.pyrosequencing.com>), using mass spectrometry, *e.g.* the Mass-
 20 code™ system (Howbert *et al* WO 99/05319; Howber *et al* WO 97/27331, all of which are
 herein incorporated by reference in their entirety; <http://www.rapigene.com>; Becker *et al* PCT
 application WO 98/26095; Becker *et al* PCT application; WO 98/12355; Becker *et al* PCT
 application WO 97/33000; Monforte *et al* US 5,965,363, all of which are herein incorporated
 by reference in their entirety), invasive cleavage of oligonucleotide probes (Lyamichev *et al*
 25 *Nature Biotechnology* 17:292-296, herein incorporated by reference in its entirety;
<http://www.twt.com>), and using high density oligonucleotide arrays (Hacia *et al* *Nature*
Genetics 22:164-167; herein incorporated by reference in its entirety;
<http://www.affymetrix.com>).

Polymorphisms may also be detected using allele-specific oligonucleotides (ASO),
 30 which, can be for example, used in combination with hybridization based technology

including southern, northern, and dot blot hybridizations, reverse dot blot hybridizations and hybridizations performed on microarray and related technology.

The stringency of hybridization for polymorphism detection is highly dependent upon a variety of factors, including length of the allele-specific oligonucleotide, sequence composition, degree of complementarity (*i.e.* presence or absence of base mismatches), concentration of salts and other factors such as formamide, and temperature. These factors are important both during the hybridization itself and during subsequent washes performed to remove target polynucleotide that is not specifically hybridized. In practice, the conditions of the final, most stringent wash are most critical. In addition, the amount of target polynucleotide that is able to hybridize to the allele-specific oligonucleotide is also governed by such factors as the concentration of both the ASO and the target polynucleotide, the presence and concentration of factors that act to "tie up" water molecules, so as to effectively concentrate the reagents (*e.g.*, PEG, dextran, dextran sulfate, *etc.*), whether the nucleic acids are immobilized or in solution, and the duration of hybridization and washing steps.

Hybridizations are preferably performed below the melting temperature (T_m) of the ASO. The closer the hybridization and/or washing step is to the T_m , the higher the stringency. T_m for an oligonucleotide may be approximated, for example, according to the following formula: $T_m = 81.5 + 16.6 \times (\log_{10}[\text{Na}^+]) + 0.41 \times (\%G+C) - 675/n$; where $[\text{Na}^+]$ is the molar salt concentration of Na^+ or any other suitable cation and n = number of bases in the oligonucleotide. Other formulas for approximating T_m are available and are known to those of ordinary skill in the art.

Stringency is preferably adjusted so as to allow a given ASO to differentially hybridize to a target polynucleotide of the correct allele and a target polynucleotide of the incorrect allele. Preferably, there will be at least a two-fold differential between the signal produced by the ASO hybridizing to a target polynucleotide of the correct allele and the level of the signal produced by the ASO cross-hybridizing to a target polynucleotide of the incorrect allele (*e.g.*, an ASO specific for a mutant allele cross-hybridizing to a wild-type allele). In more preferred embodiments of the present invention, there is at least a five-fold signal differential. In highly preferred embodiments of the present invention, there is at least an order of magnitude signal differential between the ASO hybridizing to a target polynucleotide of

the correct allele and the level of the signal produced by the ASO cross-hybridizing to a target polynucleotide of the incorrect allele.

While certain methods for detecting polymorphisms are described herein, other detection methodologies may be utilized. For example, additional methodologies are known and set forth, in Birren *et al.*, *Genome Analysis*, 4:135-186, *A Laboratory Manual. Mapping Genomes*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1999); Maliga *et al.*, *Methods in Plant Molecular Biology. A Laboratory Course Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1995); Paterson, *Biotechnology Intelligence Unit: Genome Mapping in Plants*, R.G. Landes Co., Georgetown, TX, and Academic Press, San Diego, CA (1996); *The Maize Handbook*, Freeling and Walbot, eds., Springer-Verlag, New York, NY (1994); *Methods in Molecular Medicine: Molecular Diagnosis of Genetic Diseases*, Elles, ed., Humana Press, Totowa, NJ (1996); Clark, ed., *Plant Molecular Biology: A Laboratory Manual*, Clark, ed., Springer-Verlag, Berlin, Germany (1997), all of which are herein incorporated by reference in their entirety.

Requirements for marker-assisted selection in a plant breeding program are: (1) the marker(s) should co-segregate or be closely linked with the desired trait; (2) an efficient means of screening large populations for the molecular marker(s) should be available; and (3) the screening technique should have high reproducibility across laboratories and preferably be economical to use and be user-friendly.

The genetic linkage of marker molecules can be established by a gene mapping model such as, without limitation, the flanking marker model reported by Lander and Botstein, *Genetics* 121:185-199 (1989) and the interval mapping, based on maximum likelihood methods described by Lander and Botstein, *Genetics* 121:185-199 (1989) and implemented in the software package MAPMAKER/QTL (Lincoln and Lander, *Mapping Genes Controlling Quantitative Traits Using MAPMAKER/QTL*, Whitehead Institute for Biomedical Research, Massachusetts, (1990). Additional software includes Qgene, Version 2.23 (1996), Department of Plant Breeding and Biometry, 266 Emerson Hall, Cornell University, Ithaca, NY). Use of Qgene software is a particularly preferred approach.

A maximum likelihood estimate (MLE) for the presence of a marker is calculated, together with an MLE assuming no QTL effect, to avoid false positives. A log₁₀ of an odds

ratio (LOD) is then calculated as: $LOD = \log_{10} (MLE \text{ for the presence of a QTL} / MLE \text{ given no linked QTL})$.

The LOD score essentially indicates how much more likely the data are to have arisen assuming the presence of a QTL than in its absence. The LOD threshold value for avoiding a false positive with a given confidence, say 95%, depends on the number of markers and the length of the genome. Graphs indicating LOD thresholds are set forth in Lander and Botstein, *Genetics* 121:185-199 (1989) and further described by Arús and Moreno-González, *Plant Breeding*, Hayward *et al.*, (eds.) Chapman & Hall, London, pp. 314-331 (1993).

In a preferred embodiment of the present invention the nucleic acid marker exhibits a LOD score of greater than 2.0, more preferably 2.5, even more preferably greater than 3.0 or 4.0 with the trait or phenotype of interest. In a preferred embodiment, the trait of interest is altered, preferably increased phytosterol levels or compositions.

Additional models can be used. Many modifications and alternative approaches to interval mapping have been reported, including the use non-parametric methods (Kruglyak and Lander, *Genetics* 139:1421-1428 (1995)). Multiple regression methods or models can be also be used, in which the trait is regressed on a large number of markers (Jansen, *Biometrics in Plant Breeding*, van Oijen and Jansen (eds.), Proceedings of the Ninth Meeting of the Eucarpia Section Biometrics in Plant Breeding, The Netherlands, pp. 116-124 (1994); Weber and Wricke, *Advances in Plant Breeding*, Blackwell, Berlin, 16 (1994)). Procedures combining interval mapping with regression analysis, whereby the phenotype is regressed onto a single putative QTL at a given marker interval and at the same time onto a number of markers that serve as 'cofactors,' have been reported by Jansen and Stam, *Genetics* 136:1447-1455 (1994), and Zeng, *Genetics* 136:1457-1468 (1994). Generally, the use of cofactors reduces the bias and sampling error of the estimated QTL positions (Utz and Melchinger, *Biometrics in Plant Breeding*, van Oijen and Jansen (eds.) Proceedings of the Ninth Meeting of the Eucarpia Section Biometrics in Plant Breeding, The Netherlands, pp.195-204 (1994), thereby improving the precision and efficiency of QTL mapping (Zeng, *Genetics* 136:1457-1468 (1994), herein incorporated by reference in its entirety). These models can be extended to multi-environment experiments to analyze genotype-environment interactions (Jansen *et al.*, *Theo. Appl. Genet.* 91:33-37 (1995), herein incorporated by reference in its entirety).

It is understood that one or more of the nucleic acid molecules of the invention may be used as molecular markers. It is also understood that one or more of the protein molecules of the invention may be used as molecular markers.

In a preferred embodiment, the polymorphism is present and screened for in a mapping population, *e.g.* a collection of plants capable of being used with markers such as polymorphic markers to map genetic position of traits. The choice of appropriate mapping population often depends on the type of marker systems employed (Tanksley *et al.*, *J.P. Gustafson and R. Appels* (eds.). Plenum Press, New York, pp. 157-173 (1988), the entirety of which is herein incorporated by reference). Consideration must be given to the source of parents (adapted vs. exotic) used in the mapping population. Chromosome pairing and recombination rates can be severely disturbed (suppressed) in wide crosses (adapted x exotic) and generally yield greatly reduced linkage distances. Wide crosses will usually provide segregating populations with a relatively large number of polymorphisms when compared to progeny in a narrow cross (adapted x adapted).

An F_2 population is the first generation of selfing (self-pollinating) after the hybrid seed is produced. Usually a single F_1 plant is selfed to generate a population segregating for all the genes in Mendelian (1:2:1) pattern. Maximum genetic information is obtained from a completely classified F_2 population using a codominant marker system (Mather, *Measurement of Linkage in Heredity*: Methuen and Co., (1938), the entirety of which is herein incorporated by reference). In the case of dominant markers, progeny tests (*e.g.*, F_3 , BCF_2) are required to identify the heterozygotes, in order to classify the population. However, this procedure is often prohibitive because of the cost and time involved in progeny testing. Progeny testing of F_2 individuals is often used in map construction where phenotypes do not consistently reflect genotype (*e.g.* disease resistance) or where trait expression is controlled by a QTL. Segregation data from progeny test populations *e.g.* F_3 or BCF_2) can be used in map construction. Marker-assisted selection can then be applied to cross progeny based on marker-trait map associations (F_2 , F_3), where linkage groups have not been completely dissociated by recombination events (*i.e.*, maximum disequilibrium).

Recombinant inbred lines (RIL) (genetically related lines; usually $>F_5$, developed from continuously selfing F_2 lines towards homozygosity) can be used as a mapping popu-

lation. Information obtained from dominant markers can be maximized by using RIL because all loci are homozygous or nearly so. Under conditions of tight linkage (*i.e.*, about <10% recombination), dominant and co-dominant markers evaluated in RIL populations provide more information per individual than either marker type in backcross populations (Reiter. *Proc. Natl. Acad. Sci. (U.S.A.)* 89:1477-1481 (1992), the entirety of which is herein incorporated by reference). However, as the distance between markers becomes larger (*i.e.*, loci become more independent), the information in RIL populations decreases dramatically when compared to codominant markers.

Backcross populations (*e.g.*, generated from a cross between a successful variety (recurrent parent) and another variety (donor parent) carrying a trait not present in the former) can be utilized as a mapping population. A series of backcrosses to the recurrent parent can be made to recover most of its desirable traits. Thus a population is created consisting of individuals nearly like the recurrent parent but each individual carries varying amounts or mosaic of genomic regions from the donor parent. Backcross populations can be useful for mapping dominant markers if all loci in the recurrent parent are homozygous and the donor and recurrent parent have contrasting polymorphic marker alleles (Reiter *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 89:1477-1481 (1992), the entirety of which is herein incorporated by reference). Information obtained from backcross populations using either codominant or dominant markers is less than that obtained from F₂ populations because one, rather than two, recombinant gamete is sampled per plant. Backcross populations, however, are more informative (at low marker saturation) when compared to RILs as the distance between linked loci increases in RIL populations (*i.e.* about .15% recombination). Increased recombination can be beneficial for resolution of tight linkages, but may be undesirable in the construction of maps with low marker saturation.

Near-isogenic lines (NIL) (created by many backcrosses to produce a collection of individuals that is nearly identical in genetic composition except for the trait or genomic region under interrogation) can be used as a mapping population. In mapping with NILs, only a portion of the polymorphic loci is expected to map to a selected region.

Bulk segregant analysis (BSA) is a method developed for the rapid identification of linkage between markers and traits of interest (Michelmore *et al.*, *Proc. Natl. Acad. Sci.*

U.S.A. 88:9828-9832 (1991), the entirety of which is herein incorporated by reference). In BSA, two bulked DNA samples are drawn from a segregating population originating from a single cross. These bulks contain individuals that are identical for a particular trait (resistant or susceptible to particular disease) or genomic region but arbitrary at unlinked regions (*i.e.* heterozygous). Regions unlinked to the target region will not differ between the bulked samples of many individuals in BSA.

In an aspect of the present invention, one or more of the nucleic molecules of the present invention are used to determine the level (*i.e.*, the concentration of mRNA in a sample, *etc.*) in a plant (preferably maize, canola, soybean, crambe, mustard, castor bean, peanut, sesame, cottonseed, linseed, safflower, oil palm, flax or sunflower) or pattern (*i.e.*, the kinetics of expression, rate of decomposition, stability profile, *etc.*) of the expression of a protein encoded in part or whole by one or more of the nucleic acid molecule of the present invention (collectively, the "Expression Response" of a cell or tissue).

As used herein, the Expression Response manifested by a cell or tissue is said to be "altered" if it differs from the Expression Response of cells or tissues of plants not exhibiting the phenotype. To determine whether a Expression Response is altered, the Expression Response manifested by the cell or tissue of the plant exhibiting the phenotype is compared with that of a similar cell or tissue sample of a plant not exhibiting the phenotype. As will be appreciated, it is not necessary to re-determine the Expression Response of the cell or tissue sample of plants not exhibiting the phenotype each time such a comparison is made; rather, the Expression Response of a particular plant may be compared with previously obtained values of normal plants. As used herein, the phenotype of the organism is any of one or more characteristics of an organism (*e.g.* disease resistance, pest tolerance, environmental tolerance such as tolerance to abiotic stress, male sterility, quality improvement or yield *etc.*). A change in genotype or phenotype may be transient or permanent. Also as used herein, a tissue sample is any sample that comprises more than one cell. In a preferred aspect, a tissue sample comprises cells that share a common characteristic (*e.g.* derived from root, seed, flower, leaf, stem or pollen *etc.*).

In one aspect of the present invention, an evaluation can be conducted to determine whether a particular mRNA molecule is present. One or more of the nucleic acid molecules

of the present invention are utilized to detect the presence or quantity of the mRNA species. Such molecules are then incubated with cell or tissue extracts of a plant under conditions sufficient to permit nucleic acid hybridization. The detection of double-stranded probe-mRNA hybrid molecules is indicative of the presence of the mRNA; the amount of such hybrid formed is proportional to the amount of mRNA. Thus, such probes may be used to ascertain the level and extent of the mRNA production in a plant's cells or tissues. Such nucleic acid hybridization may be conducted under quantitative conditions (thereby providing a numerical value of the amount of the mRNA present). Alternatively, the assay may be conducted as a qualitative assay that indicates either that the mRNA is present, or that its level exceeds a user set, predefined value.

A number of methods can be used to compare the expression response between two or more samples of cells or tissue. These methods include hybridization assays, such as north-erns, RNase protection assays, and *in situ* hybridization. Alternatively, the methods include PCR-type assays. In a preferred method, the expression response is compared by hybridizing nucleic acids from the two or more samples to an array of nucleic acids. The array contains a plurality of suspected sequences known or suspected of being present in the cells or tissue of the samples.

An advantage of *in situ* hybridization over more conventional techniques for the detection of nucleic acids is that it allows an investigator to determine the precise spatial population (Angerer *et al.*, *Dev. Biol.* 101:477-484 (1984); Angerer *et al.*, *Dev. Biol.* 112:157-166 (1985); Dixon *et al.*, *EMBO J.* 10:1317-1324 (1991)). *In situ* hybridization may be used to measure the steady-state level of RNA accumulation (Hardin *et al.*, *J. Mol. Biol.* 202:417-431 (1989)). A number of protocols have been devised for *in situ* hybridization, each with tissue preparation, hybridization and washing conditions (Meyerowitz, *Plant Mol. Biol. Rep.* 5:242-250 (1987); Cox and Goldberg, In: *Plant Molecular Biology: A Practical Approach*, Shaw (ed.), pp. 1-35, IRL Press, Oxford (1988); Raïkhel *et al.*, *In situ RNA hybridization in plant tissues*, In: *Plant Molecular Biology Manual*, vol. B9:1-32, Kluwer Academic Publisher, Dordrecht, Belgium (1989)).

In situ hybridization also allows for the localization of proteins within a tissue or cell (Wilkinson, *In Situ Hybridization*, Oxford University Press, Oxford (1992); Langdale, *In Situ*

Hybridization In: *The Maize Handbook*, Freeling and Walbot (eds.), pp. 165-179, Springer-Verlag, New York (1994)). It is understood that one or more of the molecules of the invention, preferably one or more of the nucleic acid molecules or fragments thereof of the invention or one or more of the antibodies of the invention may be utilized to detect the level or

5 pattern of a protein or mRNA thereof by *in situ* hybridization.

Fluorescent *in situ* hybridization allows the localization of a particular DNA sequence along a chromosome, which is useful, among other uses, for gene mapping, following chromosomes in hybrid lines, or detecting chromosomes with translocations, transversions or deletions. *In situ* hybridization has been used to identify chromosomes in several plant species

10 (Griffor *et al.*, *Plant Mol. Biol.* 17:101-109 (1991); Gustafson *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 87:1899-1902 (1990); Mukai and Gill, *Genome* 34:448-452 (1991); Schwarzacher and Heslop-Harrison, *Genome* 34:317-323 (1991); Wang *et al.*, *Jpn. J. Genet.* 66:313-316 (1991); Parra and Windle, *Nature Genetics* 5:17-21 (1993)). It is understood that the nucleic acid molecules of the invention may be used as probes or markers to localize sequences along

15 a chromosome.

Another method to localize the expression of a molecule is tissue printing. Tissue printing provides a way to screen, at the same time on the same membrane many tissue sections from different plants or different developmental stages (Yomo and Taylor, *Planta* 112:35-43 (1973); Harris and Chrispeels, *Plant Physiol.* 56:292-299 (1975); Cassab and

20 Varner, *J. Cell. Biol.* 105:2581-2588 (1987); Spruce *et al.*, *Phytochemistry* 26:2901-2903 (1987); Barres *et al.*, *Neuron* 5:527-544 (1990); Reid and Pont-Lezica, *Tissue Printing: Tools for the Study of Anatomy, Histochemistry and Gene Expression*, Academic Press, New York, New York (1992); Reid *et al.*, *Plant Physiol.* 93:160-165 (1990); Ye *et al.*, *Plant J.* 1:175-183 (1991)).

25 One skilled in the art can refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include *Current Protocols in Molecular Biology* Ausubel, *et al.*, eds., John Wiley & Sons, N. Y. (1989), and supplements through September (1998), *Molecular Cloning, A Laboratory Manual*, Sambrook *et al.*, 2nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, New York (1989),

30 *Genome Analysis: A Laboratory Manual 1: Analyzing DNA*, Birren *et al.*, Cold Spring

Harbor Press, Cold Spring Harbor, New York (1997); *Genome Analysis: A Laboratory Manual 2: Detecting Genes*, Birren *et al.*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1998); *Genome Analysis: A Laboratory Manual 3: Cloning Systems*, Birren *et al.*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1999); *Genome Analysis: A Laboratory Manual 4: Mapping Genomes*, Birren *et al.*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1999); *Plant Molecular Biology: A Laboratory Manual*, Clark, Springer-Verlag, Berlin, (1997), *Methods in Plant Molecular Biology*, Maliga *et al.*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1995). These texts can, of course, also be referred to in making or using an aspect of the invention. It is understood that any of the agents of the invention can be substantially purified and/or be biologically active and/or recombinant.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

Example 1

Identification of Yeast HES1

The yeast strain LPY9 (MATa, leu2, Ura3, his3) is grown overnight and inoculated into SD+ hul (histidine, uracil, leucine) media. Aliquots of the culture are treated with ketoconazole (an inhibitor of C-14 α demethylase (P450_{14DM}) enzyme) at 10ug/ml, 50ug/ml, and 100ug/ml, corresponding to 10ppm, 50ppm, and 100ppm, respectively. A sample of each is collected at 2, 4, and 6 hours after treatment. Control samples treated with DMSO (dimethyl sulfoxide-solvent for ketoconazole) but not with ketoconazole are also collected. Total RNA from each sample is collected by conventional methods, such as a Zirconium/Silica bead binding and extraction method. The sequence content of each sample is analyzed and compared by hybridizing each of them to a number of yeast ORF sequences immobilized on a Nylon membrane in an array format.

A similar comparison of a wild type yeast strain and a double mutant strain is made. The double mutant CJ517 (MATa, erg11::URA3, erg3::LEU2, leu2, ura3, his4) [erg11, erg3 double mutant] is compared to LPY9 after growth in both YPD and SD+hul media. Samples are collected at approximately 0, 2, 4, and 6 hours after inoculation.

Using this method, over 600 RNA transcripts levels are shown to be altered. A yeast transcript that encodes HES1 is identified as a transcript that is particularly effected by the addition of ketoconazole (SEQ ID NO: 5)(Table 1).

Table 1*

Seq. Num.	Clone ID	ALIAS	CJ-4hr/ LP-4hr	K-50/CK	K-100/CK	Gene Description
5	YOR237W	(HES1)	134.648161	1417.6262	1358.1235	Protein implicated in ergosterol biosynthesis, member of the KES1/HES1/OSH1/YKR003W family of oxysterol-binding (OSBP) proteins

- 5 *Table Headings: Clone ID: A clone ID designation number; Alias: Alternative gene names used in the literature. This information is provided by YPD™, Hodges *et al.* *Nucl. Acids Res.* 27: 69-73 (1999), the entirety of which is herein incorporated by reference; CJ-4hr/LP-4hr: Expression level in the mutant CJ517 as compared with the respective wild type strain LPY9 at 4hr sampling of log phase growth of yeast (ratio of mutant expression level/control expression level). CJ refers to the mutant CJ517 (The mutant is defective in the gene (ERG11) codes for C14 demethylase enzyme in the sterol biosynthetic pathway). LP refers to the respective wild type strain LPY9, used to compare the gene expression profile with the mutant; K-50/CK: Expression level in the wild type yeast LPY9, at 2 hr after treatment with 50micro gram/ml ketoconazole as compared to the wild type LPY9 strain without ketoconazole treatment (ratio of treatment expression level/control expression level). K refers to ketoconazole treatment; K-100/CK: Expression level in the wild type yeast LPY9, at 2 hr after treatment with 100micro gram/ml ketoconazole as compared to the wild type LPY9 strain without ketoconazole treatment (ratio of treatment expression level/control expression level); Gene Description: Description of the clone listed in column 1.

Example 2

- Sequences that encode for the yeast HES1 protein are used to search databases for homologues from other species. A number of different databases can be used for these searches, including, for example, dbEST, GenBank, EMBL, SwissProt, PIR, and GENES. In addition, various algorithms for searching can be selected, such as, for example, the BLAST suite of programs at the default values. Typically, matches found with BLAST P values

equal or less than 0.001 (probability) or BLAST Score of equal or greater than 90 are classified as hits. If the program is used to determine the hit is HMMSW then the score refers to HMMSW score. The GenBank database is searched with BLASTN and BLASTX (default values) using sequences as series. Sequences that pass the hit probability threshold of $10e^{-8}$ are considered hits.

Table 2

Seq. Num.	Clone ID	Sequence: DNA/Protein	Hit description	Species
1	701100307CPR9855	DNA	Yeast HES 1 homolog	soybean
2	701001443CPR9857	DNA	Yeast HES 1 homolog	soybean
3	701010572CPR9854	DNA	Yeast HES 1 homolog	soybean
4	701176735CPR9736	DNA	Yeast HES 1 homolog	maize
5	Z75145	DNA	Protein implicated in ergosterol biosynthesis, member of the KES1/HES1/OSH1/YKR003W family of oxysterol-binding (OSBP) proteins	yeast
30	701100307CPR9855	Protein	Yeast HES 1 homolog	soybean
31	701001443CPR9857	Protein	Yeast HES 1 homolog	soybean
32	701010572CPR9854	Protein	Yeast HES 1 homolog	soybean
33	701176735CPR9736	Protein	Yeast HES 1 homolog	maize
34	Z75145	Protein	Protein implicated in ergosterol biosynthesis, member of the KES1/HES1/OSH1/YKR003W family of oxysterol-binding (OSBP) proteins	yeast
6	701003888H1	DNA	Yeast HES 1 homolog	soybean
7	701001351H1	DNA	Yeast HES 1 homolog	soybean
8	700672545H1	DNA	Yeast HES 1 homolog	soybean
9	700664054H1	DNA	Yeast HES 1 homolog	soybean
10	700665644H1	DNA	Yeast HES 1 homolog	soybean
11	700764248H1	DNA	Yeast HES 1 homolog	soybean
12	700851444H1	DNA	Yeast HES 1 homolog	soybean
13	700971910H1	DNA	Yeast HES 1 homolog	soybean
14	700652932H1	DNA	Yeast HES 1 homolog	soybean
15	700982894H1	DNA	Yeast HES 1 homolog	soybean
16	701120140H1	DNA	Yeast HES 1 homolog	soybean
17	701064234H1	DNA	Yeast HES 1 homolog	soybean
18	700954013H1	DNA	Yeast HES 1 homolog	soybean
19	701129375H1	DNA	Yeast HES 1 homolog	soybean
20	701043941H1	DNA	Yeast HES 1 homolog	soybean
21	LIB24-114-Q1-E1-H8	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>
22	LIB22-016-Q1-E1-F3	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>
23	LIB25-101-Q1-E1-F1	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>
24	AA042357	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>
25	AA720163	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>
26	Z29936	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>
27	T76850	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>
28	T76580	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>
29	AA586043	DNA	Arabidopsis HES 1 homolog	<i>A. thaliana</i>

What is claimed is:

1. A substantially purified nucleic acid molecule that encodes a protein comprising the amino acid sequence of SEQ ID NO: 30.
2. The substantially purified nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 1.
3. A substantially purified nucleic acid molecule that specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 1 or its complement, wherein the nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 30.
4. The substantially purified nucleic acid molecule according to claim 3, wherein said nucleic acid molecule specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 1 or its complement under high stringency conditions.
5. The substantially purified nucleic acid molecule according to claim 3, wherein said nucleic acid molecule specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 1 or its complement under low stringency conditions.
6. A substantially purified nucleic acid molecule that encodes a protein comprising the amino acid sequence of SEQ ID NO: 31.
7. The substantially purified nucleic acid molecule of claim 6, wherein the nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 2.
8. A substantially purified nucleic acid molecule that specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 2 or its complement, wherein the nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 31.
9. The substantially purified nucleic acid molecule according to claim 8, wherein said nucleic acid molecule specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 2 or its complement under high stringency conditions.
10. The substantially purified nucleic acid molecule according to claim 8, wherein said nucleic acid molecule specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 2 or its complement under low stringency conditions.
11. A substantially purified nucleic acid molecule that encodes a protein comprising the amino acid sequence of SEQ ID NO: 32.
12. The substantially purified nucleic acid molecule of claim 11, wherein the nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 3.

13. A substantially purified nucleic acid molecule that specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 3 or its complement, wherein the nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 32.

14. The substantially purified nucleic acid molecule according to claim 13, wherein said nucleic acid molecule specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 3 or its complement under high stringency conditions.

15. The substantially purified nucleic acid molecule according to claim 13, wherein said nucleic acid molecule specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 3 or its complement under low stringency conditions.

16. A substantially purified nucleic acid molecule that encodes a protein comprising the amino acid sequence of SEQ ID NO: 33.

17. The substantially purified nucleic acid molecule of claim 16, wherein the nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 4.

18. A substantially purified nucleic acid molecule that specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 4 or its complement, wherein the nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 33.

19. The substantially purified nucleic acid molecule according to claim 18, wherein said nucleic acid molecule specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 4 or its complement under high stringency conditions.

20. The substantially purified nucleic acid molecule according to claim 18, wherein said nucleic acid molecule specifically hybridizes to a nucleic acid sequence of SEQ ID NO: 4 or its complement under low stringency conditions.

21. A substantially purified nucleic acid molecule comprising a nucleic acid sequence which encodes a plant HES1 protein.

22. A substantially purified protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 31, 32, and 33.

23. An antibody capable of specifically binding a protein with the amino acid sequence of SEQ ID NO: 30.

24. An antibody capable of specifically binding a protein with the amino acid sequence of SEQ ID NO: 33.

25. A plant having a nucleic acid molecule which comprises: (A) a promoter region which functions in a plant cell to cause the production of a mRNA molecule; (B) an exogenous structural nucleic acid molecule encoding a protein or fragment thereof comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 30,
5 31, 32, 33 and 34 and fragments thereof, and (C) a 3' non-translated sequence that functions in the plant cell to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of the mRNA molecule.

26. The plant according to claim 25, wherein said plant is selected from the group consisting of maize, canola, soybean, crambe, mustard, castor bean, peanut, sesame,
10 cottonseed, linseed, safflower, oil palm, flax and sunflower.

27. The plant according to claim 25, wherein said plant exhibits increased phytosterol levels relative to a plant with a similar genetic background but lacking said exogenous structural nucleic acid molecule.

28. A transformed plant having a nucleic acid molecule which comprises: (A) an exo-
15 genous promoter region which functions in a plant cell to cause the production of a mRNA molecule; which is linked to (B) a transcribed nucleic acid molecule with a transcribed strand and a non-transcribed strand, wherein the transcribed strand is complementary to a nucleic acid molecule encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 31, 32, 33 and 34; which is linked to (C) a 3' non-translated
20 sequence that functions in plant cells to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of the mRNA molecule.

29. The transformed plant according to claim 28, wherein said plant is selected from the group consisting of maize, canola, soybean, crambe, mustard, castor bean, peanut, sesame, cottonseed, linseed, safflower, oil palm, flax and sunflower.

30. A plant having a nucleic acid molecule which comprises: (A) a promoter region which functions in a plant cell to cause the production of a mRNA molecule; (B) an exogenous structural nucleic acid molecule encoding a HES1 protein or fragment thereof, and (C) a
25 3' non-translated sequence that functions in the plant cell to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of the mRNA molecule.

31. The plant according to claim 30, wherein said plant is selected from the group consisting of maize, canola, soybean, crambe, mustard, castor bean, peanut, sesame, cottonseed, linseed, safflower, oil palm, flax and sunflower.

32. The plant according to claim 31, wherein said plant exhibits increased phytosterol levels relative to a plant with a similar genetic background but lacking said exogenous structural nucleic acid molecule.

33. The plant according to claim 31, wherein said HES1 protein has the amino acid sequence of a yeast HES1 protein.

34. The plant according to claim 31, wherein said HES1 protein has the amino acid sequence of a plant HES1 protein.

35. The plant according to claim 34, wherein said HES1 protein has the amino acid sequence of a maize or soybean HES1 protein

36. A method of producing a plant containing an expressed HES1 protein or fragment thereof in a plant comprising: (A) transforming the plant with a functional nucleic acid molecule, wherein the functional nucleic acid molecule comprises a promoter region, wherein the promoter region is linked to a structural region, wherein the structural region comprises a nucleic acid sequence that encodes a protein having an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 31, 32, 33 and 34, wherein the structural region is linked to a 3' non-translated sequence that functions in the plant to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of a mRNA molecule; and wherein the functional nucleic acid molecule results in overexpression of the protein; and (B) growing the transformed plant.

37. The method of producing a plant according to claim 36, wherein said plant is selected from the group of maize, canola, soybean, crambe, mustard, castor bean, peanut, sesame, cottonseed, linseed, safflower, oil palm, flax and sunflower.

38. The method of producing a plant according to claim 36, wherein said plant exhibits increased phytosterol levels relative to a plant with a similar genetic background but lacking said exogenous structural nucleic acid molecule.

39. A method of producing a plant containing an expressed HES1 protein or fragment thereof in a plant comprising: (A) transforming the plant with a functional nucleic acid molecule, wherein the functional nucleic acid molecule comprises a promoter region, wherein

the promoter region is linked to a structural region, wherein the structural region comprises a nucleic acid sequence that encodes a HES1 protein, wherein the structural region is linked to a 3' non-translated sequence that functions in the plant to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of a mRNA molecule; and wherein
5 the functional nucleic acid molecule results in overexpression of the protein; and (B) growing the transformed plant.

40. The method of producing a plant according to claim 39, wherein said plant is selected from the group of maize, canola, soybean, crambe, mustard, castor bean, peanut, sesame, cottonseed, linseed, safflower, oil palm, flax and sunflower.

10 41. The method of producing a plant according to claim 40, wherein said plant exhibits increased phytosterol levels relative to a plant with a similar genetic background but lacking said exogenous structural nucleic acid molecule.

42. A method for reducing expression of a HES1 protein in a plant comprising: (A) trans-
forming a plant with a nucleic acid molecule, said nucleic acid molecule having an exoge-
15 nous promoter region which functions in plant cells to cause the production of a mRNA molecule, wherein said exogenous promoter region is linked to a transcribed nucleic acid molecule having a transcribed strand and a non-transcribed strand, wherein the transcribed strand is complementary to a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1-4, and 6-29 or complement thereof or fragment
20 of either; and wherein the transcribed nucleic acid molecule is linked to a 3' non-translated sequence that functions in the plant cells to cause termination of transcription and addition of polyadenylated ribonucleotides to the 3' end of the mRNA sequence; and (B) growing said transformed plant.

43. A method for screening for increased phytosterol levels in a plant comprising inter-
25 rogating genomic DNA for the presence or absence of a marker molecule that specifically hybridizes to a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-4 and 6-29 or complement thereof; and detecting said presence or absence of said marker.

44. A method for determining a genomic polymorphism in a plant that is predictive of an
30 increased phytosterol levels comprising the steps: (A) incubating a marker nucleic acid molecule, under conditions permitting nucleic acid hybridization, and a complementary nucleic

acid molecule obtained from said plant, wherein said marker nucleic acid molecule specifically hybridizes to a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-4 and 6-29 or complement thereof; (B) permitting hybridization between said marker nucleic acid molecule and said complementary nucleic acid molecule obtained from said plant; and (C) detecting the presence of said polymorphism.

45. A method for determining a level or pattern of HES1 expression in a plant cell or plant tissue comprising: (A) incubating under conditions permitting nucleic acid hybridization: a marker nucleic acid molecule, said marker nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-4 and 6-29 or complement thereof, with a complementary nucleic acid molecule obtained from a plant cell or plant tissue, wherein nucleic acid hybridization between said marker nucleic acid molecule, and said complementary nucleic acid molecule obtained from said plant cell or plant tissue permits the detection of said HES1 protein; (B) permitting hybridization between said marker nucleic acid molecule and said complementary nucleic acid molecule obtained from said plant cell or plant tissue; and (C) detecting the level or pattern of said complementary nucleic acid, wherein the detection of said complementary nucleic acid is predictive of the level or pattern of said HES1 protein.

46. A method for determining a level or pattern of a HES1 in a plant cell or plant tissue under evaluation which comprises assaying the concentration of a molecule, whose concentration is dependent upon the expression of a gene, said gene having a nucleic acid sequence which specifically hybridizes to a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-4 and 6-29 or complement thereof or fragment of either, said molecule being present in the plant cell or plant tissue, in comparison to the concentration of that molecule present in a plant cell or plant tissue with a known level or pattern of said HES1 protein, wherein the assayed concentration of said molecule is compared to the assayed concentration of said molecule in the plant cell or plant tissue with a known level or pattern of said HES1 protein.

Combined Declaration and Power of Attorney for Patent Application

Docket Number: 16516.130

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled **NUCLEIC ACID MOLECULES AND PROTEINS ASSOCIATED WITH STEROL SYNTHESIS AND METABOLISM**, the specification of which is attached hereto unless the following box is checked:

☒ was filed on 11 July 2000;
as PCT International Application Number PCT/US00/18813; and
was amended on 11 January 2002 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Claimed
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Application No.)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Application No.)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

<u>60/142,981</u>	<u>12 July 1999</u>
(Application No.)	(Filing Date)

_____	_____
(Application No.)	(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner

provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application No.)

(Filing Date)

(Status - patented, pending, abandoned)

(Application No.)

(Filing Date)

(Status - patented, pending, abandoned)

(Application No.)

(Filing Date)

(Status - patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Timothy C. Bickham, Reg. No. 41,618Andrew S. Brenc, Reg. No. 45,534Scott A. Chambers, Reg. No. 37,573Jay Chawla, Reg. No. 44,073June E. Cohan, Reg. No. 43,741James R. Farrand, Reg. No. 38,136Joel M. Freed, Reg. No. 25,101Barry Herman, Reg. No. 51,254Dennis R. Hoerner, Jr., Reg. No. 30,914Leslie L. Jacobs, Jr., Reg. No. 40,659David R. Marsh, Reg. No. 41,408Joseph Micallef, Reg. No. 39,772Lisa A. Penoyer, Reg. No. 51,204Holly Logue Prutz, Reg. No. 47,755Joseph W. Ricigliano, Reg. No. 48,511Sidney A. Rosenzweig, Reg. No. 43,893William Sekyi, Reg. No. 45,831Michael J. Songer, Reg. No. 39,841Brian K. Stierwalt, Reg. No. 33,213Milan M. Vinnola, Reg. No. 45,979Robert Jones Worrall, Reg. No. 37,969

Send Correspondence to:


David R. Marsh
ARNOLD & PORTER
 555 12th Street, N.W.
 Washington, D.C. 20004-1206
 Facsimile: (202) 942-5999

Direct Telephone Calls to: (202) 942-5000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: <u>Balasulojini KARUNANANDAA</u>	
Inventor's signature <u>B. Karunanandaa</u>	Date <u>4/1/02</u>
Residence <u>Creve Coeur, Missouri, USA</u>	<u>MO</u>
Citizenship <u>LK</u>	
Post Office Address <u>724 Bellerive Manor, Creve Coeur, Missouri 63141, USA</u>	
Full name of second inventor: <u>Jaehyuk YU</u>	
Inventor's signature	Date
Residence <u>North Andover, Massachusetts, USA</u>	<u>Ma</u>
Citizenship <u>KR</u>	
Post Office Address <u>361 Sutton Street, North Andover, Massachusetts 01845, USA</u>	
Full name of third inventor: <u>Ganesh M. KISHORE</u>	
Inventor's signature	Date
Residence <u>Creve Coeur, Missouri, USA</u>	<u>MO</u>
Citizenship <u>US</u>	
Post Office Address <u>11966 Sackston Ridge Drive, Creve Coeur, Missouri 63141, USA</u>	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Balasulojini KARUNANANDAA	
Inventor's signature	Date
Residence	Creve Coeur, Missouri, USA
Citizenship	LK
Post Office Address	724 Bellerive Manor, Creve Coeur, Missouri 63141, USA
Full name of second inventor: Jaehyuk YU	
Inventor's signature 	Date 4/1/2002
Residence	North Andover, Massachusetts, USA Madison, WI, USA
Citizenship	KR
Post Office Address	361 Sutton Street, North Andover, Massachusetts 01845, USA 758 S. Gammon Rd #1, Madison, WI, 53719 USA
Full name of third inventor: Ganesh M. KISHORE	
Inventor's signature	Date
Residence	Creve Coeur, Missouri, USA
Citizenship	US
Post Office Address	11966 Sackston Ridge Drive, Creve Coeur, Missouri 63141, USA

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Balasulojini KARUNANANDAA	
Inventor's signature	Date
Residence	Creve Coeur, Missouri, USA
Citizenship	LK
Post Office Address	724 Bellerive Manor, Creve Coeur, Missouri 63141, USA
Full name of second inventor: Jaehyuk YU	
Inventor's signature	Date
Residence	North Andover, Massachusetts, USA
Citizenship	KR
Post Office Address	361 Sutton Street, North Andover, Massachusetts 01845, USA
Full name of third inventor: Ganesh M. KISHORE	
Inventor's signature / <i>Ganesh M. Kishore</i>	Date March 28, 2002
Residence	Creve Coeur, Missouri, USA
Citizenship	US
Post Office Address	11966 Sackston Ridge Drive, Creve Coeur, Missouri 63141, USA

<110> Karunanandaa, Balasulojini
Yu, Jaehyuk
Kishore, Ganesh M.

<120> NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED
WITH STEROL SYNTHESIS AND METABOLISM

<130> 16516.130

<150> US 60/142,981

<151> 1999-07-12

<160> 34

<210> 1

<211> 1358

<212> DNA

<213> Glycine max

<220>

<221> CDS

<222> (24)...(1100)

<400> 1

```

gaattcggct cgagtttgaa cca atg aca atg ctt cag aaa atg gct gag ctt      53
          Met Thr Met Leu Gln Lys Met Ala Glu Leu
                1                5                10

atg gag tac tct tac ctg tta gat atg gcg gac aag act gag gat cca      101
Met Glu Tyr Ser Tyr Leu Leu Asp Met Ala Asp Lys Thr Glu Asp Pro
                15                20                25

tac atg aga cta gta tat gct tca tca ttc ttt ata tct gtc tac tat      149
Tyr Met Arg Leu Val Tyr Ala Ser Ser Phe Phe Ile Ser Val Tyr Tyr
                30                35                40

gcc tat caa cga acg tgg aag cca ttc aat cca att ctt ggt gag act      197
Ala Tyr Gln Arg Thr Trp Lys Pro Phe Asn Pro Ile Leu Gly Glu Thr
                45                50                55

tat gaa atg gtt aac cat ggt ggc att aca ttt ata tca gag cag gtc      245
Tyr Glu Met Val Asn His Gly Gly Ile Thr Phe Ile Ser Glu Gln Val
                60                65                70

agt cat cac cct cca atg agt gct ggg cat gct gaa act gaa cat ttc      293
Ser His His Pro Pro Met Ser Ala Gly His Ala Glu Thr Glu His Phe
                75                80                85                90

act tat gat gtt aca tca aaa ttg aaa acc aaa ttt ctc ggc aac tca      341
Thr Tyr Asp Val Thr Ser Lys Leu Lys Thr Lys Phe Leu Gly Asn Ser
                95                100                105

gtt gat gta tat cct gtt gga aga acg cgt gtt acc ctc aaa aga gat      389
Val Asp Val Tyr Pro Val Gly Arg Thr Arg Val Thr Leu Lys Arg Asp
                110                115                120

```

ggt Gly	gtg Val	gtc Val 125	ctt Leu	gat Asp	ttg Leu	gtg Val	cct Pro 130	cct Pro	cct Pro	aca Thr	aaa Lys	gtt Val 135	agc Ser	aac Asn	ttg Leu	437
att Ile	ttt Phe 140	gga Gly	cga Arg	act Thr	tgg Trp	att Ile 145	gat Asp	tca Ser	cca Pro	gga Gly	gag Glu 150	atg Met	atc Ile	ctg Leu	aca Thr	485
aat Asn 155	ctg Leu	act Thr	aca Thr	ggg Gly 160	gac Asp	aaa Lys	gtg Val	gtg Val	ctg Leu	tat Tyr 165	ttt Phe	caa Gln	cca Pro	tgt Cys	ggc Gly 170	533
tgg Trp	ttt Phe	gga Gly	tat Tyr	gaa Glu 175	gtg Val	gat Asp	ggg Gly	tac Tyr	gtg Val 180	tat Tyr	aat Asn	tct Ser	gct Ala	gac Asp 185	gag Glu	581
cct Pro	aag Lys	ata Ile	ctg Leu 190	atg Met	act Thr	gga Gly	aaa Lys	tgg Trp 195	aat Asn	gag Glu	gct Ala	atg Met 200	aat Asn	tat Tyr	caa Gln	629
gtt Val	tgt Cys	gac Asp 205	tca Ser	gag Glu	gga Gly	gaa Glu 210	cca Pro	ctt Leu	cca Pro	ggc Gly	act Thr 215	gag Glu	ttg Leu	aaa Lys	gag Glu	677
att Ile	tgg Trp 220	aga Arg	gtt Val	gct Ala	gat Asp	acc Thr 225	ccg Pro	aag Lys	aag Lys	gac Asp 230	aag Lys	ttc Phe	cag Gln	tac Tyr	acg Thr	725
cat His 235	ttt Phe	gca Ala	cac His	aag Lys	att Ile 240	aac Asn	agc Ser	ttt Phe	gac Asp	act Thr 245	gct Ala	ccc Pro	aag Lys	aag Lys	ttg Leu 250	773
ttg Leu	gca Ala	tct Ser	gac Asp	tct Ser 255	cgt Arg	cta Leu	cgt Arg	cct Pro	gat Asp 260	aga Arg	atg Met	gcc Ala	ctt Leu	gag Glu 265	aag Lys	821
ggt Gly	gac Asp	cta Leu 270	tcc Ser	aca Thr	tct Ser	ggt Gly	tat Tyr	gag Glu 275	aag Lys	agc Ser	agt Ser	ttg Leu 280	gag Glu	gag Glu	agg Arg	869
caa Gln	aga Arg	gct Ala 285	gag Glu	aag Lys	aga Arg	aac Asn	cga Arg 290	gag Glu	gcc Ala	aag Lys	ggc Gly 295	cat His 295	aag Lys	ttc Phe	act Thr	917
cct Pro	aga Arg 300	tgg Trp	ttt Phe	gat Asp	tta Leu	aca Thr 305	gat Asp	gaa Glu	gta Val	act Thr	cct Pro 310	acc Thr	cct Pro	tgg Trp	ggc Gly	965
gac Asp 315	ttg Leu	gaa Glu	gtt Val	tac Tyr	caa Gln 320	tac Tyr	aac Asn	ggt Gly	aaa Lys	tat Tyr 325	acc Thr	caa Gln	cat His	tgt Cys	gct Ala 330	1013
gcc Ala	gtt Val	gat Asp	agt Ser	tct Ser 335	gag Glu	tgc Cys	att Ile	gaa Glu	gtg Val 340	cct Pro	gac Asp	atc Ile	aga Arg	cca Pro	gaa Glu 345	1061

```

ttc aac cct tgg caa tat gat aat ttg gat gct gaa tag tgagcatcct      1110
Phe Asn Pro Trp Gln Tyr Asp Asn Leu Asp Ala Glu
          350                      355

tgttgaattc tttctatctt ttttaaatat cattttgtta ttaagtttgt aatgtaattct  1170

tgatttgaat gcttgaaatt tggtttttgt tttgggttgt tttatcactg tagtatttga  1230

ttaattaata gtagctatgt tagttcatca gttcactttg catggataaa tgctagtagg  1290

gaaattaaag ttatcttcca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagggc  1350

ggccgccg                                           1358

```

```

<210>      2
<211>     1136
<212>     DNA
<213>    Glycine max

```

```

<220>
<221>     CDS
<222>    (73)...(975)

```

```

<400>      2

```

```

gaattcggct cgaggtcaca acttcagtgc tatggtgaat cagtgtattg cacaggttcg      60

gacttgctaa gc atg tgc aac aat ggt cag agt cca ctt gat agg ttc ata      111
          Met Cys Asn Asn Gly Gln Ser Pro Leu Asp Arg Phe Ile
            1              5              10

tct gtg gta gca tgg tgc ata tct acc act cgc cct gtg act ttt ggt      159
Ser Val Val Ala Trp Cys Ile Ser Thr Thr Arg Pro Val Thr Phe Gly
          15              20              25

gtt gct cct tat aat ccc att ctt ggt gag aca cac cat gtt tca agg      207
Val Ala Pro Tyr Asn Pro Ile Leu Gly Glu Thr His His Val Ser Arg
          30              35              40              45

gga aat ctt aat gtg tta ttg gag cag att tca cat cac cct cca gta      255
Gly Asn Leu Asn Val Leu Leu Glu Gln Ile Ser His His Pro Pro Val
          50              55              60

act gct ctc cat gca aca gat gag aag gaa aac att gaa atg tta tgg      303
Thr Ala Leu His Ala Thr Asp Glu Lys Glu Asn Ile Glu Met Leu Trp
          65              70              75

tgc cag cga cct gat cca aag ttt aat ggc aca tca gtt gaa gct aaa      351
Cys Gln Arg Pro Asp Pro Lys Phe Asn Gly Thr Ser Val Glu Ala Lys
          80              85              90

gtg cat gga ata cgc cag ttg aag ctc cta aat cat ggt gaa aca tat      399
Val His Gly Ile Arg Gln Leu Lys Leu Leu Asn His Gly Glu Thr Tyr
          95              100              105

gaa atg aat tgt cct cgc ctt tta ctt aga att ctt cca gtt cct ggt      447

```

Glu Met Asn Cys Pro Arg Leu Leu Leu Arg Ile Leu Pro Val Pro Gly	
110 115 120 125	
gct gat tgg gct ggt aca gtt aat ata cgg tgc cta gag aca ggt cta	495
Ala Asp Trp Ala Gly Thr Val Asn Ile Arg Cys Leu Glu Thr Gly Leu	
130 135 140	
gta gct gaa tta tcc tac aga tca agt tct ttt cta gga att ggg ggg	543
Val Ala Glu Leu Ser Tyr Arg Ser Ser Phe Leu Gly Ile Gly Gly	
145 150 155	
aat cat aga gtg atc aaa ggg aag atc ctt gac tct tca tca ttg aaa	591
Asn His Arg Val Ile Lys Gly Lys Ile Leu Asp Ser Ser Ser Leu Lys	
160 165 170	
gtt cta tat gaa gtt gat ggt cat tgg gat agg acc gta aaa gtg aag	639
Val Leu Tyr Glu Val Asp Gly His Trp Asp Arg Thr Val Lys Val Lys	
175 180 185	
gac aca aat aat ggg aaa gta aga gtg ata tat gat gca aag gaa gtt	687
Asp Thr Asn Asn Gly Lys Val Arg Val Ile Tyr Asp Ala Lys Glu Val	
190 195 200 205	
atg tca ggt ctc gaa act cct ata ctc aag gac ata gag ggt gtg tgg	735
Met Ser Gly Leu Glu Thr Pro Ile Leu Lys Asp Ile Glu Gly Val Trp	
210 215 220	
caa aca gaa tca gct cat gtt tgg ggt gaa tta aac caa gcc att gtg	783
Gln Thr Glu Ser Ala His Val Trp Gly Glu Leu Asn Gln Ala Ile Val	
225 230 235	
agc aaa gac tgg gag aaa gca aga gaa gca aag cta aaa gtt gag gaa	831
Ser Lys Asp Trp Glu Lys Ala Arg Glu Ala Lys Leu Lys Val Glu Glu	
240 245 250	
aga caa agg gag ctt gtg aga gaa aga gaa tca aaa gga gaa aca tgg	879
Arg Gln Arg Glu Leu Val Arg Glu Arg Glu Ser Lys Gly Glu Thr Trp	
255 260 265	
att tct aag cat ttt gta gtt tct aac aac aaa gaa ggg tgg caa tgt	927
Ile Ser Lys His Phe Val Val Ser Asn Asn Lys Glu Gly Trp Gln Cys	
270 275 280 285	
tca cct att cat aag agt gta cct gcg gcc ccc atc aca gcc cta taa	975
Ser Pro Ile His Lys Ser Val Pro Ala Ala Pro Ile Thr Ala Leu	
290 295 300	
ttgtttgtcac tgtcaagtag tgtaaagcat taaagtacat tttagaagag aatgttcata	1035
aaaaaattta atggttgaaa ttttgacaac aatgaagtat ataacaaaat ttaaaattag	1095
ttacaatttt aaaaaaaaaa aaaaaaaaaaag ggcggccgcc g	1136

<210> 3
 <211> 1355
 <212> DNA

<213> Glycine max

<220>

<221> CDS

<222> (32)...(1099)

<400> 3

ggaattcggc tcgaggacaa tgcttcagaa a atg gct gag ctt atg gag tac 52
Met Ala Glu Leu Met Glu Tyr
1 5

tct tac ctg tta gat atg gcg gac aag act gag gat cca tac atg aga 100
Ser Tyr Leu Leu Asp Met Ala Asp Lys Thr Glu Asp Pro Tyr Met Arg
10 15 20

cta gta tat gct tca tca ttc ttt ata tct gtc tac tat gcc tat caa 148
Leu Val Tyr Ala Ser Ser Phe Phe Ile Ser Val Tyr Tyr Ala Tyr Gln
25 30 35

cga acg tgg aag cca ttc aat cca att ctt ggt gag act tat gaa atg 196
Arg Thr Trp Lys Pro Phe Asn Pro Ile Leu Gly Glu Thr Tyr Glu Met
40 45 50 55

gtt aac cat ggt ggc att aca ttt ata tca gag cag gtc agt cat cac 244
Val Asn His Gly Gly Ile Thr Phe Ile Ser Glu Gln Val Ser His His
60 65 70

cct cca atg agt gct ggg cat gct gaa act gaa cat ttc act tat gat 292
Pro Pro Met Ser Ala Gly His Ala Glu Thr Glu His Phe Thr Tyr Asp
75 80 85

gtt aca tca aaa ttg aaa acc aaa ttt ctc ggc aac tca gtt gat gta 340
Val Thr Ser Lys Leu Lys Thr Lys Phe Leu Gly Asn Ser Val Asp Val
90 95 100

tat cct gtt gga aga acg cgt gtt acc ctc aaa aga gat ggt gtg gtc 388
Tyr Pro Val Gly Arg Thr Arg Val Thr Leu Lys Arg Asp Gly Val Val
105 110 115

ctt gat ttg gtg cct cct cct aca aaa gtt agc aac ttg att ttt gga 436
Leu Asp Leu Val Pro Pro Pro Thr Lys Val Ser Asn Leu Ile Phe Gly
120 125 130 135

cga act tgg att gat tca cca gga gag atg atc ctg aca aat ctg act 484
Arg Thr Trp Ile Asp Ser Pro Gly Glu Met Ile Leu Thr Asn Leu Thr
140 145 150

aca ggg gac aaa gtg gtg ctg tat ttt caa cca tgt ggc tgg ttt gga 532
Thr Gly Asp Lys Val Val Leu Tyr Phe Gln Pro Cys Gly Trp Phe Gly
155 160 165

gct ggt aga tat gaa gtg gat ggg tac gtg tat aat tct gct gac gag 580
Ala Gly Arg Tyr Glu Val Asp Gly Tyr Val Tyr Asn Ser Ala Asp Glu
170 175 180

cct aag ata ctg atg act gga aaa tgg aat gag gct atg aat tat caa 628

Pro Lys Ile Leu Met Thr Gly Lys Trp Asn Glu Ala Met Asn Tyr Gln	
185 190 195	
ggt tgt gac tca gag gga gaa cca ctt cca ggc act gag ttg aaa gag	676
Val Cys Asp Ser Glu Gly Glu Pro Leu Pro Gly Thr Glu Leu Lys Glu	
200 205 210 215	
att tgg aga gtt gct gat acc ccg aag aag gac aag ttc cag tac acg	724
Ile Trp Arg Val Ala Asp Thr Pro Lys Lys Asp Lys Phe Gln Tyr Thr	
220 225 230	
cat ttt gca cac aag att aac agc ttt gac act gct ccc aag aag ttg	772
His Phe Ala His Lys Ile Asn Ser Phe Asp Thr Ala Pro Lys Lys Leu	
235 240 245	
ttg gca tct gac tct cgt cta cgt cct gat aga atg gcc ctt gag aag	820
Leu Ala Ser Asp Ser Arg Leu Arg Pro Asp Arg Met Ala Leu Glu Lys	
250 255 260	
ggt gac cta tcc aca tct ggt tat gag aag agc agt ttg gag gag agg	868
Gly Asp Leu Ser Thr Ser Gly Tyr Glu Lys Ser Ser Leu Glu Glu Arg	
265 270 275	
caa aga gct gag aag aga aac cga gag gcc aag ggc cat aag ttc act	916
Gln Arg Ala Glu Lys Arg Asn Arg Glu Ala Lys Gly His Lys Phe Thr	
280 285 290 295	
cct aga tgg ttt gat tta aca gat gaa gta act cct acc cct tgg ggt	964
Pro Arg Trp Phe Asp Leu Thr Asp Glu Val Thr Pro Thr Pro Trp Gly	
300 305 310	
gac ttg gaa gtt tac caa tac aac ggt aaa tat acc caa cat tgt gct	1012
Asp Leu Glu Val Tyr Gln Tyr Asn Gly Lys Tyr Thr Gln His Cys Ala	
315 320 325	
gcc gtt gat agt tct gag tgc att gaa gtg cct gac atc aga cca gaa	1060
Ala Val Asp Ser Ser Glu Cys Ile Glu Val Pro Asp Ile Arg Pro Glu	
330 335 340	
ttc aac cct tgg caa tat gat aat ttg gat gct gaa tag tgagcatcct	1109
Phe Asn Pro Trp Gln Tyr Asp Asn Leu Asp Ala Glu	
345 350 355	
tgtggaattc tttctatattt tttgaaatat cattttgtta ttaagtttgt aatgtaatct	1169
tgattggaat gcttgaaatt tggttttgtt tttgggttgt tttatcactg tagtatttga	1229
ttaattaata gtagctatgt tagttcatca gttcactttg catggataaa tgctagtaga	1289
gaaattaaag ttaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaagggcgg	1349
ccgccg	1355

<210>	4
<211>	1422
<212>	DNA

<213> Zea mays

<220>

<221> CDS

<222> (1)...(1245)

<400> 4

atg gct acc aaa gaa gaa gct agc gct gtc ccc gcc gcc agt aaa act	48
Met Ala Thr Lys Glu Glu Ala Ser Ala Val Pro Ala Ala Ser Lys Thr	
1 5 10 15	

tca tgg agt agc ttc ctg aag tcc atc gca tcc ttc aac ggc gac ctc	96
Ser Trp Ser Ser Phe Leu Lys Ser Ile Ala Ser Phe Asn Gly Asp Leu	
20 25 30	

tcc tct ctc acc gca ccg ccg ttc atc ctc tca aca acc tct tta acc	144
Ser Ser Leu Thr Ala Pro Pro Phe Ile Leu Ser Thr Thr Ser Leu Thr	
35 40 45	

gag tat tct gcg tac tgg tgc gaa cat cct gca ctc ttc gtt gcc ccc	192
Glu Tyr Ser Ala Tyr Trp Cys Glu His Pro Ala Leu Phe Val Ala Pro	
50 55 60	

gca cgt gag ccc gat cct gcg aag aga gcg ctc ttg gtg ctg aaa tgg	240
Ala Arg Glu Pro Asp Pro Ala Lys Arg Ala Leu Leu Val Leu Lys Trp	
65 70 75 80	

ttc ctg agc aca ttg cac caa cag tac tgc tct cga agc gaa aag cta	288
Phe Leu Ser Thr Leu His Gln Gln Tyr Cys Ser Arg Ser Glu Lys Leu	
85 90 95	

gga agc gag aaa aag ccg ctc aac ccg ttc ctg ggc gag ctt ttc ctg	336
Gly Ser Glu Lys Lys Pro Leu Asn Pro Phe Leu Gly Glu Leu Phe Leu	
100 105 110	

ggc aag tgg ata gag gat gag gat gtg ggc gag aca agg ttg atc agc	384
Gly Lys Trp Ile Glu Asp Glu Asp Val Gly Glu Thr Arg Leu Ile Ser	
115 120 125	

gag caa gtc agc cat cat cct cct gcg aca gcg tat tca ata gtc aat	432
Glu Gln Val Ser His His Pro Pro Ala Thr Ala Tyr Ser Ile Val Asn	
130 135 140	

gag aaa cat gga gtt gag ctc caa gga tac aac gcc caa aaa gcc tcc	480
Glu Lys His Gly Val Glu Leu Gln Gly Tyr Asn Ala Gln Lys Ala Ser	
145 150 155 160	

ttc tcc agc acc atc caa gtg aaa caa cta ggc cac gcc tat ctc tcc	528
Phe Ser Ser Thr Ile Gln Val Lys Gln Leu Gly His Ala Tyr Leu Ser	
165 170 175	

tta acg ccg ccc gga aaa gat gca aac aac gaa gac gac cgt gag cac	576
Leu Thr Pro Pro Gly Lys Asp Ala Asn Asn Glu Asp Asp Arg Glu His	
180 185 190	

tac ctc atc acc ctc ccc aac ctc cac atc gaa tcc ctg atc tat ggg	624
---	-----

Tyr	Leu	Ile	Thr	Leu	Pro	Asn	Leu	His	Ile	Glu	Ser	Leu	Ile	Tyr	Gly		
	195						200					205					
aca	cca	ttc	gtt	gaa	ttg	gaa	aag	agt	tgc	aag	atc	gcc	agc	tca	acc	672	
Thr	Pro	Phe	Val	Glu	Leu	Glu	Lys	Ser	Cys	Lys	Ile	Ala	Ser	Ser	Thr		
	210					215					220						
ggg	tac	atc	tct	aag	ata	gac	ttt	tcg	ggc	aaa	ggc	tgg	ctg	agc	gga	720	
Gly	Tyr	Ile	Ser	Lys	Ile	Asp	Phe	Ser	Gly	Lys	Gly	Trp	Leu	Ser	Gly		
225					230					235					240		
aag	aaa	aat	acc	ttc	tcc	gca	gtg	tta	tac	aag	gaa	agc	gac	ggc	gaa	768	
Lys	Lys	Asn	Thr	Phe	Ser	Ala	Val	Leu	Tyr	Lys	Glu	Ser	Asp	Gly	Glu		
			245						250					255			
aaa	aat	cct	tta	tac	aca	gcc	gac	ggt	caa	tgg	tcg	agc	agc	ttc	act	816	
Lys	Asn	Pro	Leu	Tyr	Thr	Ala	Asp	Gly	Gln	Trp	Ser	Ser	Ser	Phe	Thr		
		260						265						270			
atc	cgc	gat	gca	cgc	gct	aag	aag	gat	att	gag	acc	ttc	act	atc	agc	864	
Ile	Arg	Asp	Ala	Arg	Ala	Lys	Lys	Asp	Ile	Glu	Thr	Phe	Thr	Ile	Ser		
		275						280						285			
aat	ctg	aaa	aca	acc	ccc	tta	aca	gtc	gcc	cct	ctt	gat	gaa	caa	gat	912	
Asn	Leu	Lys	Thr	Thr	Pro	Leu	Thr	Val	Ala	Pro	Leu	Asp	Glu	Gln	Asp		
	290					295					300						
gaa	tgg	gaa	act	cgc	cgt	gca	tgg	cgc	gac	gta	gca	gcc	gcc	atc	gaa	960	
Glu	Trp	Glu	Thr	Arg	Arg	Ala	Trp	Arg	Asp	Val	Ala	Ala	Ala	Ile	Glu		
305					310					315					320		
cgc	ggc	gac	atg	gaa	gcc	aca	tca	aac	gcc	aaa	acc	aag	atc	gaa	gtc	1008	
Arg	Gly	Asp	Met	Glu	Ala	Thr	Ser	Asn	Ala	Lys	Thr	Lys	Ile	Glu	Val		
			325						330					335			
gcg	caa	cga	gaa	ctc	cgc	aaa	aag	gag	aaa	gag	caa	ggc	gag	gag	tgg	1056	
Ala	Gln	Arg	Glu	Leu	Arg	Lys	Lys	Glu	Lys	Glu	Gln	Gly	Glu	Glu	Trp		
			340					345					350				
gaa	cga	cga	ttc	ttc	aag	cga	gtc	aac	gaa	aag	gat	gaa	cct	acc	ttt	1104	
Glu	Arg	Arg	Phe	Phe	Lys	Arg	Val	Asn	Glu	Lys	Asp	Glu	Pro	Thr	Phe		
		355					360					365					
atg	aga	ttg	gcg	gcg	atg	ctg	gat	ttg	acg	caa	ggc	atc	gaa	agt	gac	1152	
Met	Arg	Leu	Ala	Ala	Met	Leu	Asp	Leu	Thr	Gln	Gly	Ile	Glu	Ser	Asp		
	370					375						380					
cgc	acc	ggg	gga	gtt	tgg	agg	ttt	gat	cct	tca	cgt	gct	gtg	gat	gcg	1200	
Arg	Thr	Gly	Gly	Val	Trp	Arg	Phe	Asp	Pro	Ser	Arg	Ala	Val	Asp	Ala		
385					390					395					400		
aat	ccg	ccg	tat	cac	aag	gtt	ggc	ggc	gaa	ggg	ttg	gga	ttg	taa		1245	
Asn	Pro	Pro	Tyr	His	Lys	Val	Gly	Gly	Glu	Gly	Leu	Gly	Leu				
				405					410								
tttatttatg	aggcatcttt	tatatattcat	aaaaacaggg	totaggccgt	ttattcatta	1305											

aatgtgtatt aagtagcgct ttttctcgac cgttgagatt catggatgca agtgtaccta 1365
 atagctcaat gcgagactct ttccaagcaa aaaaaaaaaa aaaaaaaggc cggccgc 1422

<210> 5
 <211> 2126
 <212> DNA
 <213> Saccharomyces cerevisiae

<220>
 <221> CDS
 <222> (453)...(1757)

<400> 5

aacctctccg cccgtatatt ttttttaata tgtaaataag tgatagaact gataagcctc 60

atcttctttt attgggctcc aagacgcgaa ctgttcgtag ggtaaccgtt tgacaccta 120

acgacctttc agcctcacct gcagtatttc ttcaacaacg cctgtcgcta tgtaaataa 180

tagcaatcgt ttgtgatcac cattgtcgaa ttgacgcgc ttaaacaaaa accattgttt 240

tggcctcgtt ccttgcattc aacaaaagag caaggatgc cgtcaaacag tcgttaaaag 300

agaaggttta taaactatct tgttttgtac ttgtctgtcc cggatccagt tgggtcttct 360

tttcaacctg tctgagtcgc atctttcttt ccctacttga agctccatat atctaagtca 420

tctaagtgtg tcttgcctaga ttacaaacga aa atg tct caa cac gca agc tca 473
 Met Ser Gln His Ala Ser Ser
 1 5

tct tct tgg act tct ttt ttg aaa tcg ata agt tcg ttc aac gga gat 521
 Ser Ser Trp Thr Ser Phe Leu Lys Ser Ile Ser Ser Phe Asn Gly Asp
 10 15 20

cta tcg tct ttg tct gca cca ccg ttt att ctt tct ccc act tcc tta 569
 Leu Ser Ser Leu Ser Ala Pro Pro Phe Ile Leu Ser Pro Thr Ser Leu
 25 30 35

aca gag ttt tct cag tat tgg gct gaa cat cca gct tta ttt ctg gag 617
 Thr Glu Phe Ser Gln Tyr Trp Ala Glu His Pro Ala Leu Phe Leu Glu
 40 45 50 55

cct tcg ttg att gat ggt gaa aac tac aaa gat cac tgt ccc ttt gac 665
 Pro Ser Leu Ile Asp Gly Glu Asn Tyr Lys Asp His Cys Pro Phe Asp
 60 65 70

cca aat gtg gaa tca aag gaa gtg gcg cag atg ttg gcg gtt gtt agg 713
 Pro Asn Val Glu Ser Lys Glu Val Ala Gln Met Leu Ala Val Val Arg
 75 80 85

tgg ttt att tct act ttg aga tct caa tac tgc tct aga agc gaa tcg 761
 Trp Phe Ile Ser Thr Leu Arg Ser Gln Tyr Cys Ser Arg Ser Glu Ser
 90 95 100

atg ggt tct gaa aag aag cct ttg aac cca ttc ttg ggt gag gta ttt	809
Met Gly Ser Glu Lys Lys Pro Leu Asn Pro Phe Leu Gly Glu Val Phe	
105 110 115	
gtt gga aag tgg aaa aat gat gag cat cca gag ttt ggt gaa acg gtt	857
Val Gly Lys Trp Lys Asn Asp Glu His Pro Glu Phe Gly Glu Thr Val	
120 125 130 135	
ctt tta agt gag caa gtt tca cat cat cca cct atg aca gca ttt tcg	905
Leu Leu Ser Glu Gln Val Ser His His Pro Pro Met Thr Ala Phe Ser	
140 145 150	
att ttt aat gaa aaa aat gat gtt tct gtt caa gga tac aat caa att	953
Ile Phe Asn Glu Lys Asn Asp Val Ser Val Gln Gly Tyr Asn Gln Ile	
155 160 165	
aaa act ggt ttt acc aaa aca ttg acg cta acg gtc aaa cca tac ggg	1001
Lys Thr Gly Phe Thr Lys Thr Leu Thr Leu Thr Val Lys Pro Tyr Gly	
170 175 180	
cat gtc att ttg aag att aaa gat gag acc tac ctg att aca acc ccg	1049
His Val Ile Leu Lys Ile Lys Asp Glu Thr Tyr Leu Ile Thr Thr Pro	
185 190 195	
cct ttg cat atc gaa ggt att tta gtc gct tct cca ttt gtt gaa tta	1097
Pro Leu His Ile Glu Gly Ile Leu Val Ala Ser Pro Phe Val Glu Leu	
200 205 210 215	
gga ggc agg tca ttc ata cag tca tca aat ggt atg tta tgt gtt ata	1145
Gly Gly Arg Ser Phe Ile Gln Ser Ser Asn Gly Met Leu Cys Val Ile	
220 225 230	
gaa ttt tca gga agg ggg tat ttc aca ggg aag aag aac tcc ttt aag	1193
Glu Phe Ser Gly Arg Gly Tyr Phe Thr Gly Lys Lys Asn Ser Phe Lys	
235 240 245	
gca aga att tac aga agc cca caa gag cat agt cat aaa gaa aat gcg	1241
Ala Arg Ile Tyr Arg Ser Pro Gln Glu His Ser His Lys Glu Asn Ala	
250 255 260	
cta tac cta atc tct ggc caa tgg tca ggt gtt tca aca att ata aaa	1289
Leu Tyr Leu Ile Ser Gly Gln Trp Ser Gly Val Ser Thr Ile Ile Lys	
265 270 275	
aaa gac tcg caa gtt tca cat cag ttt tac gat tca tcg gaa act cct	1337
Lys Asp Ser Gln Val Ser His Gln Phe Tyr Asp Ser Ser Glu Thr Pro	
280 285 290 295	
act gaa cat tta tta gtt aag cca atc gaa gaa caa cat cct ctg gaa	1385
Thr Glu His Leu Leu Val Lys Pro Ile Glu Glu Gln His Pro Leu Glu	
300 305 310	
agt agg agg gca tgg aag gat gtg gca gaa gca atc aga caa gga aat	1433
Ser Arg Arg Ala Trp Lys Asp Val Ala Glu Ala Ile Arg Gln Gly Asn	
315 320 325	

```

att agt atg ata aaa aag act aag gaa gaa cta gaa aat aag caa aga 1481
Ile Ser Met Ile Lys Lys Thr Lys Glu Glu Leu Glu Asn Lys Gln Arg
      330                      335                      340

gcc ttg aga gaa caa gaa cgc gta aaa ggt gtg gaa tgg caa aga aga 1529
Ala Leu Arg Glu Gln Glu Arg Val Lys Gly Val Glu Trp Gln Arg Arg
      345                      350                      355

tgg ttc aaa caa gtg gac tac atg aat gaa aat aca tca aat gat gta 1577
Trp Phe Lys Gln Val Asp Tyr Met Asn Glu Asn Thr Ser Asn Asp Val
      360                      365                      370

gag aaa gca agt gaa gat gat gcc ttt agg aaa ttg gcg tcc aaa ctg 1625
Glu Lys Ala Ser Glu Asp Asp Ala Phe Arg Lys Leu Ala Ser Lys Leu
      380                      385                      390

cag ctt tct gtg aaa aat gtg cca agt ggg aca ttg att ggc ggc aaa 1673
Gln Leu Ser Val Lys Asn Val Pro Ser Gly Thr Leu Ile Gly Gly Lys
      395                      400                      405

gat gat aag aaa gat gtt tca acc gca ttg cat tgg agg ttt gat aaa 1721
Asp Asp Lys Lys Asp Val Ser Thr Ala Leu His Trp Arg Phe Asp Lys
      410                      415                      420

aat ttg tgg atg agg gag aac gaa att act ata taa tataaatggt 1767
Asn Leu Trp Met Arg Glu Asn Glu Ile Thr Ile
      425                      430

tttaaaagaa taaatatcaa aaattaatac taattgatgt ttgcattgct ttttttaagg 1827

gaaaatgcaa gcgtttttat ttttaacttt tggttttgaa gctcgtaatt caacaaaaaa 1887

gaattaaata atcttcaagt ccgataacaa gatgtagaaa aaacatccca atgaagttac 1947

aagtcaaacc attcactgag aatttttgta actcaccacc gatttttttg ataaaatgta 2007

ttcctgcaac tttttttttt gaagagataa aaagaattga atagaatatg cagtaaaaaa 2067

agaatctcga aaaaaaaagg acaagaaatc ttaactacca tcaaacaatt gaaaattga 2126

<210>      6
<211>      266
<212>      DNA
<213>      Glycine max

<400>      6

ccattcaatc caattcttgg tgagacttat gaaatgggta accatgggtg cattacattt 60

atatcagagc aggtcagtca tcaccctcca atgagtgtctg ggcattgtga aactgaacat 120

ttcacttatg atgttacatc aaaattgaaa accaaatttc tcggcaactc agttgatgta 180

tatcctgttg gaagaacgcg tgttaccctc aaaagagatg gtgtgggcct tgatttggtg 240

cctcctccta caaaagttag caactt 266

```


cattgtgctg ccgttgatag ttctgagtgc attgaagtgc ctgacatcag accagaattc 120
aacccttggc aatatgataa ttgggatgct gaatagtgag catccttggtg gaattctttc 180
tattttttttt aaatatcatt ttgttattaa gtttgtaatg taatcttgat tggaagcttg 240
aaatttggtt ttgtt 255

<210> 10
<211> 250
<212> DNA
<213> Glycine max

<400> 10

taactcctac cccttggggt gacttgggaag tttaaccaata caacggtaaa tatacccaac 60
attgtgctgc cgttgatagt tctgagtgc ttgaagtgcc tgacatcaga ccagaattca 120
acccttggca atatgataat ttgggatgctg aatagtgagc atccttggtg aattctttct 180
atTTTTTTTtT aaatatcattt tgttattaag tttgtaatgt aatcttgatt ggaatgcttg 240
aaatttggtt 250

<210> 11
<211> 283
<212> DNA
<213> Glycine max

<220>
<221> unsure
<222> (1) ... (283)
<223> Unsure at all n locations

<400> 11

cgcctgtgnt taatttccca aaatctcaac ttcaatgcta nggtgaatca gtgtactgca 60
catcttccaa cttgctaagc caatgcaaac agtgggcaga gtccactgga caggttcaca 120
tcagtagtag catggagcat atctaccaca cgccccacat cttttggtgt tgctccttat 180
aattccactc ttggagagac ccaccatggt tccaagggca atctcaacgt cctagttgag 240
caggtttcac tcaatcctcc agtatctgcc ctccatgcaa cag 283

<210> 12
<211> 255
<212> DNA
<213> Glycine max

<400> 12

```

ggagagtgtg tggccaaccg aatcagccct tgtttggagt gagttgagcc aagccattat 60
gaacaaagat tgggaaagag caagagaagc aaagcaagac gtggaagaaa gacagaggaa 120
tatgttgaga gacagagcca tgaaaggaga aacttggttt cctaagaatt ttaggggtgc 180
ttacagtaaa gacacatggg aatgggactg ttcaccaact cataaatggg tccctgaggg 240
cccatcata gctca 255

```

```

<210> 13
<211> 259
<212> DNA
<213> Glycine max

<220>
<221> unsure
<222> (1) ... (259)
<223> Unsure at all n locations

```

```

<400> 13

agtcaaccct ccagtatctg ccctccatgc aacagatgag anggaaaaca ttgagatgat 60
atggtcccag caacctgttc caaagtttcg gggtagatct atgaagctca agtgcattgt 120
aaacgtcata tgtttctcca tgatttagga gcttcagctg acgtttacca tgcacttgag 180
ctgangctcc taaatcatgg agaaacatat gaaatgaatt gtcctcacct ttcaattaga 240
attcttccgg ttcttgga 259

```

```

<210> 14
<211> 355
<212> DNA
<213> Glycine max

<220>
<221> unsure
<222> (1) ... (355)
<223> Unsure at all n locations

```

```

<400> 14

gcagcttttg ctgtgtctag ctatgcgtca actgaangtc gacaatgtaa accttttaat 60
cctttactcg gggagacctg cgaagctgac tatccagata aaggacttaa gtttttttct 120
gaaaaggtta gtcacatccc aatgattggt gcttgctact gtgagggaag gggatggaag 180
ttttgggcag attctaattt gaaaggaaaa ttctgggggc gttctatcca gttagatcct 240
gtgggtgtcc tcaactotaca gtttgaggat ggtgaaacat ttcagtggag caaggtcacc 300

```


acttcgattt acaatatcat actangtaaa atttattgtg accactaagg tacca 355

<210> 15
 <211> 279
 <212> DNA
 <213> Glycine max

<220>
 <221> unsure
 <222> (1) ... (279)
 <223> Unsure at all n locations

<400> 15

cagattcgga ggaggaagct cagagaggaa gatggaaaca ggaggaaaga gatggttact 60
 ggaagatgat gcagaagtat attggctcgg atgtaacatc aatgggtgaca ctaccagtta 120
 ttatatattga accaatgact atgattcaga aaattgctga gttgatggag tactcctact 180
 tgttagatca agcagatgaa tcagaggatc catacatgca gttagtttat gcaatggatg 240
 taacttnatgt atcatcacag catccatggg ccatatcgg 279

<210> 16
 <211> 191
 <212> DNA
 <213> Glycine max

<400> 16

gttgatagtt ctgagtgcac agaggtgcct gacagcagaa cagaattcaa cccttggtcaa 60
 tatgataatt tggatgctga ataataagca tccttgtaga attctttcta ttctttgaac 120
 tatcattttg ttattaagtt tgcaatgtat ctgattggaa tgcttgaaat ttgggtttgt 180
 ttttgggtaa a 191

<210> 17
 <211> 267
 <212> DNA
 <213> Glycine max

<220>
 <221> unsure
 <222> (1) ... (267)
 <223> Unsure at all n locations

<400> 17

tcaactcctt ggggtgattt ggaaatctat caatataatg gtaaatacag tgaacatcga 60
 gctgctgcag ataactcagg aagcattgat gatgttgatg ctaaatcaat tgaattcaat 120

ccatggcagt atggtaattt ggccacggaa tgaactagtt tcaatttctt tggttttgga 180
 tgntncagtt agttcatgta actnttnncn antganacna gaanacaact ncctncnca 240
 ncnnanngtt agttgggcng tgtacgc 267

<210> 18
 <211> 252
 <212> DNA
 <213> Glycine max

<400> 18

gtcttataga gctcccaatc tcctacatcg cttgttaagt ttactcaaga acgtgcggcc 60
 aggatcagat ctacacact tccaactgcc agctgtgttt aacttcccaa aatctcaact 120
 tcaatgctat ggtgaatcag tgtactgcac atcttcaaac ttgctgagca aatgcaacaa 180
 tgggcagagt ccaactggaca ggttcacatc agtagtagca tggagcatat ctaccacacg 240
 cccacatct tt 252

<210> 19
 <211> 241
 <212> DNA
 <213> Glycine max

<400> 19

gtcagtcac accctccaat gagtgtctggg catgtctgaaa ctgaacattt cacttatgat 60
 gttacatcaa aattgaaaac caaatttctc ggcaactcag ttgatgtata tcctgttgga 120
 agaacgcgtg ttaccctcaa aagagatggt gtggctccttg atttggtgcc tcctcctaca 180
 aaagtttagca acttgatttt tggacgaact tggattgatt caccaggaga gatgatcctg 240
 a 241

<210> 20
 <211> 262
 <212> DNA
 <213> Glycine max

<400> 20

tctcgagcct attcggctcg aggccaaaga agccatttca ggtcactaaa ctctattat 60
 catatgatgt ggagagtgtg tattcaaccg aatcagccct tgtttggagt gagttgagcc 120
 aagccattat gaacaaagat tgggaaagag caagagaagc aaagcaagac gtggaagaaa 180

gacagaggaa tatgttgaga gacagagcca tgacaggaga aactggttgt ctaagaattt 240
agggtgtctt acagtaaaga ca 262

<210> 21
<211> 463
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> unsure
<222> (1) ... (463)
<223> Unsure at all n locations

<400> 21

ggggaacccc ttccaggaac agagctgaaa gaggtgtggc atttggctga tgtcccaaaa 60
aacgacaact ttcagtacac tcactttgct cacaagataa acagcttcga cacagcgcct 120
gctaagctct tggcttcaga ctcacgtatc cgtcctgata gatattccct tgagcaggg 180
gacctttcta aagctggttc cgagaaacac agccttgagg agagacaaag ggccgaaaag 240
aggaccagag agacaaaggg acaaaagttc actccaagat ggttcgatct aacggatgag 300
atcacaccta ctccatgggg agatattgaa gtataccant acaacgggaa gtacaatgaa 360
caccgagaca cggcagagag ctcaagtagt gcctccaacg aaacgggact caaatccatc 420
gagtttaatc ottggcaata tggtaatatc tcaaccgaat gaa 463

<210> 22
<211> 399
<212> DNA
<213> Arabidopsis thaliana

<400> 22

agtgaacctc tcccaggcac cgaactgaaa gaggtatgga aactcgctga tgtgccaaaag 60
gatgacaaat atcaatacac tcactttgct cacaagatta atagcttcga cactgccccg 120
aaaaagctgt tgccctctga ttcaagggtta cgacctgata gatacgact tgagatgggc 180
gacatgtcca aatcaggcta tgagaagagc agcatggaag agagacagag agctgacaag 240
agaacccgcg aacataaagg ccaagccttt actccaaaat ggttcgatgt aacggaagaa 300
gtcactgcta caccatgggg tgatctggaa gtttaccat tcaactggaaa gtactcagaa 360
catcgtgcag ctgacgataa ctctgaagat aagaccgac 399

<210> 23

<211> 343
 <212> DNA
 <213> Arabidopsis thaliana

<400> 23

acggacgcgt gggcaactcc aatgttacgg cgagatggtc tacagcttcg tcggtcagga 60
 tctgcttggg gaatgcagcc gccgtgatct tccattgaa cggtcaaata cagtgggtgac 120
 gtggaacatc tccacactcc gtccgggtgt ctttggcatg tctccgtaca actccgttct 180
 cggcgagact caccacgtat cgaacggta catcaacgtc atcgccgaac aagtagtgca 240
 tcatectccg gtttccgctc ttcatgagac tcacgaacaa gaaaatatcg acgtgacatg 300
 gtgtcaatat ttcactccta aatttcgtgg tactcacgtg gac 343

<210> 24
 <211> 510
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> unsure
 <222> (1) ... (510)
 <223> Unsure at all n locations

<400> 24

gaaagctagc agatgtagaa caaagttttt tgtaactacg agagaataag aatacatttg 60
 ttccaaaaaa gatttgatct tttctgtctt ttggagcgat acatttaagt agacagatct 120
 tggaattgcc atgggttgaa ttgatcgac ttagggtcgg tggtatcttc agagttatcc 180
 gcagctgcac gatgttccga gtactttcca ttgaattggg aaacttccag atcaccccat 240
 ggtgtagcag tgacttcttc cgttacatcg aaccattttg gagtaaaggc ttggcctttc 300
 tcttcgctgg gtcncttttc aagtctctgt cncctttcca tgggtgntctt cccanagcct 360
 gatttgnaca tggcggccan cccaaggng gatcaatcag gccgnaacgg ggaatcaggn 420
 ggnaacagct tttcnnggna ntgncgaagc aataaacntt gggggcaaag gggggggatt 480
 ggaaattggc aacccttggg naacaggggc 510

<210> 25
 <211> 282
 <212> DNA
 <213> Arabidopsis thaliana

<220>

<221> unsure
 <222> (1) ... (282)
 <223> Unsure at all n locations

<400> 25

gatacatttg gattcgaaaa gagcagccta gaggatagac aaagagctga gaagaaaagc 60
 agagaagaga aaggccaaaa ntttccncca aaatggtttn atgaaacana agangtcact 120
 cctacaccat ggggtgatct cgaagtttac caattcantg gaaagtactc ggtgcaccgn 180
 gccacagctg aaaactntga ggatacaacc gntgtgaagt tgncccaatt caacccttgg 240
 caattccaag atctctntgc ttaatccttt ggtgccatth gt 282

<210> 26
 <211> 380
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> unsure
 <222> (1) ... (380)
 <223> Unsure at all n locations

<400> 26

cgttggtggc ngcggaagtg gtttcttcgc ctctcttgct tcgtcgatct ccaatttngg 60
 ntctgctatg accaaatcag ttaatggtht ggttccctat gagggacttg aagttatcaa 120
 tctgaagga agtacagatg atgctgagga ggaagcaagc agaggaagat ggaagcaaga 180
 ggatcgagat ggctattgga agatgatgca gaagtacata ggatctgatg ttacatcaat 240
 ggtgaccctt cctgtgatta tttttgaacc aatgacaatg cttcagaaaa tggcggagtt 300
 gatggaatac tcgcatctgc tagacatggc agacaaaacc gaggaccctt atttnogcat 360
 ggtgtatgca tcatcgtggg 380

<210> 27
 <211> 359
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> unsure
 <222> (1) ... (359)
 <223> Unsure at all n locations

<400> 27

ggtaatgaag gagttgaggt cataaatcca gaaggtggca aggaagatnc tgaagaggaa 60


```

cctttcccaa tnggnnttgg gngngccccc ttggangggg ccggggcttt aaagggcccc 120
ncgnagggaa ggccagcctt tctcccaaatt ggtcgatgta ccggaggaag tctactgtac 180
cccatgggggt gatctggaag tttcccaatt caatggaaag tactcggaac atcgtgcagc 240
tgccgataac tctgaagata acaccgaccc taagtcgata caattcaacc catggcaatt 300
ccaagatctg tctacttaaa tgtatcgctc caaaagacag aaaagatcaa atcttttttg 360
aaacaaatgt attcttattc tctcgtagtt acaaaaaact ttgttctaca tctgctagct 420
ttccattgac tttctctagt attagtgtac aacttctact gttttgtctt aaattcattc 480
aaatctttct ttg 493

```

```

<210>      30
<211>      358
<212>      PRT
<213>      Glycine max
<400>      30

```

```

Met Thr Met Leu Gln Lys Met Ala Glu Leu Met Glu Tyr Ser Tyr Leu
1          5          10          15
Leu Asp Met Ala Asp Lys Thr Glu Asp Pro Tyr Met Arg Leu Val Tyr
20        25        30
Ala Ser Ser Phe Phe Ile Ser Val Tyr Tyr Ala Tyr Gln Arg Thr Trp
35        40        45
Lys Pro Phe Asn Pro Ile Leu Gly Glu Thr Tyr Glu Met Val Asn His
50        55        60
Gly Gly Ile Thr Phe Ile Ser Glu Gln Val Ser His His Pro Pro Met
65        70        75        80
Ser Ala Gly His Ala Glu Thr Glu His Phe Thr Tyr Asp Val Thr Ser
85        90        95
Lys Leu Lys Thr Lys Phe Leu Gly Asn Ser Val Asp Val Tyr Pro Val
100       105       110
Gly Arg Thr Arg Val Thr Leu Lys Arg Asp Gly Val Val Leu Asp Leu
115       120       125
Val Pro Pro Pro Thr Lys Val Ser Asn Leu Ile Phe Gly Arg Thr Trp
130       135       140
Ile Asp Ser Pro Gly Glu Met Ile Leu Thr Asn Leu Thr Thr Gly Asp
145       150       155       160
Lys Val Val Leu Tyr Phe Gln Pro Cys Gly Trp Phe Gly Tyr Glu Val
165       170       175

```

```

Asp Gly Tyr Val Tyr Asn Ser Ala Asp Glu Pro Lys Ile Leu Met Thr
      180                      185                      190

Gly Lys Trp Asn Glu Ala Met Asn Tyr Gln Val Cys Asp Ser Glu Gly
      195                      200                      205

Glu Pro Leu Pro Gly Thr Glu Leu Lys Glu Ile Trp Arg Val Ala Asp
      210                      215                      220

Thr Pro Lys Lys Asp Lys Phe Gln Tyr Thr His Phe Ala His Lys Ile
      225                      230                      235                      240

Asn Ser Phe Asp Thr Ala Pro Lys Lys Leu Leu Ala Ser Asp Ser Arg
      245                      250                      255

Leu Arg Pro Asp Arg Met Ala Leu Glu Lys Gly Asp Leu Ser Thr Ser
      260                      265                      270

Gly Tyr Glu Lys Ser Ser Leu Glu Glu Arg Gln Arg Ala Glu Lys Arg
      275                      280                      285

Asn Arg Glu Ala Lys Gly His Lys Phe Thr Pro Arg Trp Phe Asp Leu
      290                      295                      300

Thr Asp Glu Val Thr Pro Thr Pro Trp Gly Asp Leu Glu Val Tyr Gln
      305                      310                      315                      320

Tyr Asn Gly Lys Tyr Thr Gln His Cys Ala Ala Val Asp Ser Ser Glu
      325                      330                      335

Cys Ile Glu Val Pro Asp Ile Arg Pro Glu Phe Asn Pro Trp Gln Tyr
      340                      345                      350

Asp Asn Leu Asp Ala Glu
      355

<210>      31
<211>      300
<212>      PRT
<213>      Glycine max

<400>      31

Met Cys Asn Asn Gly Gln Ser Pro Leu Asp Arg Phe Ile Ser Val Val
1      5                      10                      15

Ala Trp Cys Ile Ser Thr Thr Arg Pro Val Thr Phe Gly Val Ala Pro
      20                      25                      30

Tyr Asn Pro Ile Leu Gly Glu Thr His His Val Ser Arg Gly Asn Leu
      35                      40                      45

Asn Val Leu Leu Glu Gln Ile Ser His His Pro Pro Val Thr Ala Leu
      50                      55                      60

His Ala Thr Asp Glu Lys Glu Asn Ile Glu Met Leu Trp Cys Gln Arg

```


65		70		75		80
Pro Asp Pro Lys Phe Asn Gly Thr Ser Val Glu Ala Lys Val His Gly						
	85			90		95
Ile Arg Gln Leu Lys Leu Leu Asn His Gly Glu Thr Tyr Glu Met Asn						
	100			105		110
Cys Pro Arg Leu Leu Leu Arg Ile Leu Pro Val Pro Gly Ala Asp Trp						
	115			120		125
Ala Gly Thr Val Asn Ile Arg Cys Leu Glu Thr Gly Leu Val Ala Glu						
	130			135		140
Leu Ser Tyr Arg Ser Ser Ser Phe Leu Gly Ile Gly Gly Asn His Arg						
	145			150		155
Val Ile Lys Gly Lys Ile Leu Asp Ser Ser Ser Leu Lys Val Leu Tyr						
	165			170		175
Glu Val Asp Gly His Trp Asp Arg Thr Val Lys Val Lys Asp Thr Asn						
	180			185		190
Asn Gly Lys Val Arg Val Ile Tyr Asp Ala Lys Glu Val Met Ser Gly						
	195			200		205
Leu Glu Thr Pro Ile Leu Lys Asp Ile Glu Gly Val Trp Gln Thr Glu						
	210			215		220
Ser Ala His Val Trp Gly Glu Leu Asn Gln Ala Ile Val Ser Lys Asp						
	225			230		235
Trp Glu Lys Ala Arg Glu Ala Lys Leu Lys Val Glu Glu Arg Gln Arg						
	245			250		255
Glu Leu Val Arg Glu Arg Glu Ser Lys Gly Glu Thr Trp Ile Ser Lys						
	260			265		270
His Phe Val Val Ser Asn Asn Lys Glu Gly Trp Gln Cys Ser Pro Ile						
	275			280		285
His Lys Ser Val Pro Ala Ala Pro Ile Thr Ala Leu						
	290			295		300

<210> 32
 <211> 355
 <212> PRT
 <213> Glycine max
 <400> 32

Met Ala Glu Leu Met Glu Tyr Ser Tyr Leu Leu Asp Met Ala Asp Lys						
1		5			10	15
Thr Glu Asp Pro Tyr Met Arg Leu Val Tyr Ala Ser Ser Phe Phe Ile						
	20			25		30

Ser	Val	Tyr	Tyr	Ala	Tyr	Gln	Arg	Thr	Trp	Lys	Pro	Phe	Asn	Pro	Ile		
		35					40					45					
Leu	Gly	Glu	Thr	Tyr	Glu	Met	Val	Asn	His	Gly	Gly	Ile	Thr	Phe	Ile		
	50					55					60						
Ser	Glu	Gln	Val	Ser	His	His	Pro	Pro	Met	Ser	Ala	Gly	His	Ala	Glu		
65					70					75					80		
Thr	Glu	His	Phe	Thr	Tyr	Asp	Val	Thr	Ser	Lys	Leu	Lys	Thr	Lys	Phe		
				85					90					95			
Leu	Gly	Asn	Ser	Val	Asp	Val	Tyr	Pro	Val	Gly	Arg	Thr	Arg	Val	Thr		
			100					105						110			
Leu	Lys	Arg	Asp	Gly	Val	Val	Leu	Asp	Leu	Val	Pro	Pro	Pro	Thr	Lys		
		115					120					125					
Val	Ser	Asn	Leu	Ile	Phe	Gly	Arg	Thr	Trp	Ile	Asp	Ser	Pro	Gly	Glu		
		130				135					140						
Met	Ile	Leu	Thr	Asn	Leu	Thr	Thr	Gly	Asp	Lys	Val	Val	Leu	Tyr	Phe		
145					150					155					160		
Gln	Pro	Cys	Gly	Trp	Phe	Gly	Ala	Gly	Arg	Tyr	Glu	Val	Asp	Gly	Tyr		
				165					170					175			
Val	Tyr	Asn	Ser	Ala	Asp	Glu	Pro	Lys	Ile	Leu	Met	Thr	Gly	Lys	Trp		
			180					185					190				
Asn	Glu	Ala	Met	Asn	Tyr	Gln	Val	Cys	Asp	Ser	Glu	Gly	Glu	Pro	Leu		
		195					200					205					
Pro	Gly	Thr	Glu	Leu	Lys	Glu	Ile	Trp	Arg	Val	Ala	Asp	Thr	Pro	Lys		
	210					215					220						
Lys	Asp	Lys	Phe	Gln	Tyr	Thr	His	Phe	Ala	His	Lys	Ile	Asn	Ser	Phe		
225					230					235					240		
Asp	Thr	Ala	Pro	Lys	Lys	Leu	Leu	Ala	Ser	Asp	Ser	Arg	Leu	Arg	Pro		
				245					250					255			
Asp	Arg	Met	Ala	Leu	Glu	Lys	Gly	Asp	Leu	Ser	Thr	Ser	Gly	Tyr	Glu		
			260					265					270				
Lys	Ser	Ser	Leu	Glu	Glu	Arg	Gln	Arg	Ala	Glu	Lys	Arg	Asn	Arg	Glu		
		275					280					285					
Ala	Lys	Gly	His	Lys	Phe	Thr	Pro	Arg	Trp	Phe	Asp	Leu	Thr	Asp	Glu		
	290					295					300						
Val	Thr	Pro	Thr	Pro	Trp	Gly	Asp	Leu	Glu	Val	Tyr	Gln	Tyr	Asn	Gly		
305					310					315					320		
Lys	Tyr	Thr	Gln	His	Cys	Ala	Ala	Val	Asp	Ser	Ser	Glu	Cys	Ile	Glu		
				325					330					335			

Val Pro Asp Ile Arg Pro Glu Phe Asn Pro Trp Gln Tyr Asp Asn Leu
 340 345 350

Asp Ala Glu
 355

<210> 33
 <211> 414
 <212> PRT
 <213> Zea mays
 <400> 33

Met Ala Thr Lys Glu Glu Ala Ser Ala Val Pro Ala Ala Ser Lys Thr
 1 5 10 15

Ser Trp Ser Ser Phe Leu Lys Ser Ile Ala Ser Phe Asn Gly Asp Leu
 20 25 30

Ser Ser Leu Thr Ala Pro Pro Phe Ile Leu Ser Thr Thr Ser Leu Thr
 35 40 45

Glu Tyr Ser Ala Tyr Trp Cys Glu His Pro Ala Leu Phe Val Ala Pro
 50 55 60

Ala Arg Glu Pro Asp Pro Ala Lys Arg Ala Leu Leu Val Leu Lys Trp
 65 70 75 80

Phe Leu Ser Thr Leu His Gln Gln Tyr Cys Ser Arg Ser Glu Lys Leu
 85 90 95

Gly Ser Glu Lys Lys Pro Leu Asn Pro Phe Leu Gly Glu Leu Phe Leu
 100 105 110

Gly Lys Trp Ile Glu Asp Glu Asp Val Gly Glu Thr Arg Leu Ile Ser
 115 120 125

Glu Gln Val Ser His His Pro Pro Ala Thr Ala Tyr Ser Ile Val Asn
 130 135 140

Glu Lys His Gly Val Glu Leu Gln Gly Tyr Asn Ala Gln Lys Ala Ser
 145 150 155 160

Phe Ser Ser Thr Ile Gln Val Lys Gln Leu Gly His Ala Tyr Leu Ser
 165 170 175

Leu Thr Pro Pro Gly Lys Asp Ala Asn Asn Glu Asp Asp Arg Glu His
 180 185 190

Tyr Leu Ile Thr Leu Pro Asn Leu His Ile Glu Ser Leu Ile Tyr Gly
 195 200 205

Thr Pro Phe Val Glu Leu Glu Lys Ser Cys Lys Ile Ala Ser Ser Thr
 210 215 220

20240 "LEEDS"

65		70		75		80
Gln Met Leu Ala Val Val Arg Trp Phe Ile Ser Thr Leu Arg Ser Gln						
		85		90		95
Tyr Cys Ser Arg Ser Glu Ser Met Gly Ser Glu Lys Lys Pro Leu Asn						
		100		105		110
Pro Phe Leu Gly Glu Val Phe Val Gly Lys Trp Lys Asn Asp Glu His						
		115		120		125
Pro Glu Phe Gly Glu Thr Val Leu Leu Ser Glu Gln Val Ser His His						
		130		135		140
Pro Pro Met Thr Ala Phe Ser Ile Phe Asn Glu Lys Asn Asp Val Ser						
		145		150		155
Val Gln Gly Tyr Asn Gln Ile Lys Thr Gly Phe Thr Lys Thr Leu Thr						
		165		170		175
Leu Thr Val Lys Pro Tyr Gly His Val Ile Leu Lys Ile Lys Asp Glu						
		180		185		190
Thr Tyr Leu Ile Thr Thr Pro Pro Leu His Ile Glu Gly Ile Leu Val						
		195		200		205
Ala Ser Pro Phe Val Glu Leu Gly Gly Arg Ser Phe Ile Gln Ser Ser						
		210		215		220
Asn Gly Met Leu Cys Val Ile Glu Phe Ser Gly Arg Gly Tyr Phe Thr						
		225		230		235
Gly Lys Lys Asn Ser Phe Lys Ala Arg Ile Tyr Arg Ser Pro Gln Glu						
		245		250		255
His Ser His Lys Glu Asn Ala Leu Tyr Leu Ile Ser Gly Gln Trp Ser						
		260		265		270
Gly Val Ser Thr Ile Ile Lys Lys Asp Ser Gln Val Ser His Gln Phe						
		275		280		285
Tyr Asp Ser Ser Glu Thr Pro Thr Glu His Leu Leu Val Lys Pro Ile						
		290		295		300
Glu Glu Gln His Pro Leu Glu Ser Arg Arg Ala Trp Lys Asp Val Ala						
		305		310		315
Glu Ala Ile Arg Gln Gly Asn Ile Ser Met Ile Lys Lys Thr Lys Glu						
		325		330		335
Glu Leu Glu Asn Lys Gln Arg Ala Leu Arg Glu Gln Glu Arg Val Lys						
		340		345		350
Gly Val Glu Trp Gln Arg Arg Trp Phe Lys Gln Val Asp Tyr Met Asn						
		355		360		365
Glu Asn Thr Ser Asn Asp Val Glu Lys Ala Ser Glu Asp Asp Ala Phe						

370

375

380

Arg Lys Leu Ala Ser Lys Leu Gln Leu Ser Val Lys Asn Val Pro Ser
385 390 395 400

Gly Thr Leu Ile Gly Gly Lys Asp Asp Lys Lys Asp Val Ser Thr Ala
405 410 415

Leu His Trp Arg Phe Asp Lys Asn Leu Trp Met Arg Glu Asn Glu Ile
420 425 430

Thr Ile

202410-230000T

<110> Karunanandaa, Balasulojini
Yu, Jaehyuk
Kishore, Ganesh M.

<120> NUCLEIC ACID MOLECULES AND OTHER MOLECULES ASSOCIATED
WITH STEROL SYNTHESIS AND METABOLISM

<130> 05686.0004.PC0000

<150> US 60/142,981

<151> 1999-07-12

<160> 34

<210> 1

<211> 1358

<212> DNA

<213> Glycine max

<220>

<221> CDS

<222> (24)...(1100)

<400> 1

```

gaattcggct cgagtttgaa cca atg aca atg ctt cag aaa atg gct gag ctt      53
                Met Thr Met Leu Gln Lys Met Ala Glu Leu
                  1                      5                      10

atg gag tac tct tac ctg tta gat atg gcg gac aag act gag gat cca      101
Met Glu Tyr Ser Tyr Leu Leu Asp Met Ala Asp Lys Thr Glu Asp Pro
                  15                      20                      25

tac atg aga cta gta tat gct tca tca ttc ttt ata tct gtc tac tat      149
Tyr Met Arg Leu Val Tyr Ala Ser Ser Phe Phe Ile Ser Val Tyr Tyr
                  30                      35                      40

gcc tat caa cga acg tgg aag cca ttc aat cca att ctt ggt gag act      197
Ala Tyr Gln Arg Thr Trp Lys Pro Phe Asn Pro Ile Leu Gly Glu Thr
                  45                      50                      55

tat gaa atg gtt aac cat ggt ggc att aca ttt ata tca gag cag gtc      245
Tyr Glu Met Val Asn His Gly Gly Ile Thr Phe Ile Ser Glu Gln Val
                  60                      65                      70

agt cat cac cct cca atg agt gct ggg cat gct gaa act gaa cat ttc      293
Ser His His Pro Pro Met Ser Ala Gly His Ala Glu Thr Glu His Phe
                  75                      80                      85                      90

act tat gat gtt aca tca aaa ttg aaa acc aaa ttt ctc ggc aac tca      341
Thr Tyr Asp Val Thr Ser Lys Leu Lys Thr Lys Phe Leu Gly Asn Ser
                  95                      100                      105

gtt gat gta tat cct gtt gga aga acg cgt gtt acc ctc aaa aga gat      389
Val Asp Val Tyr Pro Val Gly Arg Thr Arg Val Thr Leu Lys Arg Asp
                  110                      115                      120

```

ggt gtg gtc ctt gat ttg gtg cct cct cct aca aaa gtt agc aac ttg 437
 Gly Val Val Leu Asp Leu Val Pro Pro Pro Thr Lys Val Ser Asn Leu
 125 130 135

att ttt gga cga act tgg att gat tca cca gga gag atg atc ctg aca 485
 Ile Phe Gly Arg Thr Trp Ile Asp Ser Pro Gly Glu Met Ile Leu Thr
 140 145 150

aat ctg act aca ggg gac aaa gtg gtg ctg tat ttt caa cca tgt ggc 533
 Asn Leu Thr Thr Gly Asp Lys Val Val Leu Tyr Phe Gln Pro Cys Gly
 155 160 165 170

tgg ttt gga tat gaa gtg gat ggg tac gtg tat aat tct gct gac gag 581
 Trp Phe Gly Tyr Glu Val Asp Gly Tyr Val Tyr Asn Ser Ala Asp Glu
 175 180 185

cct aag ata ctg atg act gga aaa tgg aat gag gct atg aat tat caa 629
 Pro Lys Ile Leu Met Thr Gly Lys Trp Asn Glu Ala Met Asn Tyr Gln
 190 195 200

gtt tgt gac tca gag gga gaa cca ctt cca ggc act gag ttg aaa gag 677
 Val Cys Asp Ser Glu Gly Glu Pro Leu Pro Gly Thr Glu Leu Lys Glu
 205 210 215

att tgg aga gtt gct gat acc ccg aag aag gac aag ttc cag tac acg 725
 Ile Trp Arg Val Ala Asp Thr Pro Lys Lys Asp Lys Phe Gln Tyr Thr
 220 225 230

cat ttt gca cac aag att aac agc ttt gac act gct ccc aag aag ttg 773
 His Phe Ala His Lys Ile Asn Ser Phe Asp Thr Ala Pro Lys Lys Leu
 235 240 245 250

ttg gca tct gac tct cgt cta cgt cct gat aga atg gcc ctt gag aag 821
 Leu Ala Ser Asp Ser Arg Leu Arg Pro Asp Arg Met Ala Leu Glu Lys
 255 260 265

ggt gac cta tcc aca tct ggt tat gag aag agc agt ttg gag gag agg 869
 Gly Asp Leu Ser Thr Ser Gly Tyr Glu Lys Ser Ser Leu Glu Glu Arg
 270 275 280

caa aga gct gag aag aga aac cga gag gcc aag ggc cat aag ttc act 917
 Gln Arg Ala Glu Lys Arg Asn Arg Glu Ala Lys Gly His Lys Phe Thr
 285 290 295

cct aga tgg ttt gat tta aca gat gaa gta act cct acc cct tgg ggt 965
 Pro Arg Trp Phe Asp Leu Thr Asp Glu Val Thr Pro Thr Pro Trp Gly
 300 305 310

gac ttg gaa gtt tac caa tac aac ggt aaa tat acc caa cat tgt gct 1013
 Asp Leu Glu Val Tyr Gln Tyr Asn Gly Lys Tyr Thr Gln His Cys Ala
 315 320 325 330

gcc gtt gat agt tct gag tgc att gaa gtg cct gac atc aga cca gaa 1061
 Ala Val Asp Ser Ser Glu Cys Ile Glu Val Pro Asp Ile Arg Pro Glu
 335 340 345

ttc aac cct tgg caa tat gat aat ttg gat gct gaa tag tgagcatcct 1110
 Phe Asn Pro Trp Gln Tyr Asp Asn Leu Asp Ala Glu

350

355

tgtggaattc tttctatattt ttttaaataat cattttgtta ttaagtttgt aatgtaatct 1170
 tgattggaat gcttgaaatt tggtttttgtt tttgggttgt tttatcactg tagtatttga 1230
 ttaattaata gtagctatgt tagttcatca gttcactttg catggataaa tgctagtagg 1290
 gaaattaaag ttatcttcca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagggc 1350
 ggccgccc 1358

<210> 2
 <211> 1136
 <212> DNA
 <213> Glycine max

<220>
 <221> CDS
 <222> (73)...(975)

<400> 2

gaattcggct cgaggtcaca acttcagtgc tatggtgaat cagtgtattg cacaggttcg 60
 gacttgctaa gc atg tgc aac aat ggt cag agt cca ctt gat agg ttc ata 111
 Met Cys Asn Asn Gly Gln Ser Pro Leu Asp Arg Phe Ile
 1 5 10

tct gtg gta gca tgg tgc ata tct acc act cgc cct gtg act ttt ggt 159
 Ser Val Val Ala Trp Cys Ile Ser Thr Thr Arg Pro Val Thr Phe Gly
 15 20 25

gtt gct cct tat aat ccc att ctt ggt gag aca cac cat gtt tca agg 207
 Val Ala Pro Tyr Asn Pro Ile Leu Gly Glu Thr His His Val Ser Arg
 30 35 40 45

gga aat ctt aat gtg tta ttg gag cag att tca cat cac cct cca gta 255
 Gly Asn Leu Asn Val Leu Leu Glu Gln Ile Ser His His Pro Pro Val
 50 55 60

act gct ctc cat gca aca gat gag aag gaa aac att gaa atg tta tgg 303
 Thr Ala Leu His Ala Thr Asp Glu Lys Glu Asn Ile Glu Met Leu Trp
 65 70 75

tgc cag cga cct gat cca aag ttt aat ggc aca tca gtt gaa gct aaa 351
 Cys Gln Arg Pro Asp Pro Lys Phe Asn Gly Thr Ser Val Glu Ala Lys
 80 85 90

gtg cat gga ata cgc cag ttg aag ctc cta aat cat ggt gaa aca tat 399
 Val His Gly Ile Arg Gln Leu Lys Leu Leu Asn His Gly Glu Thr Tyr
 95 100 105

gaa atg aat tgt cct cgc ctt tta ctt aga att ctt cca gtt cct ggt 447
 Glu Met Asn Cys Pro Arg Leu Leu Leu Arg Ile Leu Pro Val Pro Gly
 110 115 120 125

gct gat tgg gct ggt aca gtt aat ata cgg tgc cta gag aca ggt cta 495
Ala Asp Trp Ala Gly Thr Val Asn Ile Arg Cys Leu Glu Thr Gly Leu
130 135 140

gta gct gaa tta tcc tac aga tca agt tct ttt cta gga att ggg ggg 543
Val Ala Glu Leu Ser Tyr Arg Ser Ser Ser Phe Leu Gly Ile Gly Gly
145 150 155

aat cat aga gtg atc aaa ggg aag atc ctt gac tct tca tca ttg aaa 591
Asn His Arg Val Ile Lys Gly Lys Ile Leu Asp Ser Ser Ser Leu Lys
160 165 170

gtt cta tat gaa gtt gat ggt cat tgg gat agg acc gta aaa gtg aag 639
Val Leu Tyr Glu Val Asp Gly His Trp Asp Arg Thr Val Lys Val Lys
175 180 185

gac aca aat aat ggg aaa gta aga gtg ata tat gat gca aag gaa gtt 687
Asp Thr Asn Asn Gly Lys Val Arg Val Ile Tyr Asp Ala Lys Glu Val
190 195 200 205

atg tca ggt ctc gaa act cct ata ctc aag gac ata gag ggt gtg tgg 735
Met Ser Gly Leu Glu Thr Pro Ile Leu Lys Asp Ile Glu Gly Val Trp
210 215 220

caa aca gaa tca gct cat gtt tgg ggt gaa tta aac caa gcc att gtg 783
Gln Thr Glu Ser Ala His Val Trp Gly Glu Leu Asn Gln Ala Ile Val
225 230 235

agc aaa gac tgg gag aaa gca aga gaa gca aag cta aaa gtt gag gaa 831
Ser Lys Asp Trp Glu Lys Ala Arg Glu Ala Lys Leu Lys Val Glu Glu
240 245 250

aga caa agg gag ctt gtg aga gaa aga gaa tca aaa gga gaa aca tgg 879
Arg Gln Arg Glu Leu Val Arg Glu Arg Glu Ser Lys Gly Glu Thr Trp
255 260 265

att tct aag cat ttt gta gtt tct aac aac aaa gaa ggg tgg caa tgt 927
Ile Ser Lys His Phe Val Val Ser Asn Asn Lys Glu Gly Trp Gln Cys
270 275 280 285

tca cct att cat aag agt gta cct gcg gcc ccc atc aca gcc cta taa 975
Ser Pro Ile His Lys Ser Val Pro Ala Ala Pro Ile Thr Ala Leu
290 295 300

ttgttggtcac tgtcaagtag tgtaaagcat taaagtacat tttagaagag aatgttcata 1035

aaaaaattta atgggttgaaa ttttgacaac aatgaagtat ataacaaaat ttaaaattag 1095

ttacaatttt aaaaaaaaaa aaaaaaaaaaag ggcggccgcc g 1136

<210> 3
<211> 1355
<212> DNA
<213> Glycine max

<220>
<221> CDS

<400> 3

[illegible]

200	205	210	215	
att tgg aga gtt gct gat acc ccg aag aag gac aag ttc cag tac acg				724
Ile Trp Arg Val Ala Asp Thr Pro Lys Lys Asp Lys Phe Gln Tyr Thr				
	220	225	230	
cat ttt gca cac aag att aac agc ttt gac act gct ccc aag aag ttg				772
His Phe Ala His Lys Ile Asn Ser Phe Asp Thr Ala Pro Lys Lys Leu				
	235	240	245	
ttg gca tct gac tct cgt cta cgt cct gat aga atg gcc ctt gag aag				820
Leu Ala Ser Asp Ser Arg Leu Arg Pro Asp Arg Met Ala Leu Glu Lys				
	250	255	260	
ggt gac cta tcc aca tct ggt tat gag aag agc agt ttg gag gag agg				868
Gly Asp Leu Ser Thr Ser Gly Tyr Glu Lys Ser Ser Leu Glu Glu Arg				
	265	270	275	
caa aga gct gag aag aga aac cga gag gcc aag ggc cat aag ttc act				916
Gln Arg Ala Glu Lys Arg Asn Arg Glu Ala Lys Gly His Lys Phe Thr				
	280	285	290	295
cct aga tgg ttt gat tta aca gat gaa gta act cct acc cct tgg ggt				964
Pro Arg Trp Phe Asp Leu Thr Asp Glu Val Thr Pro Thr Pro Trp Gly				
	300	305	310	
gac ttg gaa gtt tac caa tac aac ggt aaa tat acc caa cat tgt gct				1012
Asp Leu Glu Val Tyr Gln Tyr Asn Gly Lys Tyr Thr Gln His Cys Ala				
	315	320	325	
gcc gtt gat agt tct gag tgc att gaa gtg cct gac atc aga cca gaa				1060
Ala Val Asp Ser Ser Glu Cys Ile Glu Val Pro Asp Ile Arg Pro Glu				
	330	335	340	
ttc aac cct tgg caa tat gat aat ttg gat gct gaa tag tgagcatcct				1109
Phe Asn Pro Trp Gln Tyr Asp Asn Leu Asp Ala Glu				
	345	350	355	
tggtggaattc tttctatttt tttgaaatat cattttgtta ttaagtttgt aatgtaatct				1169
tgattggaat gcttgaaatt tggttttgtt tttgggttgt tttatcactg tagtatttga				1229
ttaattaata gtagctatgt tagttcatca gttcactttg catggataaa tgctagtaga				1289
gaaattaaag ttaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaagggcgg				1349
ccgccg				1355

<210> 4
 <211> 1422
 <212> DNA
 <213> Zea mays

 <220>
 <221> CDS
 <222> (1) ... (1245)

<400>

4

atg gct acc aaa gaa gaa gct agc gct gtc ccc gcc gcc agt aaa act	48
Met Ala Thr Lys Glu Glu Ala Ser Ala Val Pro Ala Ala Ser Lys Thr	
1 5 10 15	
tca tgg agt agc ttc ctg aag tcc atc gca tcc ttc aac ggc gac ctc	96
Ser Trp Ser Ser Phe Leu Lys Ser Ile Ala Ser Phe Asn Gly Asp Leu	
20 25 30	
tcc tct ctc acc gca ccg ccg ttc atc ctc tca aca acc tct tta acc	144
Ser Ser Leu Thr Ala Pro Pro Phe Ile Leu Ser Thr Thr Ser Leu Thr	
35 40 45	
gag tat tct gcg tac tgg tgc gaa cat cct gca ctc ttc gtt gcc ccc	192
Glu Tyr Ser Ala Tyr Trp Cys Glu His Pro Ala Leu Phe Val Ala Pro	
50 55 60	
gca cgt gag ccc gat cct gcg aag aga gcg ctc ttg gtg ctg aaa tgg	240
Ala Arg Glu Pro Asp Pro Ala Lys Arg Ala Leu Leu Val Leu Lys Trp	
65 70 75 80	
ttc ctg agc aca ttg cac caa cag tac tgc tct cga agc gaa aag cta	288
Phe Leu Ser Thr Leu His Gln Gln Tyr Cys Ser Arg Ser Glu Lys Leu	
85 90 95	
gga agc gag aaa aag ccg ctc aac ccg ttc ctg ggc gag ctt ttc ctg	336
Gly Ser Glu Lys Lys Pro Leu Asn Pro Phe Leu Gly Glu Leu Phe Leu	
100 105 110	
ggc aag tgg ata gag gat gag gat gtg ggc gag aca agg ttg atc agc	384
Gly Lys Trp Ile Glu Asp Glu Asp Val Gly Glu Thr Arg Leu Ile Ser	
115 120 125	
gag caa gtc agc cat cat cct cct gcg aca gcg tat tca ata gtc aat	432
Glu Gln Val Ser His His Pro Pro Ala Thr Ala Tyr Ser Ile Val Asn	
130 135 140	
gag aaa cat gga gtt gag ctc caa gga tac aac gcc caa aaa gcc tcc	480
Glu Lys His Gly Val Glu Leu Gln Gly Tyr Asn Ala Gln Lys Ala Ser	
145 150 155 160	
ttc tcc agc acc atc caa gtg aaa caa cta ggc cac gcc tat ctc tcc	528
Phe Ser Ser Thr Ile Gln Val Lys Gln Leu Gly His Ala Tyr Leu Ser	
165 170 175	
tta acg ccg ccc gga aaa gat gca aac aac gaa gac gac cgt gag cac	576
Leu Thr Pro Pro Gly Lys Asp Ala Asn Asn Glu Asp Asp Arg Glu His	
180 185 190	
tac ctc atc acc ctc ccc aac ctc cac atc gaa tcc ctg atc tat ggg	624
Tyr Leu Ile Thr Leu Pro Asn Leu His Ile Glu Ser Leu Ile Tyr Gly	
195 200 205	
aca cca ttc gtt gaa ttg gaa aag agt tgc aag atc gcc agc tca acc	672
Thr Pro Phe Val Glu Leu Glu Lys Ser Cys Lys Ile Ala Ser Ser Thr	
210 215 220	

ggg tac atc tct aag ata gac ttt tcg ggc aaa ggc tgg ctg agc gga 720
 Gly Tyr Ile Ser Lys Ile Asp Phe Ser Gly Lys Gly Trp Leu Ser Gly
 225 230 235 240

aag aaa aat acc ttc tcc gca gtg tta tac aag gaa agc gac ggc gaa 768
 Lys Lys Asn Thr Phe Ser Ala Val Leu Tyr Lys Glu Ser Asp Gly Glu
 245 250 255

aaa aat cct tta tac aca gcc gac ggt caa tgg tcg agc agc ttc act 816
 Lys Asn Pro Leu Tyr Thr Ala Asp Gly Gln Trp Ser Ser Ser Phe Thr
 260 265 270

atc cgc gat gca cgc gct aag aag gat att gag acc ttc act atc agc 864
 Ile Arg Asp Ala Arg Ala Lys Lys Asp Ile Glu Thr Phe Thr Ile Ser
 275 280 285

aat ctg aaa aca acc ccc tta aca gtc gcc cct ctt gat gaa caa gat 912
 Asn Leu Lys Thr Thr Pro Leu Thr Val Ala Pro Leu Asp Glu Gln Asp
 290 295 300

gaa tgg gaa act cgc cgt gca tgg cgc gac gta gca gcc gcc atc gaa 960
 Glu Trp Glu Thr Arg Arg Ala Trp Arg Asp Val Ala Ala Ala Ile Glu
 305 310 315 320

cgc ggc gac atg gaa gcc aca tca aac gcc aaa acc aag atc gaa gtc 1008
 Arg Gly Asp Met Glu Ala Thr Ser Asn Ala Lys Thr Lys Ile Glu Val
 325 330 335

gcg caa cga gaa ctc cgc aaa aag gag aaa gag caa ggc gag gag tgg 1056
 Ala Gln Arg Glu Leu Arg Lys Lys Glu Lys Glu Gln Gly Glu Glu Trp
 340 345 350

gaa cga cga ttc ttc aag cga gtc aac gaa aag gat gaa cct acc ttt 1104
 Glu Arg Arg Phe Phe Lys Arg Val Asn Glu Lys Asp Glu Pro Thr Phe
 355 360 365

atg aga ttg gcg gcg atg ctg gat ttg acg caa ggc atc gaa agt gac 1152
 Met Arg Leu Ala Ala Met Leu Asp Leu Thr Gln Gly Ile Glu Ser Asp
 370 375 380

cgc acc ggg gga gtt tgg agg ttt gat cct tca cgt gct gtg gat gcg 1200
 Arg Thr Gly Gly Val Trp Arg Phe Asp Pro Ser Arg Ala Val Asp Ala
 385 390 395 400

aat ccg ccg tat cac aag gtt ggc ggc gaa ggg ttg gga ttg taa 1245
 Asn Pro Pro Tyr His Lys Val Gly Gly Glu Gly Leu Gly Leu
 405 410

tttatattatg aggcattttt tatatttcat aaaaacaggg tctaggccgt ttattcatta 1305

aatgtgtatt aagtagcgct ttttctcgac cgttgagatt catggatgca agtgtaccta 1365

atagctcaat gcgagactct ttccaagcaa aaaaaaaaaa aaaaaaaggcg cgccgc 1422

<210> 5
 <211> 2126
 <212> DNA

<215> Saccharomyces cerevisiae

<220>

<221> CDS

<222> (453)...(1757)

<400> 5

```

aacctctccg cccgtatatt ttttttaata tgtaaataag tgatagaact gataagcctc      60
atattctttt attgggctcc aagacgcgaa ctgttcgtag ggtaaccgtt tgacacctaa      120
acgacctttc agcctcacct gcagtatttc ttcaacaacg cctgtcgcta tgtaaataa      180
tagcaatcgt ttgtgatcac cattgtcgaa tttgacgcgc ttaaacaaaa accattgttt      240
tggcctcgtt ccctgcattc aacaaaagag caaggtatgc cgtcaaacag tcgttaaaag      300
agaagggtta taaactatct tgttttgtac tttgctgtcc cggatccagt tgggtcttct      360
tttcaacctg tctgagtcgg atctttcttt ccctacttga agctccatat atctaagtca      420
tctaagtgtg tctgtctaga ttacaaacga aa atg tct caa cac gca agc tca      473
                               Met Ser Gln His Ala Ser Ser
                               1           5

tct tct tgg act tct ttt ttg aaa tcg ata agt tcg ttc aac gga gat      521
Ser Ser Trp Thr Ser Phe Leu Lys Ser Ile Ser Ser Phe Asn Gly Asp
          10           15           20

cta tcg tct ttg tct gca cca ccg ttt att ctt tct ccc act tcc tta      569
Leu Ser Ser Leu Ser Ala Pro Pro Phe Ile Leu Ser Pro Thr Ser Leu
          25           30           35

aca gag ttt tct cag tat tgg gct gaa cat cca gct tta ttt ctg gag      617
Thr Glu Phe Ser Gln Tyr Trp Ala Glu His Pro Ala Leu Phe Leu Glu
          40           45           50           55

cct tcg ttg att gat ggt gaa aac tac aaa gat cac tgt ccc ttt gac      665
Pro Ser Leu Ile Asp Gly Glu Asn Tyr Lys Asp His Cys Pro Phe Asp
          60           65           70

cca aat gtg gaa tca aag gaa gtg gcg cag atg ttg gcg gtt gtt agg      713
Pro Asn Val Glu Ser Lys Glu Val Ala Gln Met Leu Ala Val Val Arg
          75           80           85

tgg ttt att tct act ttg aga tct caa tac tgc tct aga agc gaa tcg      761
Trp Phe Ile Ser Thr Leu Arg Ser Gln Tyr Cys Ser Arg Ser Glu Ser
          90           95          100

atg ggt tct gaa aag aag cct ttg aac cca ttc ttg ggt gag gta ttt      809
Met Gly Ser Glu Lys Lys Pro Leu Asn Pro Phe Leu Gly Glu Val Phe
          105          110          115

gtt gga aag tgg aaa aat gat gag cat cca gag ttt ggt gaa acg gtt      857
Val Gly Lys Trp Lys Asn Asp Glu His Pro Glu Phe Gly Glu Thr Val
          120          125          130          135

```

ctt tta agt gag caa gtt tca cat cat cca cct atg aca gca ttt tcg 905
 Leu Leu Ser Glu Gln Val Ser His His Pro Pro Met Thr Ala Phe Ser
 140 145 150

att ttt aat gaa aaa aat gat gtt tct gtt caa gga tac aat caa att 953
 Ile Phe Asn Glu Lys Asn Asp Val Ser Val Gln Gly Tyr Asn Gln Ile
 155 160 165

aaa act ggt ttt acc aaa aca ttg acg cta acg gtc aaa cca tac ggg 1001
 Lys Thr Gly Phe Thr Lys Thr Leu Thr Leu Thr Val Lys Pro Tyr Gly
 170 175 180

cat gtc att ttg aag att aaa gat gag acc tac ctg att aca acc ccg 1049
 His Val Ile Leu Lys Ile Lys Asp Glu Thr Tyr Leu Ile Thr Thr Pro
 185 190 195

cct ttg cat atc gaa ggt att tta gtc gct tct cca ttt gtt gaa tta 1097
 Pro Leu His Ile Glu Gly Ile Leu Val Ala Ser Pro Phe Val Glu Leu
 200 205 210 215

gga ggc agg tca ttc ata cag tca tca aat ggt atg tta tgt gtt ata 1145
 Gly Gly Arg Ser Phe Ile Gln Ser Ser Asn Gly Met Leu Cys Val Ile
 220 225 230

gaa ttt tca gga agg ggg tat ttc aca ggg aag aag aac tcc ttt aag 1193
 Glu Phe Ser Gly Arg Gly Tyr Phe Thr Gly Lys Lys Asn Ser Phe Lys
 235 240 245

gca aga att tac aga agc cca caa gag cat agt cat aaa gaa aat gcg 1241
 Ala Arg Ile Tyr Arg Ser Pro Gln Glu His Ser His Lys Glu Asn Ala
 250 255 260

cta tac cta atc tct ggc caa tgg tca ggt gtt tca aca att ata aaa 1289
 Leu Tyr Leu Ile Ser Gly Gln Trp Ser Gly Val Ser Thr Ile Ile Lys
 265 270 275

aaa gac tcg caa gtt tca cat cag ttt tac gat tca tcg gaa act cct 1337
 Lys Asp Ser Gln Val Ser His Gln Phe Tyr Asp Ser Ser Glu Thr Pro
 280 285 290 295

act gaa cat tta tta gtt aag cca atc gaa gaa caa cat cct ctg gaa 1385
 Thr Glu His Leu Leu Val Lys Pro Ile Glu Glu Gln His Pro Leu Glu
 300 305 310

agt agg agg gca tgg aag gat gtg gca gaa gca atc aga caa gga aat 1433
 Ser Arg Arg Ala Trp Lys Asp Val Ala Glu Ala Ile Arg Gln Gly Asn
 315 320 325

att agt atg ata aaa aag act aag gaa gaa cta gaa aat aag caa aga 1481
 Ile Ser Met Ile Lys Lys Thr Lys Glu Glu Leu Glu Asn Lys Gln Arg
 330 335 340

gcc ttg aga gaa caa gaa cgc gta aaa ggt gtg gaa tgg caa aga aga 1529
 Ala Leu Arg Glu Gln Glu Arg Val Lys Gly Val Glu Trp Gln Arg Arg
 345 350 355

tgg ttc aaa caa gtg gac tac atg aat gaa aat aca tca aat gat gta 1577
 Trp Phe Lys Gln Val Asp Tyr Met Asn Glu Asn Thr Ser Asn Asp Val

360 365 370 375

gag aaa gca agt gaa gat gat gcc ttt agg aaa ttg gcg tcc aaa ctg 1625
 Glu Lys Ala Ser Glu Asp Asp Ala Phe Arg Lys Leu Ala Ser Lys Leu
 380 385 390

cag ctt tct gtg aaa aat gtg cca agt ggg aca ttg att ggc ggc aaa 1673
 Gln Leu Ser Val Lys Asn Val Pro Ser Gly Thr Leu Ile Gly Gly Lys
 395 400 405

gat gat aag aaa gat gtt tca acc gca ttg cat tgg agg ttt gat aaa 1721
 Asp Asp Lys Lys Asp Val Ser Thr Ala Leu His Trp Arg Phe Asp Lys
 410 415 420

aat ttg tgg atg agg gag aac gaa att act ata taa tataaatggt 1767
 Asn Leu Trp Met Arg Glu Asn Glu Ile Thr Ile
 425 430

tttaaaagaa taaatatcaa aaattaatac taattgatgt ttgcattgct ttttttaagg 1827

gaaaatgcaa gcgtttttat ttttaacttt tggttttgaa gctcgtaatt caacaaaaaa 1887

gaattaaata atcttcaagt ccgataacaa gatgtagaaa aaacatccca atgaagttac 1947

aagtcaaacc attcactgag aatttttgta actcaccacc gatttttttg ataaaaatgta 2007

ttcctgcaac tttttttttt gaagagataa aaagaattga atagaatatg cagtaaaaaa 2067

agaatctcga aaaaaaaagg acaagaaatc ttaactacca tcaaacaatt gaaaattga 2126

<210> 6
 <211> 266
 <212> DNA
 <213> Glycine max

<400> 6

ccattcaatc caattcttgg tgagacttat gaaatggta accatggtgg cattacattt 60

atatcagagc aggtcagtca tcacctcca atgagtgtg ggcattgctga aactgaacat 120

ttcacttatg atgttacatc aaaattgaaa accaaatttc tcggcaactc agttgatgta 180

tatcctgttg gaagaacgcg tgttaccctc aaaagagatg gtgtggctcct tgatttggtg 240

cctcctccta caaaagttag caactt 266

<210> 7
 <211> 291
 <212> DNA
 <213> Glycine max

<220>
 <223> unsure at all n locations

<400> 7

tcacaacttc agtgctatgg tgaatcagtg tattgcacag gttcggactt gctaagcatg 60
 tgcaacaatg gtcagagtcc acttgatagg ttcatatctg tggtagcatg gtgcatactt 120
 accactcgcc ctgtgacttt tgggtgttgc ccttataatc ccantcttgg tgagacacac 180
 cncgtttcaa ggggaaatct taatgtgtta ttggagcaga tttcacatca cctccagta 240
 actgctctcc atgcaacaga tgaganggaa aacattgaaa tgttatgggtg c 291

<210> 8
 <211> 282
 <212> DNA
 <213> Glycine max
 <220>
 <223> unsure at all n locations
 <400> 8

gtgcccagng acaggtctgg tagctgaaat atcatacatg atcaagccat tgctttttta 60
 ggatttnggg gaagtcgtaa attgatcaaa gggnaaatcc ttgactcatn attactcaaa 120
 ggtctctgcg aagttgatng tcattgggat aagatagtta gagtgaagga tacnaatagt 180
 gnagaagtga gagtgatata tgatgccaaa gaagccnttt caggtctcaa aactcctatt 240
 atcaaggatg tggagagtgt gtggccaacc gaatcagccc tt 282

<210> 9
 <211> 255
 <212> DNA
 <213> Glycine max
 <400> 9

gtaactccta ccccttgggg tgacttggaa gtttaccaat acaacggtaa atatacccaa 60
 cattgtgctg ccgttgatag ttctgagtgc attgaagtgc ctgacatcag accagaattc 120
 aacccttggc aatatgataa tttggatgct gaatagttag catccttgtg gaattctttc 180
 tatttttttt aaatatcatt ttgttattaa gtttgtaatg taatcttgat tggaagcttg 240
 aaatttggtt ttgtt 255

<210> 10
 <211> 250
 <212> DNA
 <213> Glycine max
 <400> 10

taactcctac cccttgggggt gacttgggaag tttaaccaata caacggtaaa tatacccaac 60
 attgtgctgc cgttgatagt tctgagtgc ttgaagtgcc tgacatcaga ccagaattca 120
 acccttggca atatgataat ttggatgctg aatagtgagc atccttgtgg aattctttct 180
 atttttttta aatatcattt tgttattaag tttgtaatgt aatcttgatt ggaatgcttg 240
 aaatttggtt 250

<210> 11
 <211> 283
 <212> DNA
 <213> Glycine max
 <220>
 <223> unsure at all n locations
 <400> 11

cgcctgtgnt taatttccca aaatctcaac ttcaatgcta nggtgaatca gtgtactgca 60
 catcttccaa cttgctaagc caatgcaaac agtgggcaga gtccactgga cagggttcaca 120
 tcagtagtag catggagcat atctaccaca cgccccacat cttttggtgt tgctccttat 180
 aattccactc ttggagagac ccaccatggt tccaagggca atctcaacgt cctagttgag 240
 cagggtttcac tcaatcctcc agtatctgcc ctccatgcaa cag 283

<210> 12
 <211> 255
 <212> DNA
 <213> Glycine max
 <400> 12

ggagagtgtg tggccaaccg aatcagccct tgtttgaggt gagttgagcc aagccattat 60
 gaacaaagat tgggaaagag caagagaagc aaagcaagac gtggaagaaa gacagaggaa 120
 tatgttgaga gacagagcca tgaaaggaga aacttggttt cctaagaatt ttaggggtgc 180
 ttacagtaaa gacacatggg aatgggactg ttcaccaact cataaatggg tccctgaggg 240
 ccccatcata gctca 255

<210> 13
 <211> 259
 <212> DNA
 <213> Glycine max
 <220>
 <223> unsure at all n locations

<400> 13

agtcAACcct ccagtatctg ccctccatgc aacagatgag anggaaaaca ttgagatgat 60
 atgggtcccag caacctgttc caaagtttcg gggtagatct atgaagctca agtgcattgt 120
 aaacgtcata tgtttctcca tgatttagga gcttcagctg acgtttacca tgcacttgag 180
 ctgangctcc taaatcatgg agaaacatat gaaatgaatt gtcctcacct ttcaattaga 240
 attcttccgg ttcctggga 259

<210> 14

<211> 355

<212> DNA

<213> Glycine max

<220>

<223> unsure at all n locations

<400> 14

gcagcttttg ctgtgtctag ctatgcgtca actgaangtc gacaatgtaa accttttaat 60
 cctttactcg gggagacctt cgaagctgac tatccagata aaggacttaa gtttttttct 120
 gaaaagggtta gtcattcatc aatgattgtt gcttgctact gtgagggaag gggatggaag 180
 ttttgggcag attctaattt gaaaggaaaa ttctgggggc gttctatcca gttagatcct 240
 gtgggtgtcc tcaactctaca gtttgaggat ggtgaaacat ttcagtggag caaggtcacc 300
 acttcgattt acaatatcat actangtaaa atttattgtg accactacgg tacca 355

<210> 15

<211> 279

<212> DNA

<213> Glycine max

<220>

<223> unsure at all n locations

<400> 15

cagattcggg ggaggaagct cagagaggaa gatggaaaca ggaggaaaga gatgggtact 60
 ggaagatgat gcagaagtat attggctcgg atgtaacatc aatgggtgaca ctaccagtta 120
 ttatatttga accaatgact atgattcaga aaattgctga gttgatggag tactcctact 180
 tgtttagatca agcagatgaa tcagaggatc catacatgca gttagtttat gcaatggatg 240
 tactttnatg atcatcacag catccatggg ccatatcgg 279

<210> 16

<211> 191
 <212> DNA
 <213> Glycine max

<400> 16

gttgatagtt ctgagtgcac agaggtgcct gacagcagaa cagaattcaa cccttggcaa 60
 tatgataatt tggatgctga ataataagca tccttgtaga attctttcta ttctttgaac 120
 tatcattttg ttattaagtt tgcaatgtat ctgattggaa tgcttgaaat ttggttttgt 180
 ttttgggtaa a 191

<210> 17
 <211> 267
 <212> DNA
 <213> Glycine max

<220>
 <223> unsure at all n locations

<400> 17

tcaactcctt ggggtgattt ggaaatctat caatataatg gtaaatacag tgaacatcga 60
 gctgctgcag ataactcagg aagcattgat gatgttgatg ctaaatacaat tgaattcaat 120
 ccatggcagt atggtaattt ggccacggaa tgaactagtt tcaatttctt tggttttgga 180
 tgntncagtt agttcatgta actntnnncn antganacna gaanacaact ncctncnnca 240
 ncnnanngtt agttgggcng tgtacgc 267

<210> 18
 <211> 252
 <212> DNA
 <213> Glycine max

<400> 18

gtcttataga gctcccaatc tcctacatcg cttgttaagt ttactcaaga acgtgcggcc 60
 aggatcagat ctacacact tccaactgcc agctgtgttt aacttccaa aatctcaact 120
 tcaatgctat ggtgaatcag tgtactgcac atcttcaaac ttgctgagca aatgcaacaa 180
 tgggcagagt ccaactggaca ggttcacatc agtagtagca tggagcatat ctaccacacg 240
 cccacatct tt 252

<210> 19
 <211> 241
 <212> DNA
 <213> Glycine max

<400> 19

gtcagtcac accctccaat gaggctggg catgctgaaa ctgaacattt cacttatgat 60
 gttacatcaa aattgaaaac caaattttctc ggcaactcag ttgatgtata tcctgttgga 120
 agaacgcgtg ttaccctcaa aagagatggg gtggctccttg atttggtgcc tcctcctaca 180
 aaagtttagca acttgattttt tggacgaact tggattgatt caccaggaga gatgatcctg 240
 a 241

<210> 20

<211> 262

<212> DNA

<213> Glycine max

<400> 20

tctcgagcct attcggctcg aggccaaaga agccatttca ggctactaaa ctcctattat 60
 catatgatgt ggagagtgtg tattcaaccg aatcagccct tgtttgaggat gagttgagcc 120
 aagccattat gaacaaagat tgggaaagag caagagaagc aaagcaagac gtggaagaaa 180
 gacagaggaa tatgttgaga gacagagcca tgacaggaga aactggttgt ctaagaattt 240
 aggggtgtctt acagtaaaga ca 262

<210> 21

<211> 463

<212> DNA

<213> Arabidopsis thaliana

<220>

<223> unsure at all n locations

<400> 21

ggggaacccc ttccaggaac agagctgaaa gaggtgtggc atttggtga tgtccccaaa 60
 aacgacaact ttcaagtacac tcactttgct cacaagataa acagcttcga cacagcgcct 120
 gctaagctct tggcttcaga ctcacgtatc cgtcctgata gatattccct tgagcagggt 180
 gacctttcta aagctgggtc cgagaaacac agccttgagg agagacaaag ggccgaaaag 240
 aggaccagag agacaaaggg acaaaagttc actccaagat ggttcgatct aacggatgag 300
 atcacaccta ctccatgggg agatattgaa gtataccant acaacgggaa gtacaatgaa 360
 caccgagaca cggcagagag ctcaagtagt gcctccaacg aaacgggact caaatccatc 420
 gaggtttaac cttggcaata tggtaatatc tcaaccgaat gaa 463

<210> 22
 <211> 399
 <212> DNA
 <213> Arabidopsis thaliana

<400> 22

```

agtgaacctc tcccaggcac cgaactgaaa gaggtatgga aactcgctga tgtgccaaag   60
gatgacaaat atcaatacac tcaactttgct cacaagatta atagcttcga cactgccccg  120
aaaaagctgt tgccctctga ttcaagggtta cgacctgata gatacgcaact tgagatgggc  180
gacatgtcca aatcaggcta tgagaagagc agcatggaag agagacagag agctgacaag  240
agaacccgcg aacataaagg ccaagccttt actccaaaat ggttcgatgt aacggaagaa  300
gtcactgcta caccatgggg tgatctggaa gtttaccat tcaactggaa gtactcagaa  360
catcgtgcag ctgcggataa ctctgaagat aagaccgac                               399
  
```

<210> 23
 <211> 343
 <212> DNA
 <213> Arabidopsis thaliana

<400> 23

```

acggacgcgt gggcaactcc aatgttacgg cgagatggtc tacagcttcg tcggtcagga   60
tctgcttggg gaatgcagcc gccgtgatct tccattgaa cggctcaaat cagtggtgac  120
gtggaacatc tccacactcc gtccggtggt ctttggcatg tctccgtaca actccgttct  180
cggcgagact caccacgtat cgaacgggtca catcaacgtc atcgccgaac aagtagtgca  240
tcatcctccg gtttccgctc ttcatgcgac tcacgaacaa gaaaatatcg acgtgacatg  300
gtgtcaatat ttcactccta aatttcgtgg tactcacgtg gac                               343
  
```

<210> 24
 <211> 510
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <223> unsure at all n locations

<400> 24

```

gaaagctagc agatgtagaa caaagttttt tgtaactacg agagaataag aatacatttg   60
tttccaaaaa gatttgatct tttctgtctt ttggagcgat acatttaagt agacagatct  120
tggaattgcc atggggtgaa ttggatcgac ttagggtcgg tggtatcttc agagttatcc  180
  
```

gcagctgcac gatgttccga gtactttcca ttgaattggt aaacttccag atcaccccat 240
 ggtgtagcag tgactttcttc cgttacatcg aaccattttg gagtaaaggc ttggcctttc 300
 tcttcgcggg gtcncttttc aagtctctgt cnctcttcca tgggtgntctt cccanagcct 360
 gatttgnaca tggcggccan cccaaggng gatcaatcag gccgnaacgg ggaatcagnn 420
 ggnaacagct tttcngggna ntgncgaagc aataaacnt gggggcaaag gggggggatt 480
 ggaaattggc aacccttggg naacaggggc 510

<210> 25
 <211> 282
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <223> unsure at all n locations

<400> 25

gatacatTTg gattcgaaaa gagcagccta gaggatagac aaagagctga gaagaaaagc 60
 agagaagaga aaggccaaaa ntttcncca aaatggtttn atgaaacana agangtcact 120
 cctacaccat ggggtgatct cgaagtttac caattcantg gaaagtactc ggtgcaccgn 180
 gccacagctg aaaactntga ggatacaacc gntgtgaagt tgnccaatt caacccttgg 240
 caattccaag atctctntgc ttaatccttt ggtgccattt gt 282

<210> 26
 <211> 380
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <223> unsure at all n locations

<400> 26

cgttggtggc ngcggaagtg gtttcttcgc ctctcttgct tcgtcgatct ccaatttngg 60
 ntctgctatg accaaatcag ttaatggttt ggttcctat gagggacttg aagttatcaa 120
 tcctgaagga agtacagatg atgctgagga ggaagcaagc agaggaagat ggaagcaaga 180
 ggatcgagat ggctattgga agatgatgca gaagtacata ggatctgatg ttacatcaat 240
 ggtgaccctt cctgtgatta tttttgaacc aatgacaatg cttcagaaaa tggcggagtt 300
 gatggaatac tcgcatctgc tagacatggc agacaaaacc gaggaccctt atttncgcac 360
 ggtgtatgca tcacgtggg 380

<210> 27
 <211> 359
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <223> unsure at all n locations

<400> 27

```

ggtaatgaag gagttgaggt cataaatcca gaaggtggca aggaagatnc tgaagaggaa   60
gctcagaaaag gaaggtggaa ggacgaggaa cgagatagtt actggaagat gatgcagaaa  120
tatataggtt cggatattac gtcaatggtg gctcttcctg ttgtnatatt tnancctatg  180
actatnctcc anaagatggc tgagataatg gagtattctc atttnttggg tcaagcagat  240
gaatgcngag atccatactt gctgttagta tacccttcat catgggggat atctgtttac  300
tatggccttc caacggacct tggaagcctt tnaatccnat tcttgggggg gnnanttna  359
  
```

<210> 28
 <211> 510
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <223> unsure at all n locations

<400> 28

```

aaaagagaaa agtgtagcc tttggtcaat gatcaaagac antataggga aggntctcac   60
aaaagtctgt ctctctgttt acttcaacga gccactttct tctttacaga aatgttttga  120
ggatttggaa tattcgtacc ttcttgaccg agcatttgaa tatggcaaaa ggggaaatag  180
cctcatgagg atacttaatg tagctgcttt tgctgtatct gggtagcat caactgaagg  240
aagaatttgc aaacctttta atccattgtt aggtgaaaca tacgnggcag actatccaga  300
caaaggcctt cggttttttt ccaggaaagg tcagtcatca tcctatgggt gtcgnatgcc  360
attgtgatgg caccnggtgg gaattcttgg gggacagcaa tcttnggggc aaattttggg  420
gcnctctntt tagcttnacc cccttgggga ttnccttna aattnatgat ggggaanccn  480
caggggggaa ggngcccacc atnncaaacc                                     510
  
```

<210> 29
 <211> 493
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <223> unsure at all n locations

<400> 29

```

ccccnccng aaagnttccc ctgtttccgg nttnnccnt ntgnncccc ttgggggggn 60
cctttcccaa tnggnnttgg gngngcccc ttggangggg ccggggcttt aaagggcccc 120
ncgnaggga ggccagcctt tctcccaa at ggtcgatgta ccggaggaag tcaactgctac 180
cccatggggt gatctggaag tttcccaatt caatggaaag tactcggaac atcgtgcagc 240
tgcgataac tctgaagata acaccgacc taagtcgatc caattcaacc catggcaatt 300
ccaagatctg tctacttaaa tgtatcgctc caaaagacag aaaagatcaa atctttttgg 360
aaacaaatgt attcttattc tctcgtagtt aaaaaaact ttgttctaca tctgctagct 420
tcccattgc tttctctagt attagtgtac aacttctact gttttgtctt aaattcattc 480
aaatctttct ttg 493

```

<210> 30
 <211> 358
 <212> PRT
 <213> Glycine max

<400> 30

```

Met Thr Met Leu Gln Lys Met Ala Glu Leu Met Glu Tyr Ser Tyr Leu
1          5          10          15

Leu Asp Met Ala Asp Lys Thr Glu Asp Pro Tyr Met Arg Leu Val Tyr
          20          25          30

Ala Ser Ser Phe Phe Ile Ser Val Tyr Tyr Ala Tyr Gln Arg Thr Trp
          35          40          45

Lys Pro Phe Asn Pro Ile Leu Gly Glu Thr Tyr Glu Met Val Asn His
50          55          60

Gly Gly Ile Thr Phe Ile Ser Glu Gln Val Ser His His Pro Pro Met
65          70          75          80

Ser Ala Gly His Ala Glu Thr Glu His Phe Thr Tyr Asp Val Thr Ser
          85          90          95

Lys Leu Lys Thr Lys Phe Leu Gly Asn Ser Val Asp Val Tyr Pro Val
100          105          110

Gly Arg Thr Arg Val Thr Leu Lys Arg Asp Gly Val Val Leu Asp Leu
115          120          125

Val Pro Pro Pro Thr Lys Val Ser Asn Leu Ile Phe Gly Arg Thr Trp
130          135          140

```

Ile Asp Ser Pro Gly Glu Met Ile Leu Thr Asn Leu Thr Thr Gly Asp
 145 150 155 160
 Lys Val Val Leu Tyr Phe Gln Pro Cys Gly Trp Phe Gly Tyr Glu Val
 165 170 175
 Asp Gly Tyr Val Tyr Asn Ser Ala Asp Glu Pro Lys Ile Leu Met Thr
 180 185 190
 Gly Lys Trp Asn Glu Ala Met Asn Tyr Gln Val Cys Asp Ser Glu Gly
 195 200 205
 Glu Pro Leu Pro Gly Thr Glu Leu Lys Glu Ile Trp Arg Val Ala Asp
 210 215 220
 Thr Pro Lys Lys Asp Lys Phe Gln Tyr Thr His Phe Ala His Lys Ile
 225 230 235 240
 Asn Ser Phe Asp Thr Ala Pro Lys Lys Leu Leu Ala Ser Asp Ser Arg
 245 250 255
 Leu Arg Pro Asp Arg Met Ala Leu Glu Lys Gly Asp Leu Ser Thr Ser
 260 265 270
 Gly Tyr Glu Lys Ser Ser Leu Glu Glu Arg Gln Arg Ala Glu Lys Arg
 275 280 285
 Asn Arg Glu Ala Lys Gly His Lys Phe Thr Pro Arg Trp Phe Asp Leu
 290 295 300
 Thr Asp Glu Val Thr Pro Thr Pro Trp Gly Asp Leu Glu Val Tyr Gln
 305 310 315 320
 Tyr Asn Gly Lys Tyr Thr Gln His Cys Ala Ala Val Asp Ser Ser Glu
 325 330 335
 Cys Ile Glu Val Pro Asp Ile Arg Pro Glu Phe Asn Pro Trp Gln Tyr
 340 345 350
 Asp Asn Leu Asp Ala Glu
 355

<210> 31
 <211> 300
 <212> PRT
 <213> Glycine max

<400> 31

Met Cys Asn Asn Gly Gln Ser Pro Leu Asp Arg Phe Ile Ser Val Val
 1 5 10 15
 Ala Trp Cys Ile Ser Thr Thr Arg Pro Val Thr Phe Gly Val Ala Pro
 20 25 30
 Tyr Asn Pro Ile Leu Gly Glu Thr His His Val Ser Arg Gly Asn Leu

35 40 45
 Asn Val Leu Leu Glu Gln Ile Ser His His Pro Pro Val Thr Ala Leu
 50 55 60
 His Ala Thr Asp Glu Lys Glu Asn Ile Glu Met Leu Trp Cys Gln Arg
 65 70 75 80
 Pro Asp Pro Lys Phe Asn Gly Thr Ser Val Glu Ala Lys Val His Gly
 85 90 95
 Ile Arg Gln Leu Lys Leu Leu Asn His Gly Glu Thr Tyr Glu Met Asn
 100 105 110
 Cys Pro Arg Leu Leu Leu Arg Ile Leu Pro Val Pro Gly Ala Asp Trp
 115 120 125
 Ala Gly Thr Val Asn Ile Arg Cys Leu Glu Thr Gly Leu Val Ala Glu
 130 135 140
 Leu Ser Tyr Arg Ser Ser Ser Phe Leu Gly Ile Gly Gly Asn His Arg
 145 150 155 160
 Val Ile Lys Gly Lys Ile Leu Asp Ser Ser Ser Leu Lys Val Leu Tyr
 165 170 175
 Glu Val Asp Gly His Trp Asp Arg Thr Val Lys Val Lys Asp Thr Asn
 180 185 190
 Asn Gly Lys Val Arg Val Ile Tyr Asp Ala Lys Glu Val Met Ser Gly
 195 200 205
 Leu Glu Thr Pro Ile Leu Lys Asp Ile Glu Gly Val Trp Gln Thr Glu
 210 215 220
 Ser Ala His Val Trp Gly Glu Leu Asn Gln Ala Ile Val Ser Lys Asp
 225 230 235 240
 Trp Glu Lys Ala Arg Glu Ala Lys Leu Lys Val Glu Glu Arg Gln Arg
 245 250 255
 Glu Leu Val Arg Glu Arg Glu Ser Lys Gly Glu Thr Trp Ile Ser Lys
 260 265 270
 His Phe Val Val Ser Asn Asn Lys Glu Gly Trp Gln Cys Ser Pro Ile
 275 280 285
 His Lys Ser Val Pro Ala Ala Pro Ile Thr Ala Leu
 290 295 300

<210> 32
 <211> 355
 <212> PRT
 <213> Glycine max
 <400> 32

Met Ala Glu Leu Met Glu Tyr Ser Tyr Leu Leu Asp Met Ala Asp Lys
 1 5 10 15
 Thr Glu Asp Pro Tyr Met Arg Leu Val Tyr Ala Ser Ser Phe Phe Ile
 20 25 30
 Ser Val Tyr Tyr Ala Tyr Gln Arg Thr Trp Lys Pro Phe Asn Pro Ile
 35 40 45
 Leu Gly Glu Thr Tyr Glu Met Val Asn His Gly Gly Ile Thr Phe Ile
 50 55 60
 Ser Glu Gln Val Ser His His Pro Pro Met Ser Ala Gly His Ala Glu
 65 70 75 80
 Thr Glu His Phe Thr Tyr Asp Val Thr Ser Lys Leu Lys Thr Lys Phe
 85 90 95
 Leu Gly Asn Ser Val Asp Val Tyr Pro Val Gly Arg Thr Arg Val Thr
 100 105 110
 Leu Lys Arg Asp Gly Val Val Leu Asp Leu Val Pro Pro Pro Thr Lys
 115 120 125
 Val Ser Asn Leu Ile Phe Gly Arg Thr Trp Ile Asp Ser Pro Gly Glu
 130 135 140
 Met Ile Leu Thr Asn Leu Thr Thr Gly Asp Lys Val Val Leu Tyr Phe
 145 150 155 160
 Gln Pro Cys Gly Trp Phe Gly Ala Gly Arg Tyr Glu Val Asp Gly Tyr
 165 170 175
 Val Tyr Asn Ser Ala Asp Glu Pro Lys Ile Leu Met Thr Gly Lys Trp
 180 185 190
 Asn Glu Ala Met Asn Tyr Gln Val Cys Asp Ser Glu Gly Glu Pro Leu
 195 200 205
 Pro Gly Thr Glu Leu Lys Glu Ile Trp Arg Val Ala Asp Thr Pro Lys
 210 215 220
 Lys Asp Lys Phe Gln Tyr Thr His Phe Ala His Lys Ile Asn Ser Phe
 225 230 235 240
 Asp Thr Ala Pro Lys Lys Leu Leu Ala Ser Asp Ser Arg Leu Arg Pro
 245 250 255
 Asp Arg Met Ala Leu Glu Lys Gly Asp Leu Ser Thr Ser Gly Tyr Glu
 260 265 270
 Lys Ser Ser Leu Glu Glu Arg Gln Arg Ala Glu Lys Arg Asn Arg Glu
 275 280 285
 Ala Lys Gly His Lys Phe Thr Pro Arg Trp Phe Asp Leu Thr Asp Glu
 290 295 300
 Val Thr Pro Thr Pro Trp Gly Asp Leu Glu Val Tyr Gln Tyr Asn Gly

<400> 33

24

[illegible]

Thr Pro Phe Val Glu Leu Glu Lys Ser Cys Lys Ile Ala Ser Ser Thr
 210 215 220
 Gly Tyr Ile Ser Lys Ile Asp Phe Ser Gly Lys Gly Trp Leu Ser Gly
 225 230 235 240
 Lys Lys Asn Thr Phe Ser Ala Val Leu Tyr Lys Glu Ser Asp Gly Glu
 245 250 255
 Lys Asn Pro Leu Tyr Thr Ala Asp Gly Gln Trp Ser Ser Ser Phe Thr
 260 265 270
 Ile Arg Asp Ala Arg Ala Lys Lys Asp Ile Glu Thr Phe Thr Ile Ser
 275 280 285
 Asn Leu Lys Thr Thr Pro Leu Thr Val Ala Pro Leu Asp Glu Gln Asp
 290 295 300
 Glu Trp Glu Thr Arg Arg Ala Trp Arg Asp Val Ala Ala Ala Ile Glu
 305 310 315 320
 Arg Gly Asp Met Glu Ala Thr Ser Asn Ala Lys Thr Lys Ile Glu Val
 325 330 335
 Ala Gln Arg Glu Leu Arg Lys Lys Glu Lys Glu Gln Gly Glu Glu Trp
 340 345 350
 Glu Arg Arg Phe Phe Lys Arg Val Asn Glu Lys Asp Glu Pro Thr Phe
 355 360 365
 Met Arg Leu Ala Ala Met Leu Asp Leu Thr Gln Gly Ile Glu Ser Asp
 370 375 380
 Arg Thr Gly Gly Val Trp Arg Phe Asp Pro Ser Arg Ala Val Asp Ala
 385 390 395 400
 Asn Pro Pro Tyr His Lys Val Gly Gly Glu Gly Leu Gly Leu
 405 410

<210> 34
 <211> 434
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<400> 34

Met Ser Gln His Ala Ser Ser Ser Ser Trp Thr Ser Phe Leu Lys Ser
 1 5 10 15
 Ile Ser Ser Phe Asn Gly Asp Leu Ser Ser Leu Ser Ala Pro Pro Phe
 20 25 30
 Ile Leu Ser Pro Thr Ser Leu Thr Glu Phe Ser Gln Tyr Trp Ala Glu
 35 40 45
 His Pro Ala Leu Phe Leu Glu Pro Ser Leu Ile Asp Gly Glu Asn Tyr
 50 55 60

Lys Asp His Cys Pro Phe Asp Pro Asn Val Glu Ser Lys Glu Val Ala
 65 70 75 80
 Gln Met Leu Ala Val Val Arg Trp Phe Ile Ser Thr Leu Arg Ser Gln
 85 90 95
 Tyr Cys Ser Arg Ser Glu Ser Met Gly Ser Glu Lys Lys Pro Leu Asn
 100 105 110
 Pro Phe Leu Gly Glu Val Phe Val Gly Lys Trp Lys Asn Asp Glu His
 115 120 125
 Pro Glu Phe Gly Glu Thr Val Leu Leu Ser Glu Gln Val Ser His His
 130 135 140
 Pro Pro Met Thr Ala Phe Ser Ile Phe Asn Glu Lys Asn Asp Val Ser
 145 150 155 160
 Val Gln Gly Tyr Asn Gln Ile Lys Thr Gly Phe Thr Lys Thr Leu Thr
 165 170 175
 Leu Thr Val Lys Pro Tyr Gly His Val Ile Leu Lys Ile Lys Asp Glu
 180 185 190
 Thr Tyr Leu Ile Thr Thr Pro Pro Leu His Ile Glu Gly Ile Leu Val
 195 200 205
 Ala Ser Pro Phe Val Glu Leu Gly Gly Arg Ser Phe Ile Gln Ser Ser
 210 215 220
 Asn Gly Met Leu Cys Val Ile Glu Phe Ser Gly Arg Gly Tyr Phe Thr
 225 230 235 240
 Gly Lys Lys Asn Ser Phe Lys Ala Arg Ile Tyr Arg Ser Pro Gln Glu
 245 250 255
 His Ser His Lys Glu Asn Ala Leu Tyr Leu Ile Ser Gly Gln Trp Ser
 260 265 270
 Gly Val Ser Thr Ile Ile Lys Lys Asp Ser Gln Val Ser His Gln Phe
 275 280 285
 Tyr Asp Ser Ser Glu Thr Pro Thr Glu His Leu Leu Val Lys Pro Ile
 290 295 300
 Glu Glu Gln His Pro Leu Glu Ser Arg Arg Ala Trp Lys Asp Val Ala
 305 310 315 320
 Glu Ala Ile Arg Gln Gly Asn Ile Ser Met Ile Lys Lys Thr Lys Glu
 325 330 335
 Glu Leu Glu Asn Lys Gln Arg Ala Leu Arg Glu Gln Glu Arg Val Lys
 340 345 350
 Gly Val Glu Trp Gln Arg Arg Trp Phe Lys Gln Val Asp Tyr Met Asn
 355 360 365

Glu Asn Thr Ser Asn Asp Val Glu Lys Ala Ser Glu Asp Asp Ala Phe
370 375 380

Arg Lys Leu Ala Ser Lys Leu Gln Leu Ser Val Lys Asn Val Pro Ser
385 390 395 400

Gly Thr Leu Ile Gly Gly Lys Asp Asp Lys Lys Asp Val Ser Thr Ala
405 410 415

Leu His Trp Arg Phe Asp Lys Asn Leu Trp Met Arg Glu Asn Glu Ile
420 425 430

Thr Ile